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Whilst the causal mechanisms underpinning Alzheimer’s disease (AD) are still elusive, 
there is increasing evidence to support a role for oligomeric amyloid-beta (Aß) peptides 
in the progression of this neurodegenerative disease. Studies have shown that Aß42 can 
contribute to synaptic dysfunction, an early event in AD, through altering synaptic 
vesicle (SV) dynamics. However, the molecular basis of this is poorly understood. Here, 
the regulation of SynapsinI, a key modulator of SV pools and availability, was examined 
using primary rat neurons acutely exposed to Aß42. The results showed that Aß42 
induced sustained phosphorylation of SynapsinI at Ser9, which was hypothesised to 
disrupt physiological SV dynamics. Interestingly, treatment of Aß42-exposed neurons 
with Valproic acid (VPA), an approved anti-epileptic drug, restored the physiological 
phosphorylation cycle of SynapsinI at Ser9. Collectively, these findings suggest a novel 
mechanism for Aß42-mediated dysfunction in SV dynamics and support a therapeutic 
role for VPA in Aß-related pathology in AD. Another key player in AD pathophysiology is 
apolipoprotein E (apoE), a multifunctional glycoprotein that has roles in the 
cardiovascular and central nervous system. There are three variants of the APOE gene: 
APOE4 (strongest genetic risk factor for AD), the ‘neutral’ APOE3 and the 
‘neuroprotective’ APOE2. Although neuron-specific proteolysis of apoE4 is suggested to 
lead to a toxic gain of function, it is not known whether the neuroprotective role of 
apoE2 is related to differential processing when expressed in neurons. To investigate 
this, apoE2, apoE3 and apoE4 were overexpressed in neuronal cell models and the 
fragmentation of each isoform was first characterised using commercially available 
antibodies. Although the proteolytic susceptibility of apoE was isoform- and cell- 
dependent, no unique fragments were observed. Moreover, the data indicated that all 
three apoE isoforms are cleaved within the N-terminus and hinge region, generating C-
terminal fragments of similar composition. The effect of apoE isoform on cytoskeletal-
associated proteins and cell viability/survival was also explored to test for a gain of toxic 
or protective function. While isoform-specific effects on tau phosphorylation and 
vimentin levels were observed, none of the isoforms were found to be toxic. Finally, the 




that apoE2 expression in human neurons after injury or stress may contribute to 
decreased risk for AD. Collectively, these findings indicate that the differential effects of 
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SEM Standard error of the mean 
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SNPs Single nucleotide polymorphisms 
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Chapter 1 INTRODUCTION 
1.1 Clinical overview of Alzheimer’s disease 
Alzheimer’s disease (AD) is a debilitating, progressive neurodegenerative disorder that is 
placing increasing pressure on healthcare systems globally, costing an estimated total of 
817.00 billion (USD) worldwide in 2015 (Wimo et al., 2017). So far, there is no available 
cure or disease-modifying agent for AD and the vast majority of recent clinical trials have 
not been successful (Cummings et al., 2014, Amanatkar et al., 2017, Cummings et al., 
2018). Considering that the number of affected individuals worldwide, currently 
estimated at over 50 million, is predicted to triple by 2050 (ADI, 2018), there is an 
increasingly urgent need to better understand the basic mechanisms of the disease to 
find an effective clinical solution.  
 
AD involves the selective atrophy of specific brain regions (see Figure 1-1, A), as 
observed using imaging techniques such as magnetic resonance imaging (MRI), and this 
is associated with a gradual regression of cognitive and behavioural function (Frisoni et 
al., 2010, McDonald et al., 2009). Atrophy typically begins within medial temporal lobe 
structures such as the hippocampus and entorhinal cortex during the mild cognitive 
impairment (MCI) stage of AD (Spulber et al., 2013, Clerx et al., 2013, McDonald et al., 
2009), which leads to the hallmark symptomatic presentation of short-term memory 
deficits (Gaugler et al., 2016, Visser et al., 1999, Duara et al., 2008). Such deficits can 
include forgetting names, misplacing objects and struggling to recall recent events or 
conversations. As the disease spreads to the lateral temporal and parietal lobes during 
the mild AD stage (McDonald et al., 2009, Scahill et al., 2002), problems with declarative 
memory (memory of facts or events) worsen and problems with language, number and 
visuospatial processing become apparent (Bilello et al., 2015). This may affect a person’s 
ability to find the right word or have a coherent conversation, to manage their finances, 
or to find their way home. The frontal lobe is next affected during the moderate stage of 
AD (McDonald et al., 2009). Atrophy in this region can lead to Impairment of procedural 
memory (task organisation and learning of new tasks) and executive functions, which 
can result in daily activities such as making a cup of tea become challenging. Additionally, 




changes in behaviour such as irritability, aggression or even apathy may occur. In some 
cases, as the disease advances, the occipital lobe can also degenerate (McDonald et al., 
2009), leading to the presentation of visual problems. It is notable though, that the 
variety and severity of these symptoms vary in those affected by AD, but generally these 
worsen over time as atrophy of the brain becomes more severe and widespread (see 
Figure 1-1, B). This results in complete dependency and impacts the lives of not only 
those with the condition, but also their families. The final stages of the disease can be 
fatal. Whilst it is established that atrophy of the brain is due to loss of synapses and 
neurophil (axons and dendrites of neurons), neuronal death and brain shrinkage, the 
cause behind it is still poorly understood. 
 
Figure 1-1 The progressive and selective atrophy of the brain in Alzheimer’s disease 
(A) Illustration showing the brain regions typically affected in each clinical stage of AD. At the mild 
cognitive impairment stage of AD, structures within the medial temporal lobe begin to atrophy. The brain 
atrophy spreads to the lateral temporal and parietal lobes in mild AD in a cumulative manner, the frontal 
lobe in moderate AD and in some cases, the occipital lobe in the severe stage of the disease. (B) 
Illustration showing how selective atrophy in AD leads to gradual shrinkage of specific brain regions. 
Images adapted from https://www.save-years.com/alzheimers (A) and  
https://plasmalogen.me/en/pathophysiology-of-alzheimers-disease (B). 
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1.2 Histopathological hallmarks of AD 
AD is also characterised by the presence of extracellular plaques and intraneuronal 
neurofibrillary tangles, two distinct pathological lesions which were initially observed by 
Alois Alzheimer over a century ago. Isolation and purification of extracellular plaques 
from AD-afflicted brains led to the identification a small (  ̴4kDa) peptide called amyloid-
ß (Aß) as the major constituent of plaques (Glenner and Wong, 1984, Masters et al., 
1985), whilst labelling of intraneuronal neurofibrillary tangles (NFTs) with tau specific 
antibodies revealed that they contained aggregates of hyperphosphorylated tau 
(Grundke-Iqbal et al., 1986). These findings strongly implicated the build-up of Aß and 
the dysregulation of tau in the pathogenesis of the disorder. As a result, the presence 
and spread of these two lesions in the brain are still used for diagnosis of AD and as a 
reference for the staging of the disease (Braak and Braak, 1991, Braak and Braak, 1995, 
Serrano-Pozo et al., 2011). 
 
1.3 The preclinical phase of AD and biomarkers 
By the time a person presents with clinical symptoms of AD, significant changes in the 
brain at the molecular, metabolic and structural levels have already occurred (Masters 
et al., 2015). In fact, changes in the brain that are associated with AD are thought to 
occur approximately two decades before the onset of clinical symptoms at the MCI 
stage, during what is recognised as the preclinical phase of the disease (Sperling et al., 
2011). Analysis of the cerebrospinal fluid (CSF), which reflects the biochemistry of the 
brain, and positron emission tomography (PET) imaging, have been instrumental in 
monitoring these early changes at the molecular level and identifying promising 
biomarkers to diagnose AD. For instance, these approaches have revealed alterations in 
the metabolism of the Aß peptide up to 20 years prior to onset of clinical symptoms of 
AD (Skoog et al., 2003, Gustafson et al., 2007, van Harten et al., 2013, Villemagne et al., 
2013). In an early study measuring Aß42 and Aß40 (species of the Aß peptide that vary 
by 2 amino acids (aa)) in the CSF of cognitively normal elderly patients, the levels of 
Aß42, but not Aß40, were found to decline in patients who developed AD (Skoog et al., 
2003). Moreover, low CSF levels of Aß42 were determined to confer an 8-fold risk for 




Later studies have also demonstrated that low levels of CSF Aß42, detected as early as 8 
years before clinical presentation of AD, correlate with cognitive decline and the 
development of AD (Gustafson et al., 2007, Stomrud et al., 2007, van Harten et al., 2013, 
Palmqvist et al., 2015). Whilst these studies provide evidence for an early preclinical 
phase of AD, they also demonstrate that CSF levels of Aß42 can be used as a biomarker 
for the development of AD. Imaging of Aß in the brain by PET has provided further 
evidence for a link between early accumulation and deposition of Aß and the 
development of AD. In a 3-year follow up Aß PET imaging study, positive Aß PET scans 
(higher Aß burden compared to baseline) in cognitively normal individuals were found to 
be associated with a higher risk for developing AD, and a poorer prognosis in patients 
with MCI (Rowe et al., 2013). Moreover, longitudinal Aß PET imaging studies of the rates 
of Aß accumulation have provided data to support a prolonged preclinical stage of AD, 
with PET scans showing positivity for accumulation of the peptide up to 17 years before 
the full onset of AD dementia (Jack et al., 2013, Villemagne et al., 2013). In addition to 
changes in Aß42 levels, increases in the levels of total tau and phosphorylated tau (p-Tau) 
have been detected by CSF analysis and PET imaging in the preclinical and MCI stages of 
AD (Sutphen et al., 2015, Visser et al., 2009, Sjogren et al., 2001, Scholl et al., 2016, 
Betthauser et al., 2019). However, CSF total tau is considered to not be a specific 
biomarker for AD because increases in CSF total tau have also been observed in other 
neurodegenerative diseases such as Creutzfeldt–Jakob disease (Riemenschneider et al., 
2003, Skillback et al., 2014). Hence CSF total tau is considered as an indicator of the 
intensity of degeneration of the brain (Blennow, 2017). On the other hand, there is 
evidence to suggest that CSF p-Tau levels may be an accurate biomarker to distinguish 
AD from other types of dementias (Hampel et al., 2004, Vanmechelen et al., 2000, 
Buerger et al., 2002). Moreover, Tau PET imaging studies have shown that the regional 
distribution of p-Tau can be an accurate predictor of cognitive decline and also a good 
correlate of neurofibrillary tau pathology (Schwarz et al., 2016, Scholl et al., 2016). 
Therefore p-Tau levels and distribution are considered useful biomarkers for the 
progression of AD-related pathology (Masters et al., 2015). Overall, the mounting 
evidence from biomarker studies suggests that the “AD profile” of CSF biomarkers is low 




increases the sensitivity and accuracy of an AD diagnosis (Maddalena et al., 2003, 
Palmqvist et al., 2015, Dubois et al., 2014). The discovery of the preclinical phase of AD 
and biomarkers to identify it is of great importance since this period is when disease-
modifying treatments may be most effective. Furthermore, finding accurate and specific 
biomarkers for the early diagnosis of AD is crucial for correctly identifying preclinical and 
asymptomatic patients with AD to be included in clinical trials. However, since CSF 
sample collection involves an invasive procedure and the costs of PET are high, the 
detection of biomarkers in blood samples would be preferable for routine diagnosis of 
preclinical stage AD. Research into such biomarkers is underway and promising 
(Nakamura et al., 2018). 
 
1.4 Genetic basis and risk factors of AD 
It is becoming increasingly evident that the neurodegenerative process of AD involves an 
interplay of multiple risk genes and factors, some of which converge on the regulation 
and functions of Aß and tau. There are two types of AD: the rare (2-5% of AD cases) form 
called familial AD (fAD; or early-onset AD) and the more common form known as 
sporadic AD (sAD; or late-onset AD). The fAD form is inherited in an autosomal dominant 
manner and manifests symptomatically before the age of 65 years. Conversely, no 
causal mutations have been associated with sAD, which develops much later in life, 
typically after 65 years of age. However, this form also has a strong genetic component, 
with a heritability of up to 80% (Gatz et al., 2006).  
 
SAD is genetically complex, with over 21 risk genes identified (see Figure 1-2) so far by 
genome wide association studies (GWAS) (Karch and Goate, 2015). The main genetic 
determinants of AD risk are the polymorphic alleles (ε2, ε3 and ε4) of the APOE gene 
encoding the apolipoprotein E protein (referred to hereafter as apoE), located on 
chromosome 19q13. Genetic analysis identified the ε4 allele of APOE as the strongest 
genetic risk factor for sAD and it is estimated to account for up to 30% of the disease 
heritability of sAD cases (Corder et al., 1993, Chartier-Hariln et al., 1994). In fact, the risk 
for AD is estimated to be three-fold for heterozygous carriers of the ε4 allele, whilst 




al., 2016). In addition, APOE4 has a gene-dose effect on reducing the age of disease 
onset. Contrastingly, the ε2 variant was found to be associated with a decreased risk for 
AD and to delay the age of onset for the disorder (Chartier-Hariln et al., 1994, Corder et 
al., 1994), indicating that it confers a neuroprotective effect. Non-genetic risk factors 
have also been associated with sAD, which include aging, poor education attainment, 
lack of physical exercise, and vascular diseases, amongst others (Sando et al., 2008, 
Baumgart et al., 2015, Xu et al., 2015b). 
 
 
Figure 1-2 Graph showing the frequency and risk level of risk loci in Alzheimer’s Disease 
GWAS and meta analysis studies have identified polymorphisms in 21 genes to be associated with 
increased risk for AD. The frequency of these gene variants in the population vary from rare (<3%) such 
as those in ADAM10 to being more common (>20%) such as those in CLU. In addition, they confer 
different levels of risk that can also be gene-dose dependent. For instance, two copies of the APOE4 
gene confers the greatest level of risk for AD, whilst one copy decreases the risk. Nonetheless, the 
APOE4 gene remains the strongest genetic risk factor for AD so far. Image taken from (Karch and Goate, 
2015). 
 
Furthermore, causal and rare risk mutations in genes encoding Presenilin 1 (PSEN1; on 
chromosome 14), Presenilin 2 (PSEN2; on chromosome 1) and the Amyloid Precursor 
Protein (APP; on chromosome 21) have been identified in people with fAD and sAD 




mutations have been found in these genes (see database: 
http://www.molgen.ua.ac.be/ADMutations), with mutations in the PSEN1 gene being 
the most common and severe. Duplication of APP has also been found to cause fAD 
(Rovelet-Lecrux et al., 2006, Sleegers et al., 2006). Ultimately, mutations in these genes 
either alter the proteolytic processing of APP in favour of longer forms of the Aß 
peptide, or lead to increased levels of Aß produced such as in the case of APP 
duplication. These findings in conjunction with the observation of Aß deposits in post-
mortem brains from individuals with by fAD or sAD established Aß as a key player in the 
pathogenesis of AD. 
 
1.5 Aß in AD 
1.5.1 Proteolysis of APP: Generation of the Aß peptide 
APP was identified as the precursor protein to Aß in 1987 following cloning of the APP 
gene (Kang et al., 1987). Full length APP is a type 1 integral membrane protein which has 
a large extracellular domain, a transmembrane domain and a short cytoplasmic domain.  
This protein structure is conserved amongst the three major splice variants of APP that 
are generated by alternative splicing of exons 7 and 8: APP770, APP751 and APP695 
(Nalivaeva and Turner, 2013). Whilst APP770 and APP751 are expressed in many cell 
types, APP695 is predominantly expressed by neurons in the central nervous system 
(CNS) (Kang and Muller-Hill, 1990, Rohan de Silva et al., 1997). Once synthesised in the 
endoplasmic reticulum (ER), APP undergoes sequential proteolytic processing by various 
secretases. Multiple processing pathways have recently been described for APP (Andrew 
et al., 2016), however the most established are the non-amyloidogenic and 
amyloidogenic pathways (Aß forming), which are summarised in Figure 1-3. Notably, a 
Kunitz protease inhibitory (KPI) motif found in the APP751 and APP770 but not APP695, 
is thought to promote amyloidogenic processing of APP (Ho et al., 1996). The 
amyloidogenic and non-amyloidogenic pathways are distinguished by the initial 
secretase action, which leads to the generation of different proteolytic cleavage 
products. APP is predominately processed by the non-amyloidogenic pathway, which is 
initiated by -secretase mediated cleavage of APP within the Aß domain at the cell 




extracellular space and a membrane-bound carboxyl fragment (CTF). There is evidence 
to suggest that the major -secretase is ADAM10, a zinc metalloprotease, since RNAi 
knockdown or mutation of this protein significantly reduced the generation of sAPP, 
whilst overexpression of ADAM10 increased it (Kuhn et al., 2010, Lammich et al., 1999). 
The CTF fragment then undergoes cleavage by the γ-secretase complex at the cell 
surface or in the endosomal/lysosomal pathway following its internalisation (Nordstedt 
et al., 1993), liberating a 3kDa fragment termed p3 (Haass et al., 1993) and the APP 
intracellular domain (AICD). In the amyloidogenic pathway, APP is initially cleaved by ß-
secretase (BACE1) within the N-terminal domain at the cell surface, or more commonly, 
in the endosomal pathway (Nordstedt et al., 1993, Kinoshita et al., 2003). This generates 
a smaller N-terminal fragment (sAPPß) and a membrane-anchored C-terminal fragment 
(CTFß) containing an intact Aß domain. CTFß is also cleaved by the γ-secretase complex, 
generating the AICD fragment and the Aß peptide, which can vary in length due to 
variable sequential γ-secretase activity along the C-terminus of the peptide (Zhao et al., 
2007). The predominant Aß variant produced under physiological conditions is 40 aa in 
length (Aß40), and is found in abundance in the CSF, whereas the levels of the longer 
variants are much lower (Tamaoka, 1998). 
 
The γ-secretase complex contains four subunits: Presenilin (PS; comprising either PSEN1 
or PSEN2), nicastrin, anterior defective pharynx 1 (APH-1) and presenilin enhancer 2 
(PEN-2) (De Strooper, 2003, De Strooper et al., 2012). PSEN1 and PSEN2 are thought to 
form the catalytic component of the γ-secretase complex, as partly based on the 
discovery that fAD-causative mutations in the PSEN1 and PSEN2 lead to increased 
generation of Aß peptides that are 42aa in length (Aß42 variant) (Borchelt et al., 1996, 
Lemere et al., 1996, Xia et al., 1997). The notion that PSEN1 has γ-secretase activity was 
further supported by later studies showing that deficiency or mutagenesis of PSEN1 was 
associated with an accumulation of carboxyl-terminal fragments of APP and a decrease 
in Aß production (De Strooper et al., 1998, Wolfe et al., 1999). From this evidence, it was 
proposed that mutations in PSEN1 alter its ability to trim the Aß peptide due to reduced 
structural stability of the complex resulting in the release of longer (>40aa) Aß peptides, 




APP metabolites in AD pathology cannot be discounted, the discovery that Aß peptides 
with longer C-termini such as Aß42 aggregate more readily to form plaques (Jarrett et al., 
1993), further supported the notion that accumulation of Aß42 may play a pivotal role in 
AD. Collectively, these findings gave rise to the Aß cascade hypothesis, initially proposed 
by Selkoe, Hardy and fellow co-workers (Selkoe, 1991, Hardy and Allsop, 1991, Hardy 
and Higgins, 1992). 
 
 
Figure 1-3 APP Processing and Aß generation 
APP can be processed through two different pathways, the amyloidogenic and non-amyloidogenic 
pathway. The former leads to the generation of the neurotoxic peptide, Aß, implicated in the pathology of 
AD. The pathways are distinguished by the initial secretase action. The amyloidogenic pathway is initiated 
by the proteolytic action of ß-secretase, producing a 99 amino acid C-terminal fragment (CTFß) and a 
secreted fragment (sAPPß). The non-amyloidogenic pathway is instead initiated by -secretase cleavage 
of APP within the Aß domain, thus precluding subsequent generation of Aß.  A smaller C-terminal 
fragment (CTF) is subsequently produced along with sAPP which is also secreted. The C-terminal 
fragment is cleaved by -secretase in both types of processing, however cleavage of CTFß results in the 
generation of Aß, whilst cleavage of CTF leads to the generation of small fragment termed p3. Longer 
variants of Aß peptides (Aß peptides 42aa in length or more) have a high propensity to aggregate and as 






1.5.2 The Aß cascade hypothesis: a central role for soluble Aß42 oligomers 
The Aß cascade hypothesis which posits a central role for Aß42 in the pathogenesis of 
AD, is still one of the main working models for AD today. In the original hypothesis, the 
accumulation of Aß42 and its subsequent deposition as plaques was considered the 
initial trigger for a sequence of toxic events that results in neuronal death and ultimately 
AD. This was largely founded upon the histopathological observations of Aß plaques and 
the finding that fAD-causal mutations promote the production of Aß42. However, 
studies emerged showing that the soluble, oligomeric forms of Aß are a better correlate 
of cognitive decline than plaque densities (McLean et al., 1999, Naslund et al., 2000). In 
addition, soluble Aß oligomers were found to be more toxic to neurons than plaques 
(Pike et al., 1991, Pike et al., 1993), thus indicating a more causal role for this form of the 
peptide in AD. Subsequently, the Aß cascade hypothesis was reformed to incorporate 
the accumulation of soluble Aß42 oligomers as a primary driver of AD pathology 
(summarised in Figure 1-4). This updated hypothesis has been further supported by the 
recent identification of a protective missense mutation (A673T) within the Aß region of 
the APP gene (Jonsson et al., 2012), which has been found to decrease the 
amyloidogenic processing of APP (Aß forming pathway) and the ability of the Aß42 





Figure 1-4 Modified Aß cascade hypothesis showing the sequence of neuropathological events in AD 
The Aß cascade hypothesis proposes a central role for the progressive accumulation and aggregation of 
Aß in AD pathology. Dominantly inherited forms of AD typically involve altered proteolytic processing of 
APP, leading to an increased production of the toxic Aß42 peptide throughout life. Non-dominant forms 
of AD likely involve a combination of genetic, environmental and lifestyle risk factors that contribute to 
an imbalance between the production and clearance of Aß42. As a result, Aß42 levels gradually rise in 
in this form of AD, leading to a later age of onset compared to fAD. The accumulation and aggregation 
of Aß42 in the brain induces synaptic dysfunction, which may partly underlie the manifestation of 
cognitive deficits in the early stages of AD. In addition, Aß42 oligomers may mediate the deregulation 
of tau, leading to its hyperphosphorylation and oligomerisation, but also the formation of NFTs in later 
stages of AD. Pathological tau may also contribute to synaptic dysfunction. Aß42 oligomers and 
pathological tau synergistically trigger reactive gliosis, neuroinflammation and neuronal dysfunction, 




1.5.2.1 Evidence for Aß42 accumulation in sAD 
Whilst the causal mutations underlying fAD provide a clear mechanism for the 
accumulation of Aß42 in this type of dementia, the basis for this in sAD is not so clear. 
However, it is thought that the accumulation of Aß42 in sAD likely involves defective 
clearance and catabolism of the peptide (Selkoe and Hardy, 2016, Mawuenyega et al., 
2010). Aß is normally cleared from the brain by crossing the blood brain barrier (BBB) via 
interactions with receptors on endothelial cells of the BBB, such as low-density 
lipoprotein receptor (LDLR) family members (Bell et al., 2007, Kang et al., 2000, Shibata 
et al., 2000, Deane et al., 2004). LDLR family members are widely recognised as cell 
surface endocytic receptors that, when expressed by endothelial cells of the BBB, 
mediate transcytosis (Dehouck et al., 1997, Spuch et al., 2012). Several factors which can 
interfere with the clearance of Aß at the BBB in AD have been identified. For instance, 
variation in the genotype of the low-density lipoprotein receptor-related protein (LRP1), 
which belongs to the LDLR family, has been implicated in AD by genetics studies (Kang et 
al., 1997, Baum et al., 1998, Hollenbach et al., 1998, Lambert et al., 1998a, Wavrant-
DeVrieze et al., 1999). These studies showed that polymorphisms within exon 3 and 
exon 6 of the gene are associated with increased risk for AD. Although the functional 
implications of the different LRP1 genotypes in AD are yet to be fully addressed, a recent 
amyloid-based PET study of patients with AD revealed that the polymorphism in exon 3 
was associated with increased Aß load and deposition (Grimmer et al., 2014), thus 
providing more direct evidence for an effect of LRP1 genotype on Aß clearance. 
Additionally, a decrease in LRP1 levels has been observed in brain microvessels of aged 
mice, AD transgenic mice and in post-mortem brains of AD patients (Shibata et al., 2000, 
Deane et al., 2004), indicating that Aß accumulation in AD could also involve reduced 
LRP1-mediated transcytosis of Aß at the BBB due to less cell surface LRP1. 
 
Interestingly, a few LRP1 ligands such as -2-macroglobulin (-2M) and apoE which are 
genetically associated with AD (Blacker et al., 1998, Saunders et al., 2003, Corder et al., 
1993, Chartier-Hariln et al., 1994), have also been identified as interacting partners of Aß 
(Hughes et al., 1998, Du et al., 1997, Strittmatter et al., 1993, LaDu et al., 1994). In 




increased Aß load in human AD brains (Myllykangas et al., 1999, Walker et al., 2000, 
Grimmer et al., 2010, Drzezga et al., 2009), raising the prospect that these variants 
increase risk for AD by adversely affecting Aß clearance. Interestingly, it has been 
hypothesised that the risk-associated polymorphism in -2M (deletion within the 
polypyrimidine tract of intron 17) may promote the production of truncated -2M 
protein that can still bind to Aß, but cannot be endocytosed via LRP1 (Kovacs, 2000). 
Although this remains to be confirmed, this would prevent transcytosis of Aß at the BBB 
and thus reduce clearance of Aß. On the other hand, the effect of apoE isoform on Aß 
clearance has been more extensively investigated. Earlier studies revealed that apoE2 
and apoE3 bind Aß more efficiently than apoE4 (LaDu et al., 1994, Yang et al., 1997, 
Aleshkov et al., 1997), indicating that apoE4 may confer risk for AD due to being an 
ineffective chaperone for Aß removal from the brain. Interestingly, it has also been 
proposed that apoE isoforms may differentially influence clearance of Aß at the BBB due 
to differing affinity of apoE isoforms for either LRP1 or very-low density lipoprotein 
receptor (VLDLR)(Deane et al., 2008). This is based upon evidence from an in vivo 
clearance study using receptor-specific antibodies to inhibit receptor function, which 
found that Aß-apoE4 complexes were cleared from the brain primarily via interaction 
with VLDLR at a slower rate, whereas Aß and apoE2 or apoE3 complexes underwent 
rapid clearance by both LRP1 and VLDLR (Deane et al., 2008). Other in vivo studies have 
also demonstrated that Aß clearance is isoform dependent (apoE2>apoE3>apoE4) 
(Castellano et al., 2011, Bales et al., 2009). These findings suggest that the isoform-
specific effect of apoE on Aß clearance may contribute to the differential effect that 
these isoforms have on AD risk, and further support that reduced Aß clearance plays a 
role in sAD pathophysiology. 
 
Aß catabolism has been shown to be partly mediated by neprilysin (NEP) and insulin-
degrading enzyme (IDE) in vivo (Iwata et al., 2001, Newell et al., 2003, Marr et al., 2003, 
Farris et al., 2003). Interestingly, a reduction in the levels and activities of NEP and IDE 
has been observed in ageing and AD human brains (Caccamo et al., 2005, Maruyama et 
al., 2005, Carpentier et al., 2002, Morelli et al., 2004), indicating that Aß catabolism may 




accumulation of Aß in AD, alongside many of the aforementioned factors contributing to 
defective clearance of the peptide. 
 
There is also evidence to suggest that accumulation of Aß in sAD may involve increased 
production of Aß due to a combination of risk factors affecting APP expression and 
metabolism (Menendez-Gonzalez et al., 2005). For instance, analysis of APP protein and 
mRNA levels in AD brains revealed that the there is an increase in the levels of KPI-
containing APP variants (APP751 and APP770) relative to APP695 (Preece et al., 2004, 
Moir et al., 1998, Johnson et al., 1990), which has also been found to correlate with 
increased Aß deposition (Johnson et al., 1990). These results imply that dysregulation of 
APP splicing may contribute to the pathogenesis of AD. In addition, it has been 
suggested that Aß levels may increase in sAD as a result of apoE stimulating APP 
transcription in neurons through receptor mediated ERK1/2 MAPK signalling (Huang et 
al., 2017). This was demonstrated by using ES-cell-derived human neurons treated with 
apoE secreted from glia (Huang et al., 2017). Interestingly, this effect was shown to 
occur in an isoform-dependent manner too (apoE4>apoE3>apoE2), indicating that apoE 
isoforms may also influence AD risk through altering APP expression. Collectively, the 
many factors that can lead to an imbalance between Aß production and clearance 
clearly support a pivotal role for Aß accumulation in sAD too. 
 
1.5.2.2 Neurotoxic properties of Aß42 oligomers 
It is well established that soluble Aß42 oligomers have neurotoxic properties (Walsh and 
Selkoe, 2007). This is supported by several studies showing that soluble Aß42 oligomers 
reduce neuronal viability and induce neuronal death in vitro (Hoshi et al., 2003, 
Deshpande et al., 2006, Dahlgren et al., 2002, Zhang et al., 2002, Pike et al., 1991, Pike 
et al., 1993). Moreover, Aß42 oligomers have been reported to induce memory 
impairment, cognitive deficits and synaptic dysfunction in AD-transgenic mice producing 
high levels  of Aß42 (Westerman et al., 2002, Lesne et al., 2006, Oddo et al., 2003, 
Jacobsen et al., 2006), as well as in young wild-type (WT) mice injected with Aß42 
oligomers isolated from AD-transgenic mice (Lesne et al., 2006). However, it is 




range from reversible dysfunction of various cellular processes to neuronal death (Walsh 
and Selkoe, 2007). Numerous studies have since revealed that the toxic effects of Aß42 
oligomers in AD may be mediated by a variety of mechanisms such as mitochondrial 
dysfunction, cytoskeletal defects, oxidative stress, inflammation, membrane alterations 
and synaptic dysfunction (Carrillo-mora et al., 2014). Notably, Aß42 oligomers have been 
linked to the deregulation of tau, a key microtubule-associated protein that when 
hyperphosphorylated, forms the characteristic NFTs in AD. For example, soluble Aß 
oligomers isolated from the cortices of AD subjects were found to induce 
hyperphosphorylation of tau at AD-relevant epitopes in rodent hippocampal neuronal 
cultures (Jin et al., 2011, De Felice et al., 2008), leading to microtubule network 
dysfunction and neuritic dystrophy (Jin et al., 2011). Similar effects on tau 
phosphorylation were also observed from application of synthetic Aß42 oligomers to 
rodent hippocampal neurons and B103 neuroblastoma cells (Zempel et al., 2010, De 
Felice et al., 2008). Accumulation of Aß oligomers has also been demonstrated to induce 
tau hyperphosphorylation and NFT formation in AD-transgenic mice (APPOSK/tau-Tg 
mice) harbouring transgenes for WT human tau and a mutant form of APP (Osaka 
mutation E693∆) (Umeda et al., 2014). Importantly, because the Osaka mutation E693∆ 
prevents the formation of Aß plaques, the results in the study by Umeda and co-workers 
suggest that the effect was due to the oligomeric form of Aß (Umeda et al., 2014). 
Collectively, these findings provide compelling evidence for Aß oligomers as a mediator 
of tau pathology, and further support the concept that Aß42 oligomers are a key toxic 
agent that may act upstream of tau during the early stages of AD. 
 
1.5.3 Aß and synaptic dysfunction 
Although there is a growing body of literature revealing more mechanisms for Aß42-
mediated toxicity in AD, the effect of Aß on synaptic dysfunction remains an attractive 
aspect to explore since it is one of the earliest defects in AD. Loss of synaptic contacts in 
the neocortex and hippocampus is another well-established neuropathological 
characteristic of AD and there are reports showing that it is a strong correlate of 
cognitive decline and memory deficits in AD (Davies et al., 1987, Terry et al., 1991, 




in the total number of synapses are apparent in post-mortem brain tissue from human 
subjects with early AD/MCI and greater losses in synapse number are observed at the 
mild AD stage (Scheff et al., 2006, Scheff et al., 2007). Taken together, these findings 
support the notion that synapse loss is a very early event in AD that worsens as the 
disease progresses, resulting in the characteristic gradual cognitive decline. Although the 
mechanisms underpinning synaptic dysfunction and loss in AD are still not fully 
understood, there is mounting evidence supporting the involvement of Aß42 oligomers 
(Mucke and Selkoe, 2012). For instance, accumulation of Aß oligomers in AD-transgenic 
mice has been shown by immunostaining for synaptic markers, to correlate with a 
reduction in synapse number and this was found to be independent of Aß plaque 
formation (Mucke et al., 2000, Umeda et al., 2014, Tomiyama et al., 2010, Hsia et al., 
1999). In addition, behavioural tests for spatial memory showed that intraneuronal Aß 
accumulation and synapse loss are also associated with a concomitant decline in 
cognitive function and memory in vivo (Tomiyama et al., 2010, Umeda et al., 2014), thus 
revealing a relationship between the synaptic changes mediated by Aß and the 
symptomatic characteristics of AD.  
 
1.5.4 Aß oligomers affect synaptic transmission and plasticity  
Electrophysiology experiments have provided further information for the role of Aß at 
the synapse by showing that Aß oligomers can impair synaptic plasticity, an important 
process underlying learning and memory that involves a balance between long term 
potentiation (LTP) and long term depression (LTD). Indeed, accumulation of Aß 
oligomers has been linked to impairment of LTP in the CA1 region of the hippocampus in 
AD-transgenic mice (Oddo et al., 2003, Tomiyama et al., 2010). Similarly, synthetic and 
cell-derived Aß oligomers has been shown to inhibit LTP in the hippocampus of WT 
rodents following cerebral microinjection of the peptide (Walsh et al., 2002, Walsh et al., 
2005, Klyubin et al., 2005) and in rat hippocampal slices exposed to the peptide 
(Lambert et al., 1998b, Wang et al., 2002, Wang et al., 2004, Townsend et al., 2006). 
Hence there is considerable evidence to suggest that Aß oligomers may contribute to 
cognitive and memory deficits through disrupting synaptic plasticity. Intriguingly, a 




and concentration- dependent manner (Puzzo et al., 2008, Abramov et al., 2009, Parodi 
et al., 2010, Puzzo et al., 2011). For example, it was shown that picomolar 
concentrations of Aß oligomers induced LTP in hippocampal slices and improved 
performance in tests for memory in vivo, whereas nanomolar concentrations inhibited 
LTP and impaired memory function (Puzzo et al., 2008). These findings led to the notion 
that Aß may have a physiological role in regulating synaptic transmission that is 
disrupted in AD due to an imbalance of Aß levels (Mucke and Selkoe, 2012). 
 
1.5.5 Aß oligomers affect synaptic plasticity via pre- and post- synaptic mechanisms 
There is mounting evidence to suggest that Aß oligomers can inhibit LTP and facilitate 
LTD by affecting postsynaptic N-methly-D-aspartate receptors (NMDAR) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) (Mucke and Selkoe, 
2012, Koffie et al., 2011), which play a pivotal role in the induction of LTP or LTD at the 
postsynapse. In particular, synaptic NMDAR activation has important involvement in 
synaptic plasticity because it can trigger either LTP or LTD in response to strong or weak 
activation respectively, since this affects the levels of postsynaptic calcium influx and 
NMDAR-dependent signalling cascades (Hunt and Castillo, 2012, Luscher and Malenka, 
2012). A large increase in intracellular calcium from strong synaptic NMDAR activation 
induces NMDAR-dependent signalling that favours LTP, leading to recruitment of 
AMPARs and growth of dendritic spines (Lu et al., 2001, Toni et al., 1999). Conversely, a 
small increase in intracellular calcium from weak synaptic NMDAR activation induces 
NMDAR-dependent signalling that favours LTD (Harney et al., 2006, Cummings et al., 
1996), triggering shrinkage of dendritic spines and synaptic loss (Zhou et al., 2004, 
Shinoda et al., 2010). In addition, activation of extrasynaptic NMDARs by excess 
glutamate can also induce LTD (Liu et al., 2013). One explanation for the inhibition of 
LTP and induction of LTD by Aß oligomers has been suggested to involve a partial block 
in the activity of synaptic NMDARs and the subsequent induction of NMDAR-dependent 
LTD-related signalling (Shankar et al., 2007). This hypothesis was based on the finding 
that sustained exposure of rat hippocampal slices to Aß oligomers reduced NMDAR-
dependent postsynaptic calcium influx and induced loss of dendritic spines (Shankar et 




LTD by promoting endocytosis of NMDARs and AMPARs at the postsynaptic membrane 
(Snyder et al., 2005, Hsieh et al., 2006), and by enhancing activation of extrasynaptic 
NMDARs through disrupting glutamate uptake from the synaptic cleft (Li et al., 2009, Li 
et al., 2011). Taken together, these findings indicate that Aß oligomers affect synaptic 
plasticity and promote synapse loss by inhibiting NMDAR-dependent LTP-related 
signalling and promoting NMDAR-dependent LTD-related signalling at the postsynapse. 
 
There is also evidence to suggest that Aß may affect synaptic plasticity through 
modulating presynaptic mechanisms too. Several studies have demonstrated that brief 
application of Aß can positively modulate glutamatergic synaptic transmission at the 
presynaptic level by increasing the release probability of synaptic vesicles (SVs) (Puzzo et 
al., 2008, Abramov et al., 2009, Parodi et al., 2010, Puzzo et al., 2011, Brito-Moreira et 
al., 2011). A possible mechanism for this increase is believed to involve an Aß-induced 
elevation of intracellular calcium levels required for neurotransmitter release, either via 
altering the activity of α7-nicotinic acetylcholine receptors (nAChRs) (Puzzo et al., 2008) 
or by Aß oligomers forming calcium permeable pores in the synaptic membrane (Parodi 
et al., 2010, Sepulveda et al., 2010). On the other hand, it has also been shown that 
prolonged exposure of hippocampal slices to Aß oligomers impairs synaptic transmission 
by reducing the number of SVs near presynaptic active zones required for 
neurotransmitter release (Parodi et al., 2010). In consideration of this evidence, it is 
conceivable that enhancement of neurotransmitter release by low levels of Aß 
oligomers in the early stages of AD could inhibit LTP and promote LTD through 
desensitisation of NMDARs and activation of extrasynaptic NMDARs by increased 
glutamate at the synaptic cleft. In addition, it is also possible that chronic exposure and 
increasing levels of Aß oligomers in the later stages of AD disrupt the maintenance of 
SVs required for neurotransmitter release, which would ultimately lead to synaptic 
failure and loss. 
 
1.5.6 Aß oligomers disrupt the regulation of synaptic vesicle dynamics 
SVs are organised into three pools at the presynapse: (i) the readily releasable pool (RRP) 
which contains SVs docked at the active zone, some of which are primed for fusion with 




triggered calcium influx; (ii) the recycling pool which constitutes endocytosed SVs that 
replenish the RRP and contribute to neurotransmitter release upon moderate to strong 
stimulation; and (iii) the reserve pool which acts as a depot and supplies SVs for 
neurotransmitter release during intense stimulation (Rizzoli and Betz, 2005). As 
mentioned before, it has been reported that Aß can increase the release probability of 
the RRP and subsequently promote the release of glutamate into the synaptic cleft at 
low concentrations or when applied for short durations in vitro (Parodi et al., 2010, 
Russell et al., 2012, Park et al., 2013, Brito-Moreira et al., 2011). One possible 
mechanism for this effect has been suggested to involve increased priming of SVs in the 
RRP (Russell et al., 2012). In the study by Russell and co-workers, Aß42 was found to 
interact with synaptophysin, thereby disrupting the interaction between synaptophysin 
and VAMP2, two key SV-associated proteins involved in the regulation of SV priming 
(Russell et al., 2012). Since VAMP2 participates in the formation of the SNARE complex 
required to prime SVs for exocytosis (Edelmann et al., 1995), it was hypothesised that 
the interaction between intraneuronal Aß42 and synaptophysin would promote the 
availability of VAMP2 for SV priming and thus enhance neurotransmitter release. 
Consistent with this hypothesis, FM dye labelling experiments have shown that acute 
exposure of neurons to Aß oligomers increases exocytosis of the RRP (Russell et al., 2012, 
Parodi et al., 2010). These findings suggest that the early enhancement of presynaptic 
activity and induction of LTP by Aß oligomers may involve increasing SV release by 
modulating the function of key SV-associated proteins that regulate this process. 
 
On the other hand, chronic exposure (2 hours or more) and/or high concentrations of Aß 
oligomers has been associated with reduced SV release and defective SV recycling in 
neurons (Parodi et al., 2010). Indeed, electron micrographs of synapses from neurons 
exposed to Aß for a prolonged duration revealed a significant reduction in the number 
of SVs at the presynapse, particularly near active zones, and also signs of incomplete SV 
endocytosis (Parodi et al., 2010, Kelly and Ferreira, 2007). This is consistent with FM dye 
labelling experiments showing a slower rate of endocytosis in neurons exposed to Aß 
oligomers (Parodi et al., 2010, Kelly and Ferreira, 2007, Park et al., 2013). In view of 




endocytosis since this step is required to replenish the recycling pool and thus the RRP. 
It is feasible that the subsequent reduction in the RRP and SV release could be a 
significant contributing factor to LTP inhibition and LTD induction associated with 
chronic exposure of neurons to high levels of Aß oligomers, since reduced glutamate 
release would weaken postsynaptic NMDAR activation. Although the molecular basis for 
this is still poorly understood, there is evidence to suggest that the impairment in 
endocytosis may be partly mediated through a reduction in the levels of dynamin 1, a 
GTPase protein that aids endocytosis by pinching off SVs at the plasma membrane for SV 
recycling (Damke et al., 1994). Indeed, a reduction in the levels of dynamin I has been 
observed in cultured hippocampal neurons exposed to Aß oligomers for a prolonged 
duration, but also in brain tissue of human AD subjects and AD-transgenic mice (Yao et 
al., 2003, Kelly et al., 2005, Kelly and Ferreira, 2006b). There is also evidence to suggest 
that Aß oligomers promote the proteolytic degradation of dynamin I by inducing the 
activation of a protease called calpain through sustained calcium influx (Kelly and 
Ferreira, 2006a). Collectively these findings suggest that Aß oligomers impair SV 
endocytosis and recycling through altering calcium-dependent signalling cascades that 
regulate key SV-associated proteins such as dynamin I. 
 
Taken together, these studies reveal that accumulation of Aß oligomers may cause an 
imbalance between exocytosis and endocytosis, which could lead to the reported 
depletion of SVs and synaptic failure. These studies also highlight that the Aß disrupts 
many aspects of the SV cycle, raising the possibility that there may be other proteins 
involved in SV dynamics that are affected by Aß accumulation. Indeed, loss of other 
synaptic proteins in Aß-treated neuronal cultures and in brain tissue from human AD 
subjects has been documented (Parodi et al., 2010, Masliah et al., 2001, Sze et al., 2000). 
As such, targeting SV dynamics is starting to be considered an attractive therapeutic 
area (Li and Kavalali, 2017, Ovsepian et al., 2018, Marsh and Alifragis, 2018) and further 
research into elucidating other SV-associated proteins affected by Aß oligomers is a 
growing area of interest. In this thesis, evidence is presented indicating that Aß 





1.6 Apolipoprotein E in AD 
1.6.1 The apoE gene and protein 
The APOE gene, located on chromosome 19, is composed of four exons that are 
separated by three introns (shown in Figure 1-5). Exon 1 and a portion of exon 2 
contains 5’ untranslated sequence, whilst the remainder of exon 2 and exons 3-4 
contain the translated sequence. Two (C/T) single nucleotide polymorphisms (SNPs) 
within exon 4 of APOE give rise to the three main allelic variants: epsilon-2 (ε2), epsilon-
3 (ε3), and epsilon-4 (ε4) (described in Figure 1-6). Although the frequency of APOE 
alleles varies considerably amongst populations, the ε3 allele is typically the most 
common, followed by ε4 and ε2 (Gaugler et al., 2016). The three major protein isoforms 
produced from these alleles differ at residues 112 and/or 158 as follows: apoE2 (Cys112, 
Cys158), apoE3 (Cys112, Arg158) and apoE4 (Arg112, Arg158).  
 
 
Figure 1-5 APOE gene and polymorphisms encoding apoE2, apoE3 and apoE4 
The APOE gene contains four exons (boxes) that are separated by three introns. The 5’ and 3’ 
untranslated sequence regions are shown in grey, whereas the coding sequence regions are coloured 
blue. The SNPs which distinguish the three apoE isoforms are located within exon 4 and are listed in the 
table below the gene schematic. 
 
ApoE is expressed as a 317aa protein containing an 18aa N-terminal signal peptide, 
which facilitates the transfer of nascent apoE to the rough endoplasmic reticulum (RER). 




modifications (PTMs) to form a 299aa glycoprotein of approximately 34kDa (Reardon et 
al., 1984, Zannis et al., 1984). ApoE protein has two structural domains which are 
separated by a hinge region (shown in Figure 1-6) (Wetterau et al., 1988). The N-
terminal domain spans residues 1-191 and the C-terminal domain contains residues 225-
299. The N-terminal domain is composed of four -helices arranged in an anti-parallel 
bundle and contains the receptor-binding region (136-150aa) for LDLR and LRP within 
the fourth helix (Wilson et al., 1991, Innerarity et al., 1983, Lalazar et al., 1988). The C-
terminal domain has an amphipathic -helix structure and contains the lipid-binding 
region (244-272aa), which enables its interaction with lipoproteins (Rall et al., 1982, 
Westerlund and Weisgraber, 1993, Dong et al., 1994, Dong and Weisgraber, 1996). 
There are also two heparin binding sites, one located within the receptor-binding region 
and the other within the lipid binding region (Weisgraber et al., 1986, Mahley et al., 
1979, Saito et al., 2003). Whilst these structural domains are present in all three 
isoforms, there is evidence to suggest that the tertiary structure differs between them 
due to isoform-specific domain-domain interactions (Hatters et al., 2006, Frieden and 
Garai, 2013). Early X-ray crystallography and site-directed mutagenesis experiments 
comparing apoE4 and apoE3 showed that presence of Arg112 in apoE4 altered the 
positioning of the Arg61 side chain in helix 2, subsequently enabling it to form a salt 
bridge with Glu255 in the C-terminus (Dong et al., 1994, Dong and Weisgraber, 1996). 
Thus, this salt bridge was hypothesised to facilitate an inter-domain interaction in apoE4 
that affects the orientation and/or exposure of the lipid-binding region, which was 
suggested not to occur in apoE3 or apoE2 due to the presence of a cysteine at position 
112 (Mahley, 2016b). Fluorescence resonance energy transfer (FRET) studies support 
this structural model, showing that the N- and C-terminal domains were within closer 
proximity in apoE4 than in apoE3 (Hatters et al., 2005, Xu et al., 2004). Moreover, 
mutagenesis of Arg61 to threonine or Glu255 to alanine in apoE4 was found to abolish 
FRET (Xu et al., 2004), providing further evidence for a salt bridge between these two 
residues being essential for domain interaction. However, more recent structural studies 
were unable to confirm the presence of the salt bridge between Arg61 and Glu255 in 
apoE4 (Williams et al., 2015) and have also demonstrated that domain-domain 




between helix 3 and 4 of the N-terminus with the C-terminus (Chen et al., 2011b). An 
alternative model of isoform-specific domain-domain interaction in apoE has also been 
recently proposed (Frieden and Garai, 2013). In this model, the positive charge of 
Arg112 in helix 3 of apoE4 was suggested to be propagated to His140 of helix 4 via 
altering the movement of Arg114, resulting in alterations of the charge distribution of 
helix 4 and thus modifying interactions between helix 4 of the N-terminus and the C-
terminus (Frieden and Garai, 2012). Interestingly, a recent a molecular dynamics 
simulation study modelling apoE structure showed that mutating Cys112 to Arginine in 
apoE3 (i.e. converting to apoE4) produced a different distribution of charges in helix 4 
(Williams et al., 2015), supporting the model proposed by Frieden and Garai. Although 
these conflicting data show that the isoform-specific structures of apoE are yet to be 
resolved, they still support the notion that the polymorphisms cause structural 
differences between the isoforms, which may be responsible for the differences in their 
function and by extension, their risk for AD. Indeed, many apoE isoform-dependent 
effects have been reported and include differences in metabolism of lipids and 
cholesterol, metabolism of Aß, neuronal/synaptic growth and maintenance, regulation 
of the inflammation process and neuronal viability and survival (Rebeck, 2017, Mahley, 






Figure 1-6 ApoE protein structure and isoform-specific protein domain-domain interactions 
(A) A linear diagram of the three structural domains of human apolipoprotein E (apoE), which is 
composed of 299 amino acids. The two polymorphic residues that characterize the three isoforms are 
located at positions 112 and 158 within the N-terminal domain. (B) Structural models of the three apoE 
isoforms in the lipid-free state. ApoE3 and apoE4 form a salt bridge between Arg158 and Asp154. 
However, in apoE2, a salt bridge is formed between Arg150 located in the LDLR-binding region and 
Asp154. In addition, the N- and C-terminal domains interact in apoE4, whereas this occurs to a lesser 
extent in apoE2 and apoE3. This interaction is facilitated by the association of the Arg61 side chain, 
which is oriented into the aqeous environment due to Arg112, with Glu255. Cys112, found in both 
apoE2 and apoE3, results in a different conformation of Arg61, which has a reduced affinity for domain 





1.6.2 The role of apoE in phospholipid and cholesterol metabolism in AD 
ApoE plays a critical role in the transport and metabolism of lipids and cholesterol in the 
central nervous system (CNS) as well as in the peripheral circulation. However, the 
source of apoE and cholesterol is distinct in these two systems since the BBB prevents 
apoE in the circulatory system from crossing into the CNS (Liu et al., 2012, Dietschy, 
2009). Hence apoE and cholesterol in the brain are synthesised locally, predominately by 
glial cells.  In the CNS, apoE is the major apolipoprotein and is primarily expressed by 
astrocytes to form lipid poor high density lipoprotein (HDL)-like particles upon its 
secretion and lipidation by ATP- binding cassette transporters (ABC) such as ABCA1 
(LaDu et al., 1998, Pitas et al., 1987, Boyles et al., 1985). The HDL-like lipoprotein 
particles have a discoidal shape and are predominately composed of phospholipid and 
unesterified cholesterol, although they can gain cholesteryl esters and become spherical 
on route to the CSF (LaDu et al., 1998). This indicates that HDL-like lipoprotein particles 
are involved in the trafficking of cholesterol and lipids to neurons and glial cells, but also 
in the clearance of excess cholesterol from the brain. Although neurons can synthesise 
cholesterol, they are mostly reliant on cholesterol produced by astrocytes (Nieweg et al., 
2009, Pfrieger, 2003). Cholesterol uptake occurs upon endocytosis of the HDL-like 
lipoprotein particles, which is facilitated by apoE-mediated interaction with members of 
the LDLR family present on the surface of neuronal membranes (Pfrieger, 2003). This 
process ensures that neurons have sufficient levels of cholesterol and is essential for a 
variety of functions such as synaptogenesis, axonal growth, neuronal maintenance and 
neuronal repair following injury (Mauch et al., 2001, Posse De Chaves et al., 2000, 
Ignatius et al., 1986, White et al., 2001). In view of this, it is conceivable that defective 
distribution of cholesterol could contribute to AD pathology. Interestingly, there is 
evidence to suggest that this may be a possible mechanism for how apoE4 confers risk 
for AD. Studies have shown that secreted apoE3 associates with more phospholipid and 
cholesterol than apoE4 in primary cultured astrocytes from transgenic mice expressing 
human apoE3 or apoE4 (Gong et al., 2002), and also in apoE-transfected Neuro-2a (N2a) 
cells (Xu et al., 2004). Notably, the reduced phospholipid binding capacity of apoE4 was 
demonstrated to involve the domain-domain interaction mediated by the salt bridge 




at Arg61 to abolish this salt bridge, increased the phospholipid content associated with 
this isoform (Xu et al., 2004). As such, it was proposed that apoE3 secreted by astrocytes 
may promote the supply of cholesterol and phospholipids to neurons more efficiently 
than apoE4 secreted by astrocytes (Gong et al., 2002), and thus apoE4 may increase the 
risk for AD through reduced delivery of phospholipids and cholesterol to neurons. 
 
Removal of excess cholesterol in neurons is also an important process and this can occur 
through conversion of cholesterol into 24(S)-hydroxycholesterol, a more lipophilic 
metabolite that can cross the BBB and be excreted from the body (Lund et al., 2003, 
Russell et al., 2009), or through cholesterol efflux to lipid-poor apoE by ABCA1 
(Minagawa et al., 2009). There is evidence to suggest that cholesterol and lipid 
metabolism may be dysfunctional in AD, as cholesterol levels have been observed to 
increase in the AD-vulnerable brain regions in AD subjects in a manner associated with 
the clinical progression of the disease (Xiong et al., 2008, Cutler et al., 2004). It is notable 
that many factors could contribute to this such as defective cholesterol efflux by ABCA1, 
which has been observed in patients with MCI (Yassine et al., 2016). Indeed, several 
genes encoding proteins involved in cholesterol and lipid metabolism have been 
associated with increased risk for AD, including APOE and ABCA1 (Karch and Goate, 
2015). It is possible that the apoE4 variant may play a role in this by hindering removal 
of excess cholesterol, since studies have shown that apoE4 is less efficient at promoting 
cholesterol efflux than apoE3 and apoE2 (Michikawa et al., 2000, Minagawa et al., 2009). 
This isoform-specific effect on cholesterol efflux has also been attributed to the domain-
domain interaction of apoE4 as site-directed mutagenesis of Glu255 to alanine to 
abolish the Glu255-Arg61 salt bridge was shown to improve apoE4-associated 
cholesterol efflux (Minagawa et al., 2009). Whilst an imbalance in cholesterol levels may 
disrupt the aforementioned physiological neuronal functions, it has also been linked to 
Aß generation, thus providing an additional connection between apoE, cholesterol 
metabolism and Aß-driven AD pathology. It was shown that excess cholesterol in 
primary rodent neuronal cultures and N2a cell cultures increased the levels of Aß by 
promoting the amyloidogenic processing of APP (Marquer et al., 2011, Xiong et al., 




production due to cholesterol dyshomeostasis, in addition to disrupting neuronal 
functions dependent on regulated cholesterol levels. 
 
1.6.3 ApoE Influences Aß-driven AD pathology through multiple pathways 
There is increasing evidence showing that the apoE isoforms differentially affect Aß 
metabolism (Kanekiyo et al., 2014, Wildsmith et al., 2013, Potter and Wisniewski, 2012, 
Huynh et al., 2017), and thus affect the levels of Aß present in the brain, an established 
key factor in the pathogenesis of AD. As discussed previously, apoE isoforms have been 
shown to differentially affect the clearance of Aß (see section 1.5.2.1), such that apoE4 
is the least efficient isoform at clearing Aß from the brain. ApoE4 has also been 
associated with increased Aß generation compared to apoE3 by stimulating 
amyloidogenic processing of APP either through affecting cholesterol levels (see section 
1.6.2), LRP signalling (Ye et al., 2005), or increasing BACE1 levels (Dafnis et al., 2018). It 
has also been suggested that apoE isoforms can differentially affect the oligomerisation 
of Aß (Potter and Wisniewski, 2012, Huynh et al., 2017, Tai et al., 2014). Some in vitro 
studies have shown that apoE4 can promote the aggregation of Aß (Hashimoto et al., 
2012, Dafnis et al., 2018, Kang et al., 2015), whilst others have shown that apoE isoforms 
can differentially enhance (apoE4>apoE3>apoE2) the stabilsation of soluble 
intermediate species of Aß, such as the toxic oligomeric assemblies (Garai et al., 2014, 
Cerf et al., 2011, Ly et al., 2013, Hashimoto et al., 2012). In support of the latter effect, 
expression of human apoE4 in transgenic mouse models of AD such as PDAPP, Tg2576 
and 5xFAD mice has been reported to delay deposition of Aß as plaques  (Holtzman et 
al., 1999, Fryer et al., 2005, Youmans et al., 2012, Tai et al., 2011) and increase the levels 
of soluble Aß42, including oligomeric forms (Youmans et al., 2012, Bales et al., 2009). In 
agreement with these in vivo studies, the APOE4 genotype was found to be associated 
with increased levels of oligomeric Aß in post-mortem brain tissue of individuals with 
AD, when compared to those with an APOE3 genotype (Koffie et al., 2012, Tai et al., 
2013). Array tomography experiments have provided further information about the 
relationship between apoE isoform and Aß, by showing that an APOE4 genotype is 
associated with increased synaptic localisation of oligomeric Aß and enhanced synaptic 




genotype (Koffie et al., 2012). Interestingly, it was also shown that apoE4 co-localised 
with Aß oligomers to a greater degree than apoE3 at synapses in post-mortem human 
brains with AD, but also in primary neuronal cultures exposed to cell-derived Aß 
oligomers and lipidated apoE3 or apoE4. (Koffie et al., 2012). Hence Koffie and 
colleagues proposed that apoE4 may enhance the localisation of Aß oligomers at 
synapses by directly delivering the peptide. Taken together, these findings indicate that 
apoE4 drives Aß-related AD pathology (discussed in section 1.5.2.2) by promoting the 
accumulation of the toxic, oligomeric forms of Aß, through affecting the production, 
clearance, and aggregation of the peptide. Furthermore, they also suggest that apoE4 
may facilitate the early stages of AD pathology through trafficking of Aß oligomers to 
synapses and thus promoting Aß-induced synaptic dysfunction (see section 1.5.3). Hence 
the differential risk associated with each apoE isoform may be due to the different 
effects that they have on Aß metabolism. 
 
1.6.4 Intraneuronal apoE as a possible key driver of AD 
There is also increasing evidence to suggest that apoE4 (>apoE3) may induce toxicity 
independently of Aß when expressed in neurons (Huang, 2010, Huang, 2011, Mahley 
and Huang, 2012, Mahley, 2016a). Although apoE is normally synthesised by glial cells in 
the brain, studies have demonstrated that neurons can express apoE under conditions 
of stress. Indeed, kainic-acid induced excitotoxicity in rodents has been reported to 
stimulate the expression of apoE mRNA and protein in neurons, particularly those 
located in the hippocampus (Boschert et al., 1999, Xu et al., 2006b, Xu et al., 2008). 
Furthermore, increased levels of apoE protein and mRNA have been observed in 
hippocampal and cortical neurons in post-mortem brain tissue from individuals who 
suffered infarction (Aoki et al., 2003), or had AD (Han et al., 1994b, Bao et al., 1996, Xu 
et al., 1999). Considering that neurons express apoE in AD-vulnerable brain regions 
(Padurariu et al., 2012), it is plausible that intraneuronal apoE may play a role in AD and 
that this may also be isoform-dependent. In support of this, several studies have shown 
that transgenic mice expressing human apoE4 in neurons display age-dependent 
behavioural and memory impairments, synaptic defects and other pathologies 




transgenic mice mice expressing apoE3 in neurons do not (Raber et al., 1998, Tesseur et 
al., 2000b, Tesseur et al., 2000a, Harris et al., 2004, Brecht et al., 2004b). Whilst 
transgenic mice expressing human apoE isoforms in glial cells (Glial fibrillary acidic 
protein (GFAP)-apoE and apoE-knock in (KI) mice) have also been reported to show 
deficits in memory function and synaptic alterations in an isoform- (apoE4>apoE3) and 
age- dependent manner (Hartman et al., 2001, van Meer et al., 2007, Bour et al., 2008, 
Rodriguez et al., 2013), it is notable that they do not display other hallmarks of AD 
neuropathology as observed in transgenic mice expressing apoE4 in neurons (Hartman 
et al., 2001, Wang et al., 2005). This suggests that the cellular source of apoE, in addition 
to isoform, affects its role in AD. In agreement with this notion, expression of human 
apoE4 in astrocytes was shown to be protective against kainic-acid induced 
excitotoxicity in vivo (in GFAP-apoE4 mice), whereas human apoE4 expression in 
neurons (in Neuron specific enolase (NSE)-apoE4 mice) promoted neuronal death 
(Buttini et al., 2010). In contrast, expression of human apoE3 by either astrocytes in 
GFAP-apoE3 mice or neurons in NSE-apoE3 mice was shown to be excitoprotective 
(Buttini et al., 2010). Thus it was hypothesised that injured or stressed neurons may 
express apoE as part of a repair response mechanism, which in the case of apoE4 leads 
to a toxic gain of function instead (Huang, 2010, Huang, 2011, Mahley and Huang, 2012, 
Mahley, 2016a). Although the basis for this is still not fully understood, emerging 
evidence indicates that the isoform- and neuron- specific effects of apoE are linked to 
differential proteolytic processing of the protein (Mahley and Huang, 2012, Mahley, 
2016a). 
 
1.6.5 Role for differential proteolytic processing of apoE isoforms in AD pathology 
Western blotting studies have shown that apoE is fragmented to a greater extent in AD 
brains compared to control brains (Harris et al., 2003, Jones et al., 2011, Tamboli et al., 
2014, Koffie et al., 2012), raising the prospect of a role for apoE proteolysis in AD. 
Consistent with this notion, accumulation of Aß in AD-transgenic mouse models was 
found to be associated with elevated levels of murine apoE fragments (Saul and Wirths, 
2016). Moreover, accumulation of Aß in SH-SY5Y cells overexpressing FAD-mutant APP 




between apoE proteolysis and AD-related pathology (Saul and Wirths, 2016). 
Intriguingly, the level of apoE fragmentation was shown to be greater for apoE4 
compared to apoE3 in post-mortem human AD brains (Harris et al., 2003, Jones et al., 
2011, Tamboli et al., 2014), revealing differences in the proteolytic susceptibility 
between the apoE isoforms. Similarly, NSE-apoE4 mice have been reported to display 
greater levels of apoE fragments than NSE-apoE3 mice (Brecht et al., 2004b). These 
findings indicate that the loss of protective and gain of toxic function observed in 
transgenic mice expressing apoE4 in neurons may be related to the increased level of 
fragments generated due to differential processing. In further support of this, kainic-acid 
induced excitotoxicity in NSE-apoE4 and NSE-apoE3 mice was found to be associated 
with increased fragmentation of apoE4 but not of apoE3, indicating that the enhanced 
proteolysis of apoE4 in injured/stressed neurons may contribute to the increase in 
neuronal death observed in NSE-apoE4 mice (Brecht et al., 2004b). This isoform-specific 
processing has been shown to involve domain interaction since using structural 
molecule correctors to reduce the domain interaction in apoE4-expressing induced 
pluripotent stem cells (iPSC)-derived neurons and thus induce an apoE3-like structure, 
decreased the level of apoE4 fragments generated (Wang et al., 2018). Intriguingly, 
cellular source has also been shown to affect the proteolytic processing of apoE. For 
instance, apoE fragments were found to accumulate in an age-dependent manner in 
transgenic mice expressing human apoE in neurons, but not in astrocytes (Brecht et al., 
2004b). Hence the neuron-specific effects of apoE in AD were also considered to be 
related to apoE proteolysis. 
 
1.6.6 The apoE proteolysis hypothesis 
Although the identity of apoE fragments is yet to be resolved, there is evidence to 
suggest that apoE may be cleaved at various sites across the protein to generate a 
mixture of N- and C-terminal fragments. For instance, microsequencing of   ̴10kDa apoE 
fragments purified from amyloid plaques in human brain tissue revealed them to be C-
terminal fragments, containing residues 193-299 and 216-299 (Wisniewski et al., 1995). 
In addition, western blotting of human brain and NSE-apoE mice protein extracts using 




contained the N-terminus and at least the lipid binding region (241-272aa) of apoE, 
whereas the C-terminus was found to be the main constituent of the low molecular 
weight fragments (Cho et al., 2001, Huang et al., 2001, Harris et al., 2003, Brecht et al., 
2004b, Jones et al., 2011). In view of this, numerous studies have explored the role of 
apoE fragments on neuronal function by using peptides of apoE, N-terminal-based apoE 
fragments and C-terminal-based apoE fragments (Crutcher et al., 1994, Marques et al., 
1996, Tolar et al., 1997, Tolar et al., 1999, Huang et al., 2001, Harris et al., 2003, Chang 
et al., 2005, Nakamura et al., 2009). These studies demonstrated that apoE4 fragments 
but not apoE3 fragments, exert a disruptive effect on neuronal function and viability 
through a variety of mechanisms including the induction of cytoskeletal defects, tau 
hyperphosphorylation and mitochondrial dysfunction (discussed in further detail in the 
following sections). Whilst some of the neurotoxic roles were associated with cell 
surface receptor binding (Tolar et al., 1997, Tolar et al., 1999, Crutcher et al., 2010, Love 
et al., 2017), the cytoskeletal and mitochondrial defects were suggested to be mediated 
by apoE4 fragments in the cytosol (Huang et al., 2001, Chang et al., 2005, Nakamura et 
al., 2009). Intriguingly, immunofluorescence and MTT assay experiments demonstrated 
that the receptor binding region was necessary for translocation of apoE fragments to 
the cytosol, whilst exposure of the lipid binding region was required for mitochondrial 
localisation and dysfunction (Chang et al., 2005). Collectively these findings gave rise to 






Figure 1-7 ApoE proteolysis hypothesis 
ApoE expression and secretion in neurons (step 1)  is triggered by stress or injury as a protection 
response mechanism, which may occur through increased levels of oligomeric Aß42 and/or cholesterol 
dyshomeostasis in the context of AD. However, apoE undergoes neuron-specific proteolysis in an 
isoform-dependent manner (apoE4>apoE3>apoE2) due to domain interaction (step 2), facilitating a 
toxic gain of function. Fragments escape the secretory pathway and induce tau hyperphosphorylation 
and subsequently destablisation of microtubules (step 3), aggregation of tau and formation of p-Tau 
tangles (step 4) and mitochondrial dysfunction (step 5). Fragments may also be secreted (step 6) and 
induce neurotoxicity via LDLR-family mediated signalling cascades (step 7). ApoE fragmentation may 
also lead to a loss of function since secretion of full length apoE facilitates lipid distribution, a key 




1.6.7 ApoE4 and fragments disrupt the cytoskeletal network 
The neuronal cytoskeleton comprises three highly organised and interacting structural 
polymers: microtubules, neurofilaments and microfilaments. Together they provide 
architectural support and play key roles in neurite outgrowth, organelle organisation, 
signalling and intracellular transport (Kevenaar and Hoogenraad, 2015). As mentioned 
previously, there is evidence to suggest that apoE4 expression and fragmentation in 
neurons affects the cytoskeletal network. Indeed, neuronal expression of human apoE4 
in transgenic mice has been associated with dysfunctional axonal transport, axonal 
degeneration and loss of dendritic spines (Tesseur et al., 2000b, Tesseur et al., 2000a, 
Jain et al., 2013), which are hallmarks of cytoskeletal disruption. Moreover, stable 
expression and exogenous application of apoE4 in N2a cells has been reported to inhibit 
neurite outgrowth and enhance depolymerisation of microtubules in vitro (Nathan et al., 
1995, Nathan et al., 1994, Bellosta et al., 1995). It has been suggested that these effects 
may partly be due to apoE4-mediated deregulation of tau, since this protein plays an 
important role in microtubule polymerisation and stability (Mahley and Huang, 2012). 
Hyperphosphorylation of tau in AD is thought to reduce the affinity of tau for 
microtubules and thus promote microtubule disassembly (Mahley and Huang, 2012, 
Alonso et al., 1994). One line of evidence linking apoE to tau in AD is the co-localisation 
of apoE with tau tangles, as shown by immunohistochemistry of post-mortem AD brains 
and down syndrome-AD brains (Rohn et al., 2012, Day et al., 2016). Furthermore, the 
expression of apoE4 but not apoE3 in neurons of transgenic mice and in iPSC-derived 
neurons has been found to induce hyperphosphorylation of tau and formation of p-Tau 
tangles (Tesseur et al., 2000a, Tesseur et al., 2000b, Brecht et al., 2004b, Wang et al., 
2018), thus demonstrating that apoE4 may be a key driver of tau deregulation and tau-
related pathology in AD. Notably, tau hyperphosphorylation was not observed in GFAP-
apoE4 mice (Brecht et al., 2004b), supporting the idea that this effect is associated with 
apoE4 fragments. In fact, expression of C-terminally truncated apoE4 (1-272aa) in 
neurons has also been reported to induce tau hyperphosphorylation and tau-tangles in 
vitro and in vivo (Huang et al., 2001, Harris et al., 2003), which provides more direct 
evidence that apoE4 fragments contribute to the deregulation of tau and thus 




It is also possible that apoE4 disrupts the cytoskeletal network through the deregulation 
of neurofilament proteins too. Neurofilament proteins have been identified as 
components of NFTs in the AD brain and have been shown to be abnormally 
phosphorylated in AD (Dahl et al., 1982, Cork et al., 1986, Haugh et al., 1986, Wang et al., 
2001). In support of an association between apoE and neurofilament deregulation in AD, 
immunofluorescence experiments have demonstrated that apoE localises to a small 
portion of neurofilament-positive NFTs in the AD brain (Dickson et al., 1997). In addition, 
neuronal expression of apoE4 in Thy1-apoE transgenic mice has been shown to induce 
the accumulation of neurofilament-containing inclusion bodies in dilated axons (Tesseur 
et al., 2000a). There is also evidence to suggest that neuron-specific apoE proteolysis 
may contribute to the disruption of the neurofilament network in AD.  Indeed, 
overexpression studies using C-terminally truncated apoE (1-272aa) have been shown to 
induce the formation of tangle-like structures that are immunoreactive for both apoE 
and neurofilament protein in neuroblastoma cells but not non-neuronal cells (Huang et 
al., 2001, Ljungberg et al., 2002). Hence there is considerable evidence to support a role 
for neuronal apoE4 expression and proteolysis in cytoskeletal disruption and thus 
neuronal dysfunction in AD. 
  
1.6.8 ApoE4 and fragments disrupt bioenergetics pathways 
The generation of energy in the form of adenosine triphosphate (ATP) by various 
bioenergetics pathways is a core requirement for cellular function. Mitochondrial 
oxidative phosphorylation, which involves redox reactions mediated by protein 
complexes within the electron transport chain (ETC), is the most efficient of these 
pathways. It is notable though that oxidative phosphorylation is dependent on the 
supply of electrons from Nicotinamide adenine dinucleotide (NADH) and flavin adenine 
dinucleotide (FADH2), electron carriers that are produced alongside ATP either through 
the metabolism of glucose or pyruvate via glycolysis and the citric acid cycle respectively. 
Hence disruption to either of these processes can have downstream effects on 
mitochondrial function and thus the production of ATP to meet energy demands. 
Intriguingly, early PET studies using a glucose analogue called fluorodeoxyglucose-18F 




1985, Minoshima et al., 1997, Ibanez et al., 1998, Hirono et al., 1998), raising the idea 
that impaired bioenergetics pathways may contribute to AD. Later FDG PET studies have 
since shown that glucose metabolism is modulated by APOE genotype in a gene dose-
dependent manner, whereby APOE4 is associated with glucose hypometabolism 
(Mosconi et al., 2004b, Mosconi et al., 2004a, Mosconi et al., 2005, Drzezga et al., 2005). 
This led to the notion that APOE genotype may alter the risk for AD through affecting 
cellular bioenergetics in the brain. In support of this, comparisons of gene expression in 
hippocampi from post-mortem APOE4 and APOE3 AD brains by microarray analysis and 
Serial Analysis of Gene Expression (SAGE) revealed that apoE4 expression is associated 
with the downregulation of transcripts involved in mitochondrial oxidative 
phosphorylation and energy metabolism (Xu et al., 2006a, Xu et al., 2007a). However, It 
is worth noting that multiple factors can affect the integrity and molecular preservation 
of post-mortem tissue, such as conditions prior to death and the duration between 
death and sample processing (Ferrer et al., 2008). Therefore, conclusions derived from 
studies involving post-mortem brain tissue need to be validated either in vivo or in vitro. 
Interestingly, a recent histochemistry study found that the activity of cytochrome 
oxidase (complex  IV of the ETC) was lower in post-mortem brain tissue of APOE4 
carriers (Valla et al., 2010), a deficit that has also been observed in brain tissue from 
individuals with AD and AD transgenic mouse models (Valla et al., 2001, Valla et al., 
2007). Similarly, cytochrome oxidase levels and other proteins involved in oxidative 
phosphorylation, glycolysis and the citric acid cycle were found to be lower in 
synaptosomal extracts from GFAP-apoE4 mice compared to GFAP-apoE3 mice (Shi et al., 
2014), indicating that secreted apoE may also contribute to deficits in bioenergetics 
pathways and thus mitochondrial dysfunction. There is also evidence to support a role 
for neuronally expressed apoE4 and fragments in mitochondrial dysfunction. Indeed, a 
reduction in the protein levels of mitochondrial ETC complexes has been observed in 
cultured neurons from NSE-apoE4 mice, but not NSE-apoE3 mice (Chen et al., 2011a). 
Chen and colleagues also reported lower gene expression and protein levels of 
mitochondrial ETC complexes in apoE4-expressing N2a cells compared to apoE3-
expressing N2a cells. Interestingly, the levels of mitochondrial ETC complexes did not 




apoE-mediated mitochondrial dysfunction is neuron-specific (Chen et al., 2011a). 
Although the basis for this effect is still not fully understood, C-terminally truncated 
apoE4 (1-272aa) has been demonstrated to localise to the mitochondria and interact 
with ETC complexes (Chang et al., 2005, Nakamura et al., 2009), indicating that 
fragments of apoE4 may exert a direct effect on mitochondrial function. In addition to 
binding to components of complex III and complex IV (Nakamura et al., 2009), 
expression of full length apoE4 and the apoE4 1-272 fragment in N2a cells have been 
shown to reduce the activity of these complexes (Nakamura et al., 2009, Chen et al., 
2011a), thus supporting a role for neuronal apoE4 expression and apoE4 fragments in 
reduced bioenergetics and mitochondrial dysfunction. Notably, Nakamura and 
colleagues found that the apoE4 1-272aa fragment impaired the enzymatic activities of 
complex III and IV to a greater extent compared to full length apoE4, which they 
proposed may be related to the stronger association between the apoE4 1-272aa 
fragment with the ETC complexes. Although the evidence discussed so far suggests that 
apoE4 disrupts mitochondrial function, studies assessing the effect of apoE4 expression 
on mitochondrial respiration and membrane potential have provided conflicting results. 
For instance, studies using Fluorescence-activated cell sorting (FACS) analysis of 
MitoTracker Deep Red 633 staining and oxygen consumption measurements in apoE4-
expressing N2a cells have shown that full length apoE4 expression impairs mitochondrial 
membrane potential and respiration (Chang et al., 2005, Chen et al., 2011a). In contrast, 
FACS analysis of JC-1 staining and an ATP synthase activity assay did not reveal any 
significant differences in the mitochondrial membrane potential or synthesis of ATP in 
N2a cells expressing full length apoE4 or the apoE4 1-272aa fragment (Nakamura et al., 
2009). Nonetheless, these findings implicate apoE4 expression and proteolysis in the 
downregulation of bioenergetics pathways and induction of mitochondrial dysfunction, 




1.7 Research project aims 
1.7.1 Project 1 
It is well established that the accumulation of soluble Aß42 oligomers in the brain is 
associated with synaptic dysfunction (Mucke and Selkoe, 2012, Shankar and Walsh, 
2009), an early event in AD that is linked to the manifestation of cognitive deficits 
(Arendt, 2009). Recent evidence indicates that this may be partly mediated through 
alterations in SV dynamics at the presynapse (Li and Kavalali, 2017, Ovsepian et al., 
2018), although the molecular mechanisms behind this are still poorly understood. 
Interestingly, a small branch-chained fatty acid called valproic acid (VPA), which is used 
in the treatment of bipolar disorder and epilepsy, has been shown to attenuate Aß42-
induced disruption of SV recycling and to have therapeutic benefit in AD transgenic 
mouse models (Williams and Bate, 2016, Qing et al., 2008, Zhang et al., 2010). In view of 
this, the overall aim of project 1 was to investigate the molecular basis of oligomeric 
Aß42-mediated disruption to SV dynamics and to test whether VPA could be used as a 
treatment in this context. Following the identification of SnpI as a protein that may be 
deregulated by Aß42 oligomers, the work in project 1 specifically aimed to: 
1. Determine whether Aß42 oligomers deregulate SnpI; 
2. Determine whether VPA exerts a neuroprotective effect through SnpI regulation. 
  
1.7.2 Project 2 
Numerous studies have investigated the processing and function of apoE4 in neurons, 
many using apoE3 for comparison (as discussed in this chapter), to elucidate the 
mechanisms underpinning the increased risk for AD associated with the APOE4 
genotype. However, the neurobiology of the apoE2 isoform has been largely overlooked, 
even though genetics studies have revealed that this variant is associated with reduced 
risk for AD. Whilst mounting evidence has shown that the differential effects of apoE3 
and apoE4 on neuronal function are linked to differences in proteolytic susceptibility 
(apoE4>apoE3) and thus different levels of bioactive fragments (Huang, 2010, Huang, 
2011, Mahley and Huang, 2012, Mahley, 2016a), it is not known whether the ‘protective’ 
role of apoE2 is related to this. Furthermore, although the sequence identity of apoE 




fragments’ in vitro and in vivo using apoE peptides, and N-/C-terminally truncated 
variants of apoE (Crutcher et al., 2010, Huang et al., 2001, Harris et al., 2003, Chang et 
al., 2005, Nakamura et al., 2009). Although these studies have shown that neuronal 
expression of some proposed apoE4 fragments induces toxicity through disruption of 
the cytoskeletal network and mitochondrial dysfunction, the existence of these 
fragments in vitro or in vivo is yet to be verified. In addition, the effect of full length 
apoE2 or apoE2 fragment expression on neuronal function and viability has not been 
investigated. Therefore the overall aim of project 2 was to explore the effect of apoE 
isoform, using the three major isoforms, on the proteolytic processing of apoE, neuronal 
function and viability. The specific aims addressed in this research are as follows: 
1. Determine whether all three apoE isoforms are differentially processed when 
expressed in neurons by characterising the proteolytic susceptibility and 
fragment profiles of each isoform; 
2. Characterise the composition of apoE fragments for all isoforms for insight into 
potential function and differences amongst apoE isoforms; 
3. Determine whether the effect of apoE expression on neuronal function is 
isoform-dependent by using cytoskeletal-associated proteins as indicators of 






Chapter 2 Materials and Methodology 
2.1 Chemicals 
All chemicals used for the work in this thesis were purchased from Sigma-Aldrich 
Company Ltd (Poole, Dorset, UK) unless otherwise stated. 
2.2 Bacterial Cultures and Plasmids 
All bacterial work was carried out using aseptic technique. 
 
2.2.1 Bacterial Culture Reagents and Solutions 
Solution Components and Procedure 
Lysogeny Broth (LB) 
media 
20g of LB (Lennox) powder was suspended in 1L of ddH2O, 
autoclaved for 15 minutes at 121oC to sterilize and allowed to 
cool to room temperature before supplementing with 
antibiotic (if desired) 
LB agar 
35g of LB (Lennox) powder was suspended in 1L of ddH2O, 
autoclaved for 15 minutes at 121oC to sterilize and allowed to 
cool to for approximately 1 hour before supplementing with 
antibiotic 
50mg/ml ampicillin 
Ampicillin powder was dissolved in water at 50mg/ml, filter 
sterilised through a 0.2µm membrane and stored at -20oC 
Table 2-1 Recipes for solutions used in bacterial culture work 
 
2.2.2 Culturing One Shot TOP10 Electrocomp E. Coli 
Top 10 E. Coli competent cells (Invitrogen) were collected using a sterile loop and the 
bacteria streaked out on antibiotic-free LB agar plates, which were then incubated 
overnight at 37oC. A single colony was picked using a sterile pipette tip and used to 
create a starter culture by inoculating 5mL of antibiotic-free LB media (see Table 2-1 for 
formulation). Following incubation of the starter culture for approximately 16 hours at 
37oC with horizontal shaking (200 rpm), 5mL of the overnight culture was added to 
500mL of antibiotic-free LB media in a vented conical flask. This culture was incubated at 
37oC with horizontal shaking (200 rpm) until the optical density measured between 0.2 
and 0.5 (typically between the first and third hour of incubation), as determined by using 
a spectrophotometer at a wavelength of 600nm. The bacterial suspension was pelleted 
at 3000 rpm for 5 minutes at 4oC and the supernatant was removed. The cell pellet was 




adding the remainder. The bacteria were incubated on wet-ice for 20 minutes before 
pelleting again by centrifugation at 4000 rpm for 5 minutes at 4oC. Following removal of 
the supernatant, the pelleted bacteria were resuspended in 5mL (1/10th of the original 
volume) sterile ice-cold 100mM CaCl2/15% glycerol. The bacterial suspension was 
aliquoted (50 and 250µl) into pre-cooled 1.5mL micro centrifuge tubes on dry-ice 








Generated in Professor Dickon's lab (Centre of Biomedical Sciences, 
Royal Holloway University of London) and provided by PhD Candidate 
Lugi Zhang (National University of Singapore) 
pCMV6-AC-
ApoE3 
Purchased from Cambridge Bioscience (#SC319433) 
pCMV-ApoE4 
Generated in Professor Dickon's lab and provided by PhD Candidate 
Lugi Zhang (National University of Singapore) 
pCMV4-ApoE3 Provided by Professor Tadafumi Hashimoto (University of Tokyo) 
pCMV4-ApoE3-
NT 192-299 
Provided by Professor Tadafumi Hashimoto (University of Tokyo) 
pCMV4-ApoE3-
CT 1-192 
Provided by Professor Tadafumi Hashimoto (University of Tokyo) 
pCMV4-ApoE3 
243-299 
Provided by Professor Tadafumi Hashimoto (University of Tokyo) 
pCMV4-ApoE3 
243-272 
Provided by Professor Tadafumi Hashimoto (University of Tokyo) 
pCMV4-ApoE3 
272-299 
Provided by Professor Tadafumi Hashimoto (University of Tokyo) 
pRRL-CMV-
Wpre 
Provided by Professor Rafael Yáñez-Muñoz (Centre of Biomedical 
Sciences, Royal Holloway University of London) 
pRRL-CMV-
ApoE2-Wpre 
Generated by Jade Marsh via subcloning the apoE2 cDNA from 
pCMV-ApoE2 into the pRRL-CMV-Wpre backbone 
pRRL-CMV-
ApoE3-Wpre 
Generated by Jade Marsh via subcloning a segment of the apoE3 
cDNA (containing the SNPs) from pCMV6-AC-ApoE3 into the pRRL-
CMV-ApoE4-Wpre backbone that had the complimentary segment 
(containing SNPs encoding for the apoE4 isoform) removed 
pRRL-CMV-
ApoE4-Wpre 
Generated by Jade Marsh via subcloning the apoE4 cDNA from 
pCMV-ApoE4 into the pRRL-CMV-Wpre backbone 
pRRL-CMV-GFP-
Wpre 
Provided by Professor Rafael Yáñez-Muñoz (Centre of Biomedical 




Provided by Professor Rafael Yáñez-Muñoz (Centre of Biomedical 
Sciences, Royal Holloway University of London) 
pRSV-REV (Rev 
plasmid) 
Provided by Professor Rafael Yáñez-Muñoz (Centre of Biomedical 
Sciences, Royal Holloway University of London) 
pMD2-VSV-G 
(Env plasmid) 
Provided by Professor Rafael Yáñez-Muñoz (Centre of Biomedical 
Sciences, Royal Holloway University of London) 




2.2.3.1 Plasmid DNA Elution from Filter Paper 
The plasmids provided by PhD candidate Lugi Zhang and Professor Tadafumi Hashimoto 
(listed in Table 2-2) were received on filter paper. A section of filter paper containing the 
dried plasmid DNA (marked by a circle) was excised using clean scissors, transferred to a 
1.5ml micro centrifuge tube, and the plasmid DNA eluted by adding 50µl of 1X TE buffer. 
Following incubation for 5mins at room temperature, 5µl of the eluted plasmid DNA was 
used to transform bacteria to prepare plasmid stocks. 
 
2.2.3.2 Sanger Sequencing of Plasmid DNA 
To validate apoE genotype and fidelity of apoE complementary DNA (cDNA) sequences 
of plasmids, sequencing was performed by using the Mix2Seq Kit (Eurofins Genomics) 
according to manufacturer’s instructions. Plasmids were sequenced using four primers 
(shown in Table 2-3) to ensure sequence coverage. Sequence data was acquired from 
Eurofins MWG and analysed using alignment tools in CLC Main Workbench software 
(Qiagen). 
 
Primer Name Sequence (5’-3’) 
Human apoE 1_F GAGGGCGCTGATGGACGA 
Human apoE 1_R CGCCACCTGCTCCTTCACCTC 
Human apoE 2_F AAATCGGAACTGGAGGAAC 
Human apoE 2_R CTTCTGCAGGTCATCGGC 
Table 2-3 Primers used to sequence apoE cDNA 
 
2.2.4 Transformation of Bacteria using Heat Shock 
One Shot TOP10 Electrocomp E. Coli (250µl stock aliquots) were thawed on wet-ice, and 
50µl working aliquots were prepared using pre-cooled micro centrifuge tubes. 5µl of 
plasmid DNA (10-100ng) was added to 50µl of bacteria, and gently mixed by flicking the 
tube. After incubation on wet-ice for 30 minutes, the bacteria were subjected to a heat-
shock by incubation in a water bath at 42oC for 30 seconds, followed by a brief 
incubation on wet-ice for 2 minutes. Next, 250µl of antibiotic-free LB was added to the 
bacterial suspension and incubated for 1 hour at 37oC with horizontal shaking at 
200rpm. During this incubation step, agar selection plates were warmed up to room 




containing 50µg/mL ampicillin and incubated at 37oC overnight. The remaining 200µl of 
transformed bacteria were stored at 4oC for plating a larger culture volume, if a greater 
bacterial density was required.  
 
2.2.5 Culturing of transformed Bacteria 
For starter cultures, 5ml of ampicillin-supplemented (50µg/ml) LB media was inoculated 
with either a single colony picked from an LB-agar plate using a pipette, or bacteria from 
a glycerol stock that was collected using a plastic loop. The starter culture was incubated 
at 37oC for approximately 16 hours with shaking (200rpm) and used for either preparing 
glycerol stocks, inoculating maxi cultures, or plasmid DNA purification. 
 
For maxi cultures, 500µl of a starter culture was used to inoculate 250ml of ampicillin-
supplemented (50µg/ml) LB media in a 1L sterile vented conical flask, which was then 
incubated at 37oC for approximately 16 hours with shaking at 200rpm. The bacterial 
suspension was centrifuged at 3250 rpm for 30 minutes at 4oC, the supernatant 
removed and the bacterial pellet either used for plasmid purification same day or stored 
at -20oC. 
 
2.2.6 Bacterial Glycerol stocks 
Glycerol stocks were prepared by adding 500µl of bacterial culture from the previous 
step to 500µl of sterile 80% glycerol (40% final) in 1.5mL screw-top tubes. After brief 
mixing and snap-freezing on dry-ice, the tubes were transferred to -80oC for long-term 
storage. 
 
2.2.7 Extraction and Purification of Plasmid DNA 
Prior to plasmid DNA extraction and purification of starter cultures, bacterial 
suspensions were pelleted by centrifugation at 3250rpm for 10mins at 4oC and 
processed immediately, or stored at -20oC and processed at a later date. Plasmid DNA 
was extracted and purified from pelleted starter cultures using the QIAprep Spin 





For plasmid DNA extraction and purification from maxi cultures, bacterial suspensions 
were initially pelleted by centrifugation at 3250rpm for 30mins at 4oC. Plasmid DNA was 
extracted and purified from pelleted maxi cultures using the GenElute HP Endotoxin-
Free Plasmid Maxiprep Kit (#NA0410, Sigma Aldrich) as per the manufacturer’s 
instructions with some exceptions. These exceptions include further drying of the 
binding column by centrifugation at 5000 x g for 10mins at 4oC and eluting the plasmid 
DNA using 1mL of E-Toxate free water. The plasmid DNA was concentrated using the 
ethanol precipitation method. 100µl of NaOAc (3M stock) and 2.5mL ethanol (100% 
stock) was added to the 1ml of eluted plasmid DNA, which was mixed and incubated 
overnight at -80oC. The plasmid DNA was pelleted by centrifugation for 2hrs at 5000 x g 
at 4oC. The supernatant was carefully removed and the remaining ethanol allowed to 
evaporate. The pellet was resuspended using 100-500µl of E-Toxate free water to give 
concentrations between 0.5µg-1µg/µl, and the plasmid DNA was stored at -20oC. 
 
2.2.8 Nucleic Acid Quantification and Purity Assessment 
 The concentration and quality of plasmid DNA was assessed by using a Nanodrop 
Spectrophotometer. 260/280 and 260/230 ratios near 1.8 and 2.0-2.2 respectively 
indicated a relatively pure DNA sample. 
2.3 Subcloning and Generation of Lentiviral Vectors 
2.3.1 Reagents and Solutions 
Agarose (Invitrogen) 
10,000X SYBR Safe DNA Gel Stain (Invitrogen, #S33102) 
DNA Loading Buffer Blue (Bioline, #BIO-37045) 
Hyperladder I (Bioline, #BIO-33025) 
T4 DNA ligase (Promega, #M1801) 
DNAse I (Promega, #M6101) 
Diethyl pyrocarbonate (DEPC)-treated water (Ambion, #AM9906) 
Cell culture grade water (Sigma, #W-3500) 







EDTA (TAE) buffer 
242g Tris base, 57.1ml glacial acetic acid and 100ml of 500mM 
EDTA (pH 8.0) made up to 1L with ddH2O 
2X HEPES-buffered 
saline (HBS) solution 
100mM HEPES, 281mM NaCl, 1.5mM Na2HPO4, pH to 7.12, filter 
sterilised through a 0.2µm membrane and stored at -20oC 
2.5M CaCl2  
14.3g of CaCl2 dissolved in 50ml ddH2O and stored as 1ml 
aliquots at -80oC 
8mg/ml Polybrene 
Hexadimethrine bromide (polybrene) was dissolved in ddH2O at 
8mg/ml, filter sterilised through a 0.2µm membrane and stored 
as aliquots at 4oC 
Table 2-4 Recipes of solutions used for subcloning and lentiviral vector production 
 
2.3.2 General Molecular Subcloning Protocols 
2.3.2.1 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was routinely used to separate DNA for restriction mapping 
analysis and to facilitate isolation of plasmid DNA fragments for purposes such as 
subcloning. 1% agarose gels were prepared by adding 0.7g of agarose to 70ml of 1X TAE 
buffer, and the mixture dissolved by using a microwave and frequent agitation. Once 
fully dissolved, 7µl of SYBR Safe DNA Gel Stain (1X final) was added to the gel mixture, 
which was agitated once more and allowed to cool briefly, before being poured into a 
casting tray. After the gel had set at room temperature, it was placed into an 
electrophoresis tank and submerged in 1X TAE buffer. DNA samples were mixed with 
DNA Loading Buffer Blue (1X final) and added into wells alongside 5µl of Hyperladder I 
(Bioline, #BIO-33025). 1% agarose gels were run at 65V for approximately 1 hour and the 
DNA bands visualised by using ultraviolet light in a GELDOC system. 
 
2.3.2.2 Endonuclease Restriction Digests 
Endonuclease restriction digests were performed to validate plasmid DNA sequences, as 
based on digest product profiles, and for subcloning purposes. Suitable single and 
multiple cutting endonuclease restriction enzymes were identified by using SnapGene 
software, which also provided predicted digest product profiles. All restriction enzymes 
used were purchased from NEB. The compatible buffers and digest reaction conditions 






A digest reaction for restriction mapping analysis of plasmids was typically performed by 
combining 1µg of plasmid DNA, 10 units of enzyme and 1X compatible enzyme buffer in 
a total reaction volume of 20µl, which was made up with DEPC-treated water. Negative 
control reactions were also prepared by excluding the enzyme from the reaction. The 
digest reactions were incubated at 37oC for 5 hours. To examine the digest profiles for 
each plasmid, digest products and uncut plasmid DNA samples were resolved by agarose 
gel electrophoresis, which involved loading 10µl of the digested plasmid DNA mixed with 
3µl loading buffer (1X final) and 2µl DEPC-treated water. 
 
2.3.2.3 Extraction and Purification of DNA 
Desired DNA was isolated from agarose gels by using white light to visualise DNA bands 
and a sterile blade to excise individual DNA bands from the gel. Once the gel section 
containing the desired DNA was transferred to a 2.0ml sterile Eppendorf micro 
centrifuge tube, the DNA was extracted and purified using the QIAquick Gel Extraction 
Kit (Qiagen, #28704), according to the manufacturers protocol with some additional 
steps. These include: 2 repeats of Step 5, 2 repeats of Step 7, and elution of the cDNA 
(Step 9) using 50µl DEPC-treated water. 
 
2.3.2.4 DNA Ligation Reaction 
Ligation reactions were performed by using T4 DNA ligase (Promega, #M1801) to 
catalyse phosphodiester linkage between 100ng of linearised destination plasmid and 
increasing amounts of insert DNA, as based on destination plasmid to insert molar ratios 
of 1:1, 1:3, 1:5 and 1:10. The ligation reactions were prepared by mixing the plasmid 
DNA and insert DNA with 1µl of T4 DNA Ligase enzyme, 2µl of T4 DNA Ligase buffer (1X 
final) and DEPC-treated water to bring the total reaction volume to 20µl. Two negative 
control reactions were also prepared by excluding the insert DNA and T4 DNA ligase 
from the reaction, or by excluding the insert only. These negative control reactions were 
carried out to provide an indication of contamination from uncut plasmid DNA and 
background re-ligation of plasmid DNA. The ligation reactions were carried out in a PCR 
thermocycler, which incubated the mixture at 22oC for 1 hour, followed by 15oC for 16 





2.3.3 Subcloning of pRRL-CMV-ApoE2-Wpre and pRRL-CMV-ApoE4-Wpre 
pCMV-ApoE2 and pCMV-ApoE4 were used as sources for apoE2 and apoE4 cDNA, whilst 
the pRRL-CMV-Wpre plasmid (lentiviral transfer plasmid) was used as the destination 
plasmid for apoE2 and apoE4 cDNA. Preparative restriction digests to liberate apoE2 and 
apoE4 cDNA were performed by mixing 10µg of the plasmid DNA with 5µl of XbaI (100 
units) and 5µl of CutSmart Buffer (NEB, #B7204S) in a total reaction volume of 50µl, 
which was made up with DEPC-treated water. The digestion reaction to linearise pRRL-
CMV-Wpre was run in parallel and performed by mixing 2µg of the plasmid DNA with 1µl 
of XbaI (20 units) and 4µl of CutSmart Buffer (NEB, #B7204S) in a total reaction volume 
of 40µl, which was made up with DEPC-treated water. The digest reactions were 
incubated at 37oC for 10 hours, followed by an enzyme inactivation step of 65oC for 20 
minutes, and a storage step of 4oC.  
 
Linearised pRRL-CMV-Wpre was next treated with Antarctic Phosphatase (NEB, 
#M0289S) to de-phosphorylate the exposed 5’ ends of the DNA backbone, preventing 
re-ligation of the plasmid. The de-phosphorylation reaction was prepared by mixing the 
linearised plasmid DNA with 5µl of Antarctic Phosphatase Reaction Buffer (1X final), 4µl 
of Antarctic Phosphatase (20 units; 10 units/1µg of approximately 6Kb plasmid DNA) and 
1µl of DEPC-treated water to bring the reaction volume to 50µl. The sample was 
incubated at 37oC for 15 minutes, and the Antarctic Phosphatase enzyme was heat 
inactivated by incubation at 70oC for 5 minutes. The linearised pRRL-CMV-Wpre plasmid 
was stored at 4oC until further processing. 
 
The digest profiles of the samples were examined by resolving 400ng of plasmid DNA on 
1% agarose gels to ensure that the plasmids were fully digested. Once complete 
digestion was verified, the remaining volume of digested pCMV-ApoE2 and pCMV-ApoE4 
samples were resolved by agarose gel electrophoresis to enable isolation of apoE2 and 
apoE4 cDNA respectively. Following extraction and purification of the cDNA, ligation 
reactions were performed as described in sections 2.3.2.3 and 2.3.2.4 respectively. The 




were picked and starter cultures prepared (see section 2.2.5). Plasmid DNA was 
extracted and purified from starter cultures and restriction mapping analysis was 
performed to verify the generation of pRRL-CMV-ApoE2-Wpre and pRRL-CMV-ApoE4-
Wpre plasmids. Sanger sequencing (see section 2.2.3.2) was also used to validate the 
genotype of apoE cDNA and to confirm sequence fidelity. Once the plasmid sequences 
were fully validated, maxi cultures were prepared from an aliquot of starter culture, 
glycerol stocks were made, and the plasmid DNA was extracted and purified. 
 
2.3.4 Subcloning of pRRL-CMV-ApoE3-Wpre 
pCMV6-AC-ApoE3 was used the source for the desired apoE3 cDNA segment, whilst the 
pRRL-CMV-ApoE4-Wpre plasmid was used as the destination plasmid for the apoE3 
cDNA segment. A preparative restriction digest to liberate the apoE3 cDNA segment was 
performed by mixing 10µg of pCMV6-AC-ApoE3 with 2µl of BlpI (40 units), 2µl of SbfI-HF 
(40 units), 2µl of XhoI (40 units) and 7µl of CutSmart Buffer (NEB, #B7204S) in a total 
reaction volume of 70µl, which was made up with DEPC-treated water. The digestion 
reaction to remove the corresponding apoE4 cDNA segment from pRRL-CMV-ApoE4-
Wpre was run in parallel and performed by mixing 10µg of pRRL-CMV-ApoE4-Wpre with 
2.5µl of BlpI (50 units), 2.5µl of SbfI-HF (50 units) and 6µl of CutSmart Buffer (NEB, 
#B7204S) in a total reaction volume of 60µl, which was made up with DEPC-treated 
water. The digest reactions were incubated at 37oC for 4 hours, followed by an enzyme 
inactivation step of 65oC for 20 minutes, and a storage step of 4oC. 400ng of plasmid 
DNA from the digest reactions was resolved on 1% agarose gels to ensure completion of 
the reaction. Once the digest profiles were verified, the remaining volume of the digest 
reactions were also resolved by agarose gel electrophoresis to enable isolation of the 
desired apoE3 cDNA segment and the linearised pRRL-CMV-ApoE-Wpre backbone. 
These were extracted and purified from the agarose gel and ligation reactions were set 
up, as described in sections 2.3.2.3 and 2.3.2.4 respectively. The ligated products were 
transformed into bacteria (see section 2.2.4), and single colonies were picked and 
starter cultures prepared (see section 2.2.5). Plasmid DNA was extracted and purified 
from starter cultures and restriction mapping analysis was performed to verify the 




2.2.3.2) was also used to confirm sequence fidelity and to verify that the apoE cDNA was 
of APOE3 genotype. Once the plasmid sequence was fully validated, a maxi culture was 
prepared from an aliquot of starter culture, a glycerol stock was made, and the plasmid 
DNA was extracted and purified. 
 
2.3.5 Production, Purification and Concentration of apoE-expressing Lentiviral 
Vectors  
Lentiviral vectors were produced by calcium phosphate transfection of a four-plasmid 
system into HEK293T cells. HEK293T cells were seeded at 106 cells/plate on 15cm2 plates 
(Corning, #430599) containing 25ml growth media and incubated for 4 days to allow 
cells to become 80-90% confluent. The media was then replaced with 20ml of fresh 
growth media 2 hours before transfection. The plasmids were mixed in a molar ratio of 
1:1:1:2 (packaging:rev:envelope:transfer) by using 12.5µg of pMDLg-D64V, 6.25µg of 
pRSV-REV, 7µg of pMD2.VSV-G and 25µg of either pRRL-CMV-ApoE2-Wpre, or pRRL-
CMV-ApoE3-Wpre, or pRRL-CMV-ApoE4-Wpre or pRRL-CMV-GFP-Wpre. TE buffer was 
added to bring the total volume up to 112.5µl, followed by the addition of 1012.5µl of 
cell culture grade water to dilute the TE buffer to 0.1X. Once 125µl of 2.5M CaCl2 was 
added, the solution was vortexed and incubated at room temperature for 5 minutes. 
Whilst the DNA/CaCl2 mix was vortexed again, 1250µl of 2X HBS was added in a 
dropwise manner. The mix was then immediately added to the HEK293T growth media, 
and the plates gently agitated in a circular motion before incubation at 37oC with 5% CO2. 
After a 16-hour incubation period, the media was replaced with 18ml of fresh growth 
media. At 2 days post-transfection, the media was harvested to collect the lentiviral 
vectors and replaced with 18ml of fresh growth media to allow for a final harvest at 3 
days post-transfection. Harvested media was centrifuged at 2500rpm for 10 minutes at 
room temperature and then filtered through a 0.22µm filter (Nalgene, #190-2520) to 
remove cellular debris. To concentrate the lentiviral vectors, filtered media was 
transferred to high speed polyallomer centrifuge tubes (Beckman Coulter, #326823) and 
centrifuged in a SW32.1Ti rotor at 50,000 x g for 2 hours at 4oC. The supernatant was 
completely removed and the concentrated virus was resuspended in either 50µl of 
serum-free Dulbecco’s Modified Eagle’s Medium (DMEM) if media was concentrated 




from 2 plates. The vector prep was then transferred to a sterile 1.5ml micro centrifuge 
tube and spun at 4000rpm for 10 minutes at room temperature to pellet any remaining 
cellular debris. The supernatant was transferred to sterile micro centrifuge tubes and 
the vector prep was adjusted to 10mM MgCl2 before the addition of either 1 or 2µl of 
DNase I (5 units/ml). The vector prep was then incubated at 37oC for 30 minutes to allow 
the enzyme to degrade any plasmid DNA contamination. Lentiviral vector stocks were 
aliquoted and stored at - 80 oC until use. 
 
2.3.6 Titration of Lentiviral Vectors by qPCR 
HeLa cells were seeded at 105 cells per well on 6-well plates containing 2ml of growth 
media per well and incubated at 37oC and 5% CO2. The next day, the media was replaced 
with 1ml of pre-warmed DMEM containing 16µg/ml polybrene (to enhance transduction 
efficiency), followed by the addition of either 1ml of DMEM containing lentiviral vector 
diluted to 1:2000 and 1:20000, or 1ml of DMEM only (negative control). The plate was 
gently agitated in a circular motion before being returned to the incubator. At 1 day 
post-transduction, cells were harvested. This was carried out by first washing cells with 
1ml pre-warmed 1X DPBS, and then adding 150µl of trypsin-EDTA to each well. The plate 
was returned to the incubator for 5 minutes to allow for cells to detach from wells and 
then the trypsin was inactivated by the addition of 850µl pre-warmed growth media. 
The cell suspension was transferred to sterile micro centrifuge tubes and pelleted by 
centrifugation at 1000rpm for 5 minutes. Once the supernatant was removed, DNA was 
extracted and purified from the cell pellets by using a DNeasy Blood and Tissue kit 
(QIAGEN, #69504), as per manufacturer’s instructions. 
 
Quantitative polymerase chain reaction (qPCR) was used to measure the lentiviral DNA 
copy number and total cell number so that the viral titre could be calculated. To 
measure the lentiviral DNA copy number, qPCRs were set up using forward/reverse 
primers against the lentiviral late reverse transcripts (LTRs) and LTR standards of known 
copy numbers (102, 103, 104, 105, 106, 107). Total cell numbers were determined by using 
forward/reverse primers against the ß-actin and HeLa standards of known total cell 







Primer Name Sequence (5’-3’) 
LTR Forward Primer TGTGTGCCCGTCTGTTGTGT 
LRT Reverse Primer GAGTCCTGCGTCGAGAGAGC 
ß-actin Forward Primer TCACCCACACTGTGCCCATCTACGA 
ß-actin Reverse Primer CAGCGGAACCGCTCATTGCCAATGG 
Table 2-5 Primers used in qPCRs to determine lentiviral titre 
 
The standard reactions were performed in triplicate, whilst all other reactions were 
performed in duplicate. The reactions for LTR-based qPCRs were prepared by mixing 
forward and reverse primers for LRTs (final concentration of 100nM), 1X SYBR Green 
qPCR master mix, either 5µl of DNA sample or LTR standard and DEPC-treated water to 
make the total volume up to 20µl. The reactions for ß-actin-based qPCRs were prepared 
by mixing forward and reverse primers for ß-actin (final concentration of 100nM), 1X 
SYBR Green qPCR master mix, either 5µl of DNA sample or HeLa standard and DEPC-
treated water to make the total volume up to 20µl. Negative control reactions were also 
prepared by either excluding the DNA sample or by using DNA extracts from mock cells 
(not transduced). The qPCR reaction tubes were placed into a Rotor-Gene Q (QIAgen, 
UK) thermocycler and incubated using the following conditions: 50oC for 2 minutes, 95oC 
for 10 minutes and then 50 cycles of 95oC for 15 second followed by 60oC for 1 minute. 
Final lentiviral vector titres were based on the average of the vector titres derived from 
DNA extracts of HeLa cells transduced using 2x vector dilutions (1:2000 and 1:20000). 







2.4 Tissue Culture 
All cell culture work was carried out using aseptic technique and sterile plasticware 
inside a class II laminar flow hood. 
 
2.4.1 General Cell Culture Reagents and Solutions 
1X Dulbecco’s phosphate buffered saline solution (DPBS) (Gibco, #14190-094) 
1X TrypLE Express Enzyme (Thermofisher, #12604-021) 
1X ice-cold Hanks’ Balanced Salt Solution (HBSS) (Gibco, #14175-053) 
 
2.4.2 Cell Culture Media Reagents 
2.4.2.1 Media for Neuro-2a and SH-SY5Y Cell Culture 
General growth media for Neuro-2a and SH-SY5Y cells: 
DMEM (Sigma, #D5796) 
Foetal Bovine Serum (FBS), 10% final (Gibco, #10500-064) 
Glutamax, 1X final (Gibco, #35050-061) 
Penicillin-streptomycin, 100 units/ml final concentration (Gibco, #15140122) 
 
2.4.2.2 Media for HEK293T Cell Culture 
General HEK293T growth media: 
DMEM (Sigma, #D5796) 
FBS, 10% final (Gibco, #10500-064) 
Glutamax, 1X final (Gibco, #35050-061) 
Penicillin-streptomycin, 100 units/ml final concentration (Gibco, #15140122) 
 
Growth media used to culture HEK293T cells for lentiviral generation: 
DMEM with Glutamax (Gibco, #31966-021) 
FBS, 10% final (Gibco, #10500-064) 
Penicillin-streptomycin, 100 units/ml final concentration (Gibco, #15140122) 
 
2.4.2.3 Media for HeLa Cell Culture 
Growth media used to culture HeLa cells for lentiviral titration: 




FBS, 10% final (Gibco, #10500-064) 
Penicillin-streptomycin, 100 units/ml final concentration (Gibco, #15140122) 
 
2.4.2.4 Media for Primary Neuronal Culture 
Dissociation media: 
DMEM (Gibco, #21969-035) 
TrypLE Express Enzyme, 0.1X final (Thermofisher, #12604-021) 
DNase I, 100µg/ml final 
 
Plating media: 
DMEM (Gibco, #21969-035) 
FBS, 5% final (Gibco, #10500-064) 
Glutamax, 1X final (Gibco, #35050-061) 
Penicillin-streptomycin, 100 units/ml final concentration (Gibco, #15140122) 
Media was filtered through a 0.45µm filter. 
 
Growth media: 
Neurobasal Medium (Gibco, #21103-049) 
B-27 Supplement, 1X final (Gibco, #17504-044) 
Glutamax, 1X final (Gibco, #35050-061) 
Penicillin-streptomycin, 100 units/ml final concentration (Gibco, #15140122) 
Media was filtered through a 0.45µm filter. 
 
2.4.2.5 Freezing Media for Cell Lines 
DMEM (Sigma, #D5796) 
FBS, 20% final (Gibco, #10500-064) 
Dimethyl sulfoxide (DMSO), 10% final (Sigma, #D8418) 






2.4.3 Cell Lines 
The N2a cell line (murine neuroblasts) was kindly provided by Professor Robin Williams 
(Centre of Biomedical Sciences, Royal Holloway University of London). 
 
The SH-SY5Y cell line (human neuroblasts) was kindly provided by Professor George 
Dickson (Centre of Biomedical Sciences, Royal Holloway University of London). 
 
The HEK293T (human embryonic kidney cells) and HeLa cell lines were kindly provided 
by Professor Rafael Yáñez-Muñoz (Centre of Biomedical Sciences, Royal Holloway 
University of London). 
 
2.4.4 Thawing Cells 
Frozen cells were retrieved from storage in liquid nitrogen and thawed immediately by 
submersion of cryovial in a 37oC water bath for approximately 2 minutes. Once thawed, 
cells were transferred into a 15ml falcon containing 9ml of pre-warmed growth media 
and pelleted by centrifugation at 3000 rpm for 5 minutes. Once the media was carefully 
aspirated, the cell pellet was resuspended in 1ml of pre-warmed growth media. After 
the addition of another 14ml of growth media, the cell suspension was seeded in a 
T75cm3 flask (Corning, #430372). Cells were incubated at 37oC and 5% CO2 and 
subcultured when they reached approximately 70-80% confluency. 
 
2.4.5 Sub-culturing Cell Lines 
Cell confluency was monitored daily and when cells were approximately 70-80% 
confluent, they were sub-cultured. The growth media was aspirated and cells were 
washed with pre-warmed 1X DPBS. The cells were then detached from the flask by 
addition of 1ml TrypLE and incubation at 37oC and 5% CO2 for 1-2 minutes. Following 
neutralisation of TrypLE by the addition of 9ml pre-warmed growth media, the cell 
suspension was pelleted by centrifugation at 3000 rpm for 5 minutes. The media was 
carefully aspirated and cells were initially resuspended in 1ml of pre-warmed growth 
media, followed by an additional 9ml of pre-warmed growth media. A fraction of the 
suspended cells (1:10 for N2a, HEK293T and HeLa cells; 1:5 for SH-SY5Y cells) was then 




growth media was added. Cells were incubated at 37oC and 5% CO2 and subcultured 
when they reached approximately 70-80% confluency. 
 
2.4.6 Cryogenic Storage of Cell Lines 
Once cells reached 70-80% confluency, the media was aspirated and the cells washed 
with 1X DPBS. Cells were then detached from the flask by the addition of 1ml TrypLE and 
incubation at 37oC and 5% CO2 for 1-2 minutes. After inactivation of TrypLE by the 
addition of 9ml pre-warmed growth media, cells were counted using a haemocytometer. 
Cells were pelleted by centrifugation at 3000 rpm for 5 minutes and resuspended at 
1x105 cells per ml in cold freezing media. Cells were quickly aliquoted at 1ml per vial into 
screw-top cryovials and gradually cooled overnight at -80oC, prior to long-term storage 
in a liquid nitrogen tank. 
 
2.4.7 Primary Rat Hippocampal Neuronal Culture 
All animal experiments were performed according to Home Office regulations and in 
compliance with the Animals Scientific Act 1986. Poly-D-lysine coated 6-well cell culture 
plates were prepared in advance by the addition of 1ml cold poly-D-lysine (100µg/ml 
final in 0.1M Borate buffer) to wells and incubation of plates at 4oC overnight. The wells 
were washed three times with sterile H2O, air-dried and exposed to ultraviolet light for 
20 minutes in the class II laminar flow hood, prior to dissection and plating of 
hippocampal neurons. Brains were obtained from embryonic day 18 (E18) Sprague 
Dawley rats and suspended in ice-cold 1X HBSS. The hippocampi were isolated and the 
meninges removed by dissection. The hippocampi were gently triturated in 5ml of pre-
warmed dissociation media and incubated at 37oC for 10 minutes. After further 
trituration by pipetting, TrypLE was inactivated by the addition of 1.5ml FBS. Cells were 
pelleted by centrifugation at 1500 rpm for 3 minutes and the media carefully aspirated. 
Cells were resuspended in 1ml of pre-warmed plating media and counted using a 
haemocytometer. A further volume of pre-warmed plating media was added to yield a 
concentration of 2.5 x 105 cells/ml and cells were seeded at a density of 5 x 105 
cells/well on coated 6-well plates or 2.5 x 105/well on coated 12-well plates. The plating 




well plates and 1ml/well for 12 well plates) and the cultures were maintained at 37oC 
and 5% CO2. Additional growth media (500µl/well in 6 well plates and 250µl/well in 12 
well plates) was added to cultures on a weekly basis from 7 DIV and cultures were 
routinely used for experiments at 18-21DIV. 
2.5 Cell Treatments and Assays 
2.5.1 Reagents and Solutions 
Lipofectamine 2000 Transfection Reagent (Invitrogen, #11668-019) 
FuGENE HD Transfection Reagent (Promega, #E2311) 










250mg MTT powder (Sigma, #M2128) dissolved in 250ml 1XPBS, filter 
sterilised through a 0.2µm membrane, aliquoted and stored at -20oC 
protected from light 
1M VPA 
1.66g of Valproic acid sodium salt dissolved in 10ml of ddH2O, filter 
sterilised through a 0.2µm membrane and stored at 4oC 
Table 2-6 Recipes of solutions used in cell treatments 
 
2.5.2 Preparation of Aß42 peptide 
Synthetic Aß42 peptide (American peptides) was reconstituted using 100% dimethyl 
sulfoxide (DMSO) to a stock concentration of 1mM, which was immediately stored as 
aliquots at -80 oC. Working stocks were also prepared by diluting the peptide with sterile 
1X DPBS to a final concentration of 300µM and stored as aliquots at -80 oC. For use in 
cell treatments, working aliquots were thawed on wet-ice and diluted to a final 
concentration of 300nM in pre-warmed neuronal growth media and used immediately. 
 
2.5.3 Acute treatment of neurons with Aß42 peptide and VPA 
Primary hippocampal neurons were allowed to mature (18-21 DIV) in 6-well plates prior 
to treatment. Two 6-well plates were used on the same day for each experimental 
replicate. To ensure consistency for each replicate, both cultures were treated with the 





Initially, the growth media of neuronal cultures was replaced with either 2ml of pre-
warmed neuronal growth media alone or containing 300nM Aß42. Neurons were 
incubated for 30 minutes at 37 oC with 5% CO2 to allow for internalisation of the peptide, 
as has been demonstrated to occur within this time-frame (Russell et al., 2012, Marsh et 
al., 2017). The growth media was replaced again with either 2ml of fresh pre-warmed 
growth media alone, or containing 1 or 10mM VPA. After a 2-hour incubation period at 
37 oC with 5% CO2, the media was aspirated and the cells washed with a HEPES-buffered 
saline wash solution. Next, neurons were depolarised by adding 2ml of a pre-warmed 
HEPES-buffered saline wash solution containing 70mM KCl and incubation for 5 minutes 
at 37 oC with 5% CO2. Protein was then either extracted immediately or after a recovery 
period following depolarisation. Recovery of neurons from depolarisation involved a 
wash step using pre-warmed HEPES-buffered saline wash solution to remove residual 
KCl and a final incubation period of 15 minutes at 37 oC with 5% CO2 in fresh growth 
media. Recovered neurons were washed with ice-cold HEPES-buffered saline wash 
solution prior to protein extraction. 
 
2.5.4 Transient Transfection of HEK293T Cells using Lipofectamine 2000 
HEK293T cells were seeded at a density of 5 x 105 cells/well in 6-well plates containing 
2ml of growth media per well and incubated at 37 oC with 5% CO2. Cells were 
transfected when 80-90% confluent, typically 1 day after seeding. For transfection of 
HEK293T cells in 6-well plates, a ratio of 5µl Lipofectamine 2000 Transfection reagent: 
2.5µg of plasmid DNA per well was used. Initially, the Lipofectamine 2000 Transfection 
reagent and plasmid DNA were both diluted using 100µl of serum-free DMEM and 
incubated for 5 minutes at room temperature. The reagent and plasmid DNA were then 
combined and incubated for 20 minutes at room temperature so that plasmid DNA-lipid 
complexes could form. This mixture was then added to wells in a dropwise manner and 
the plate agitated and incubated again at 37 oC with 5% CO2. At 24 hours post-
transfection, the media was replaced with fresh pre-warmed growth media to reduce 
transfection-related toxicity and incubated for a further 24 hours. Cells were processed 




wells to be transfected and included a 20% excess of the total volume needed to allow 
for pipetting error. 
 
2.5.5 Transient Transfection of N2a Cells using Lipofectamine 2000 
For protein analysis experiments, N2a cells were seeded at a density of 5 x 105 cells/well 
in 6-well plates containing 2ml of growth media per well. For immunocytochemistry 
experiments, 12-well plates were first prepared by allowing 18mm coverslips (washed in 
100% ethanol overnight) to air dry in wells (1 coverslip/well), followed by exposure of 
plates containing coverslips to ultraviolet light for 20 minutes. Next, N2a cells were 
seeded at a density of 2 x 105 cells/well in 12-well plates containing 1ml of growth media 
per well. Cells were incubated at 37 oC with 5% CO2 and transfected when 70-80% 
confluent, typically 1 day after seeding. For transfection of N2a cells in 6-well plates, a 
ratio of 10µl of Lipofectamine 2000 Transfection reagent: 2.5µg of plasmid DNA per well 
was used, whereas in 12-well plates, a ratio of 4µl of Lipofectamine 2000 Transfection 
reagent: 1µg of plasmid DNA per well was used. Initially, the Lipofectamine 2000 
Transfection reagent and plasmid DNA were both diluted using 100µl of serum-free 
DMEM for 6-well plates and 50µl of serum-free DMEM for 12-well plates. After a 5-
minute incubation at room temperature, the reagent and plasmid DNA were then 
combined and incubated for 20 minutes at room temperature so that plasmid DNA-lipid 
complexes could form. This mixture was then added to wells in a dropwise manner and 
the plate agitated and incubated again at 37 oC with 5% CO2. At 24 hours post-
transfection, the media was replaced with fresh pre-warmed growth media to reduce 
transfection-related toxicity and incubated for a further 24 hours. Cells were processed 
48-hours post transfection. The volumes were scaled up according to the number of 
wells to be transfected and included a 20% excess of the total volume needed to allow 
for pipetting error. 
 
2.5.6 Transient Transfection of SH-SY5Y Cells using FuGENE 
SH-SY5Y cells were seeded at a density of 5 x 105 cells/well in 6-well plates containing 
2ml of growth media per well and incubated at 37 oC with 5% CO2. Cells were 




SH-SY5Y cells in 6-well plates, a ratio of 10µl FuGENE HD Transfection reagent: 2.5µg of 
plasmid DNA per well was used. Initially, the plasmid DNA was diluted using 200µl of 
serum-free DMEM and incubated for 5 minutes at room temperature. The FuGENE HD 
Transfection reagent was then added to the diluted plasmid DNA and the mixture was 
incubated for 15 minutes at room temperature so that plasmid DNA-FuGENE complexes 
could form. This mixture was then added to wells in a dropwise manner and the plate 
agitated and incubated again at 37 oC with 5% CO2. At 24 hours post-transfection, the 
media was replaced with fresh pre-warmed growth media to reduce transfection-
related toxicity and incubated for a further 24 hours. Cells were processed 48-hours post 
transfection. The volumes were scaled up according to the number of wells to be 
transfected and included a 20% excess of the total volume needed to allow for pipetting 
error. 
 
2.5.7 Transduction of Primary Neuronal Cultures with Lentiviral Vectors 
18-21DIV neuronal cultures on 6-well plates and 12-well plates were transduced with 
apoE and GFP-expressing lentiviral vectors respectively. Lentiviral vectors were diluted 
to the desired multiplicity of infection (MOI) in 100µl of pre-warmed serum-free DMEM 
per well. This was scaled up according to the number of wells to be transduced and 
included a 20% excess of the total volume needed to allow for pipetting error. The 
diluted lentiviral vector was added dropwise to the neuronal culture media and the 
plates were gently agitated prior to incubation again at 37oC with 5% CO2. Neuronal 
cultures were processed at either 3 or 5 days post-transduction. 
 
2.5.8 MTT Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
reduction assay is a colorimetric assay that provides an indication of cell viability, as 
based on the ability of metabolically active cells to reduce MTT to form formazan 
crystals that have an absorbance maximum near 570nm.  
 
An aliquot of MTT solution was thawed at room temperature when the assay was to be 
carried out. 100µl of the MTT solution was added to the culture media of either N2a or 




of growth media per well so that the final concentration of MTT was 0.5mg/ml. The 
plates were gently agitated to ensure mixing of the MTT solution within the media and 
then covered with foil to protect the MTT solution from light. The plates were incubated 
at 37oC with 5% CO2 for either 2 hours for N2a cells or 4 hours for SH-SY5Y cells and 
primary neurons to allow for conversion of MTT to formazan, a purple precipitate. The 
media was carefully aspirated and the plates were air dried at room temperature, 
protected from light. To solubilise the formazan crystals, 500µl of DMSO was added to 
each well and the plate was agitated on a horizontal shaker at 200rpm, protected from 
light. Once the formazan crystals had dissolved, 75µl of the formazan solution from each 
well was added to wells on a 96-well plate, followed by 75µl of DMSO for use as a blank. 
The absorbance values were read at 570nm using a GloMax-Microplate Multimode 
Reader (Promega, USA).  
 
2.5.9 Live/Dead Assay 
The NUCLEAR-ID Blue/Red cell viability reagent facilitates the determination of live and 
dead cell populations due to the differing permeability and fluorescence of the two 
nucleic acid dyes. The blue fluorescent nucleic acid dye is cell permeable and so labels all 
nuclei, whereas the red fluorescent nucleic acid dye is cell impermeable, labelling only 
nuclei of apoptotic and compromised cells. 
 
NUCLEAR-ID Blue/Red cell viability reagent was first diluted 1:1000 in pre-warmed 1X 
DPBS. The growth media was aspirated from cells seeded onto 12-well plates and 300µl 
of the diluted reagent was added to each well to cover the cell monolayer. The plates 
were covered in foil to protect the dyes from light and then incubated for 15 minutes at 
37oC with 5% CO2. The staining solution was aspirated from the wells and cells were 
processed for either FACS analysis or for fluorescence microscopy analysis as in the 
sections below. 
 
2.5.9.1 Live/Dead Assay Procedure for FACS Analysis 
350µl of 1X TrypLE was added to each well and cells were incubated at 37oC with 5% CO2 




growth media was added to each well to neutralise the trypsin and the cell suspension 
was transferred to micro centrifuge tubes. Cells were pelleted by centrifugation at 1000 
x g for 1 minute at room temperature and the supernatant was removed. Cells were 
resuspended in 100µl of cold 1X DPBS and transferred to FACS tubes on wet-ice for 
analysis by FACS.  
 
The BD FACSCanto II (BD Biosciences, UK) flow cytometer was first calibrated using Cell 
Sorting Set-up Beads (Invitrogen, #C16509) suspended in FACSFlow Solution as 
standards. The samples were processed by the flow cytometer using a medium flow rate 
and a 10,000 event count. The voltages for AmCyan-A and PerCP-Cy5 were used to 
detect blue and red fluorescence respectively. Control cells were used to set-up the 
gates to determine particular cell populations. The forward scatter (FSC) versus side 
scatter (SSC) of events was plotted and gated (P1 gate) to exclude cellular debris as 
shown in Figure 2-1, A. The area (FSC-A) versus height (FSC-H) of events from within the 
P1 gate was also plotted to facilitate selection of only single cells (P2 gate; Figure 2-1, B). 
These events were then plotted on an AmCyan-A versus PerCP-Cy5 histogram (Figure 
2-1, C) to define live and dead cell populations as based on whether cells exhibited blue 
fluorescence only (Q4) or blue and red fluorescence (Q2) respectively. The data were 
analysed using BD FACSDiva software (BD Biosciences, UK) and the percentage of dead 





Figure 2-1 Representative FACs plots showing gating methods used to distinguish cell populations 
(A) A forward scatter (FSC) versus side scatter (SSC) event plot was first used to select for the total cell 
population and to exclude cellular debris, as determined by the P1 gate. (B) An area versus height event 
plot was next used to select single cells only (P2 gate) from the events in the P1 gate. (C) An AmCyan-A 
versus PerCP-Cy5 event plot using events from P2 was used to determine the percentage of dead cells 





2.5.9.2 Live/Dead Assay Procedure for Fluorescence Microscopy Analysis 
Cells were washed 2x with pre-warmed 1X DPBS to remove excess staining solution. 
500µl of 4% paraformaldehyde (PFA) was then each well and the plate was incubated for 
7 minutes at room temperature to allow for fixation of cells. Cells were then washed 2x 
with cold 1X DPBS and imaged using an inverted fluorescence Axio Observer D1 
microscope combined with AxioVision software (Carl Zeiss, UK) at a magnification of 20x. 
The exposure settings were optimised for both the DAPI and red fluorescence channels, 
and images then taken at constant exposure settings for all conditions. Images were 
analysed using ImageJ to determine the percentage of cells that were dead out of the 
total population of cells for each condition. To count the number of total cells in each 
image, images were first converted to 8-bit images and the LUT was inverted. Next, 
manual thresholding was performed to select the cells and exclude cellular debris which 
appeared as very small irregular shapes. The images were processed using watershed to 
define individual cells and then the number of cells were counted using the analyse 
particles option. 
 
2.6 Protein Conformation, Expression and localisation Analysis 
2.6.1 Reagents and Solutions 
Bradford reagent (Bio-Rad, #500-0006) 
30% Protogel (Bis-acrylamide solution; National Diagnostics, #EC-890) 
Absolute Methanol (VWR) 
Marvel Dried Milk Powder 
16% PFA (Agar Scientific, #R1026) 
20X NuPAGE MES sodium dodecyl sulfate (SDS) Running Buffer (Invitrogen, #NP0002) 






NP40-based lysis buffer  
20mM HEPES, 1mM EDTA, 150mM NaCl, 1% Nonidet 
P-40, 1mM dithiothreitol, 1 protease inhibitor tablet 
(#11873580001, Roche) per 50ml and 1 phosphatase 
inhibitor tablet (#88667SPCL, Pierce) per 10ml 
Native loading dye 
62.5mM Tris-HCl (pH 6.8), 40% glycerol, 0.01% 
Bromophenol Blue 
1X Tris-glycine native running 
buffer 
25mM Tris, 192mM glycine; pH 8.3 
1X Tris-glycine transfer buffer 25mM Tris, 192mM glycine, 10% methanol 
1X Tris-glycine running buffer 25mM Tris, 192mM glycine, 0.1% SDS; pH 8.3 
4X Resolving buffer 1.5M Tris-base, 8mM EDTA, 0.4% SDS; pH 8.8 
4X Stacking buffer 0.5M Tris-base, 8mM EDTA, 0.4% SDS; pH 6.8 
1X Tris-buffered saline (TBS) 50mM Tris Base, 150mM NaCl 
1X Phosphate-buffered saline 
(PBS) 
1 PBS tablet (Gibco, #003002) dissolved in 500ml of 
ddH2O 
3% Bovine Serum Albumin 
(BSA)-PBST 
3g of BSA (Melford) dissolved in 100ml of 1X PBS 
containing 0.02% Triton-X 
1% BSA-PBS 1g of BSA (Melford) dissolved in 100ml of 1X PBS 











Company Cat No. 
anti- ß-actin (AC-15) Mouse  1:5000 - Sigma, A1978 
anti- ß amyloid 1-17aa Mouse  1:1000 - Abcam 
anti- pSer9-SynapsinI Rabbit 1:1000 - Novus, NB300-180 
anti- SynapsinI a/b (223) Mouse  1:1000 - Santa Cruz, sc-37662 
anti- pTyr307-PP2A-
Calpha/beta 
Rabbit 1:1000 - Santa Cruz, sc-112615-R 
anti- vGlut 1 Mouse  - 1:1000 Synaptic systems 
anti- GAD65 Mouse  - 1:1000 Chemicon, MAB351R 
anti- apolipoprotein E Goat 1:2500 1:2500 Calbiochem, 178479 
anti- apolipoprotein E (E8) Mouse  1:1000 1:500 Santa Cruz, sc-393302 
anti- apolipoprotein E Rabbit 1:1000 1:500 
Aviva System, 
ARP54283_P050 
anti- apolipoprotein E 
(16H22L18) 
Rabbit 1:1000 1:500 Thermofisher, 701241 
anti- apolipoprotein E (WU 
E-4) 
Mouse  1:1000 1:500 Santa Cruz, sc-53570 
anti- apolipoprotein E 
(3H1) 
Mouse  1:100 - 
Ottawa Heart Institute, 
3H1 
anti- vimentin (V9) Mouse  1:5000 - Sigma, V6389 
anti- α-Tubulin (DM1A) Mouse  1:5000 - Sigma, T6199 
anti- pSer9-GSK-3β 
(D85E12) 
Rabbit 1:1000 - Cell Signalling, 5558S 
anti- pThr181-Tau (AT270) Mouse  1:1000 - Thermofisher, MN1050 
anti- Tau-1 (PC1C6) Mouse  1:1000 - Chemicon, MAB3420 
anti- Tau (D-8) Mouse  1:1000 - Santa Cruz, sc-166060 





Antibody  Host nm WB dilution ICC dilution Company Cat No. 
anti- mouse Goat 680 1:5000 - Cell Signalling, 5470S 
anti- mouse (IgM) Goat 680 1:5000 - Biotium, 20384 
anti- rabbit Goat 800 1:5000 - Cell Signalling, 5151S 
anti- goat Rabbit 680 1:5000 - Biotium, 20068 
anti- mouse Donkey 568 - 1:1000 Alexafluor, A10037 
anti- mouse Donkey 488 - 1:1000 Alexafluor, A21202 
anti- rabbit Donkey 488 - 1:1000 Alexafluor, A21206 
anti- goat Donkey 488 - 1:1000 Alexafluor, A11055 
Table 2-9 Secondary antibodies used for western blotting and immunocytochemistry 
 
2.6.3 Protein Extraction 
Following cell treatment, cells were washed twice with ice-cold 1X PBS and the culture 
plates were immediately placed on wet-ice. Cells were then immediately lysed using ice-
cold NP40 lysis buffer at volumes of 100µl/well for primary neurons and 200µl/well for 
cell lines. Whilst the plate was tilted on wet-ice, wells were scrapped to collect protein 
lysate at the bottom of the well. Cell lysate was transferred to micro centrifuge tubes on 
wet-ice and cellular debris was pelleted by a brief centrifugation for 2 minutes at 
13250rpm. The supernatant was transferred to new micro centrifuge tubes and stored 
at -20oC. 
 
2.6.4 Protein quantification 
A Bradford assay was used to determine the concentration of protein for all samples. 
Whilst the protein samples were thawing on wet-ice, concentrated Bradford reagent 
(Bio-Rad, #500-0006) was diluted five-fold in ddH2O and 1ml of this was added to 1mL 
cuvettes. Next, a series of BSA standards were prepared by diluting BSA stock (Bio-Rad, 
#500-0007) in diluted Bradford reagent in 1mL cuvettes. 2µl of each protein sample was 
also added to diluted Bradford reagent, mixed and the colour allowed to develop 
between for 5 minutes. For the blank, 2µl of NP40 lysis buffer was added instead. The 
standard curve was generated by reading the absorbance values of the BSA standards at 
595nm using the SmartSpecTM3000 spectrophotometer (Bio-Rad). The absorbance 




spectrophotometer used to determine the protein concentration based on the standard 
curve. 
 
2.6.5 Preparation of Aß42 Samples for Native and SDS Polyacrylamide Gel 
Electrophoresis (PAGE) 
Initially, an aliquot of 300µM Aß42 was thawed on wet-ice and then diluted to molarities 
of 5µM, 10µM, 15µM and 20µM in a total volume of 20µl that was adjusted with 
molecular grade water. For native PAGE, Aß42 samples were mixed with 5µl of native 
loading dye (1X final) and kept on wet-ice until used for native PAGE shortly after. For 
SDS PAGE, Aß42 samples were mixed with 5µl of LDS Sample Buffer (Invitrogen, 
#NP0008; 1X final) and 2µl of dithiothreitol (100mM final). After heating the Aß42 
samples to 70oC for 10 minutes with shaking, the Aß42 samples were kept on wet-ice 
until used for SDS PAGE. 
 
2.6.6 Preparation of Protein Extracts for SDS PAGE 
Protein lysate was diluted to final concentrations of either 1µg/µl or 2µg/µl, depending 
on the amount of protein available. Protein samples were prepared in a total volume of 
100µl by diluting the lysate with 25µl of LDS Sample Buffer (Invitrogen, #NP0008; 1X 
final), 10µl of NuPAGE Reducing Agent (Invitrogen, #NP0009) and molecular grade water 
to adjust the sample volume to 100µl. Protein samples were denatured by heating to 
70oC for 10 minutes with shaking and then kept on wet-ice until used for SDS PAGE. 
  
2.6.7 Native PAGE and Protein Staining 
Non-denaturing 15% Tris-glycine gels were first prepared by pouring the resolving gel 
solution (see Table 2-10 for recipe) between glass-plate cassettes (1.0mm thickness) 
from the Mini-PROTEAN® Tetra handcast system (Bio-Rad). 100% isopropanol was 
added dropwise across the resolving gel to prevent gel dehydration and the resolving gel 
solution was incubated at room temperature until the resolving gel had polymerised. 
After removing the isopropanol overlay by washing with dH2O, the 4% stacking gel 




Table 2-10 for recipe) and the comb was inserted into the glass-plate cassette. Once the 
stacking gel had polymerised, the gel/glass-plate cassette was transferred to a Mini-
PROTEAN® Tetra Electrode Assembly, which was then placed into the buffer tank. The 
chambers were filled with cold 1X Tris-Glycine Native running buffer and the comb was 
removed from the stacking gel. Protein samples were loaded into the wells along with 
1µl of BLUeye Prestained Protein Ladder (Geneflow, #S6-0024), which was used as a 
reference for protein size (kDa). The gel tank was partially submerged in wet-ice and the 
gel was electrophoresed at 90V until the bromophenol blue dye ran off the gel, which 
occurred by approximately 4.5 hours. The gel was removed from the gel glass-plate 
cassette and then stained using GelCode Blue Stain Reagent (#24590, Pierce) as per the 
manufacturer’s instructions. The protein bands were visualised by scanning the gel using 
the Odyssey Infrared Imaging System (Li-Cor Biosciences). 
 
  Stacking Gel Resolving Gel 
  4% 15% 
30% Bis-acrylamide 1.33ml 6ml 
1.5M Tris pH8.8 - 3ml 
1M Tris pH6.8 1.15ml - 
ddH2O 7.46ml 2.93ml 
TEMED 10µl 12µl 
10% APS 50µl 60µl 
Total Volume 10ml 12ml 
 
Table 2-10 Recipes for native stacking and resolving gel solutions for native PAGE 
 
2.6.8 Western Blotting 
2.6.8.1 Hand-cast Tris-glycine based SDS PAGE 
Resolving gels of varying bis-acrylamide percentages were first prepared according to 
the size of the proteins to be analysed (see Table 2-11 for resolving gel solution). The 
resolving gel solution was cast between glass-plate cassettes (1.0mm thickness) from 
the Mini-PROTEAN® Tetra handcast system (Bio-Rad) and overlayed with 100% 
isopropanol. The resolving gel was then incubated at room temperature until the 
resolving gel had polymerised. Once the isopropanol layer was removed by washing with 




inserted into the glass-plate cassette. Following polymerisation of the stacking gel, the 
gel/glass-plate cassette was transferred to a Mini-PROTEAN® Tetra Electrode Assembly, 
which was then placed into the buffer tank. The chambers were filled with 1X Tris-
glycine running buffer and the comb was removed from the stacking gel. Equal amounts 
of protein ranging between 20-30µg were loaded into wells alongside 1µl of BLUeye 
Prestained Protein Ladder (Geneflow, #S6-0024), which was used as a reference for 
protein size (kDa). The gel was then electrophoresed at 125V until the bromophenol dye 
ran off the gel, which typically occurred after 1.5 hours. 
 
  Stacking Gel Resolving Gel 
  4% 10% 12% 15% 
30% Bis-acrylamide 1.33ml 4ml 4.8ml 6ml 
4X Resolving gel buffer pH8.8 - 3ml 3ml 3ml 
4X Stacking gel buffer pH6.8 2.5ml - - - 
ddH2O 8.81ml 4.93ml 4.13ml 2.93ml 
TEMED 10µl 12µl 12µl 12µl 
10% APS 50µl 60µl 60µl 60µl 
Total Volume 10ml 12ml 12ml 12ml 
 
Table 2-11 Recipes for 4X stacking and resolving gel solutions for SDS PAGE 
 
2.6.8.2 Pre-cast Bis-Tris based SDS PAGE 
10% Bis-Tris gels (Invitrogen, NP0303) were used to examine apoE fragmentation 
patterns from protein extracts of apoE-transfected N2a and SH-SY5Y cells, as well as 
primary neurons transduced with apoE-expressing lentiviral vectors. To set-up the Bis-
Tris gel system, the comb and the gel wells were rinsed using dH2O. The white tape at 
the bottom of the gel cassette was also removed and the gel cassette was then placed in 
the XCell SureLock Mini-Cell gel running tank. The upper chamber of the tank was filled 
with 200ml of 1X NuPAGE MES SDS Running Buffer containing 500µl of NuPAGE 
Antioxidant and the lower chamber was filled with 600ml of 1X NuPAGE MES SDS 
Running Buffer. 20µg of protein sample was loaded into each well alongside 1µl of 
BLUeye Prestained Protein Ladder (Geneflow, #S6-0024), which was used as a reference 
for protein size (kDa). The gel was then electrophoresed at 200V until the bromophenol 





2.6.8.3 Protein transfer onto nitrocellulose membranes 
Once resolving of proteins was complete, the transfer cassette was next assembled. The 
gel was released from the gel cassette and the placed onto nitrocellulose membrane of 
either 0.22µm (Amersham, #15249794) or 0.45µm pore size (Amersham, #15220033), 
which was sandwiched between 2x filter papers followed by 2x blotting sponges on 
either side, soaked in 1X Tris-glycine transfer buffer. Pressure was applied across the top 
of the sandwich using a plastic roller to ensure remove trapped air bubbles and excess 
liquid between the gel and nitrocellulose membrane. Next, the transfer cassette was 
firmly closed and placed into a transfer tank submerged in wet-ice. Once the transfer 
tank was filled with cold 1X Tris-glycine transfer buffer, the proteins were transferred 
onto the nitrocellulose membrane at 100V for 1 hour. 
 
2.6.8.4 Immunoblotting  
The nitrocellulose membranes were blocked with nonfat dried milk (typically 2.5%; 5% 
was used for goat anti- apoE) in TBS containing 0.05% Tween-20 for 1.5 hours at room 
temperature with agitation. Next, the membranes were incubated with primary 
antibodies (see Table 2-8) diluted in 2.5% or 5% nonfat dried milk in TBS for either 2 
hours at room temperature or overnight at 4oC. Following two washes in 1X TBS for 10 
minutes each, the blots were incubated with secondary antibodies (see Table 2-9) 
diluted in 2.5% or 5% nonfat dried milk in TBS for 1 hour at room temperature whilst 
protected from light. The two wash steps were repeated and the damp membrane 
placed into an Odyssey CLx Imaging System (LI-COR Biosciences) to visualise the protein 
bands. The proteins were detected by scanning the blots at near-infrared fluorescence 
detection at either 800nm or 700nm. After scanning, the blots were stored at -20 oC in 
1X TBS in sealed bags for further immunoblotting. For re-probing with additional 
antibodies, the blots were thawed at room temperature and washed briefly with 1X TBS. 
Blots were then incubated with antibodies as previously described. 
 
2.6.9 Analysis of blots 
Protein bands were quantified by using Image Studio 4.0 software (LI-COR) as per the 
Odyssey CLx Tutorial Guide. The ‘western analysis’ function was first applied after gel 




the lanes’ function was next applied to define the protein lanes, and the lane lines were 
adjusted to transect the protein bands if necessary. The protein ladder marker was next 
set up by inputting the approximate size (kDa) for each band of the protein ladder so 
that the size (kDa) of sample protein bands could be determined. Protein bands of 
interest were selected in discrete boxes by using either ‘find the bands automatically’ 
function or by using the ‘add rectangle’ function. Once all protein bands of interest were 
selected, the background subtraction method was applied by using the background 
settings of: median value, a border width of 3 and either right/left or top/bottom 
according to the proximity of neighbouring bands. The signal values were then 
calculated by the software and displayed within the western bands table. These signal 
values were then processed by using Excel software. 
 
2.6.10 Immunocytochemistry 
Following cell treatment, cells in 12-well plates were briefly washed twice with 1X PBS 
and fixed using 500µl of 4% PFA per well. After a 7-minute incubation at room 
temperature, cells were briefly washed twice again. Cells were then blocked and 
permeabilised for 45 minutes at room temperature using 500µl of 3% BSA-PBST per well. 
Coverslips containing the cell monolayer on top were then carefully transferred onto a 
12-well plate lid covered in parafilm. 100µl of primary antibody (see Table 2-8) diluted in 
1% BSA-PBS was added to each coverslip and coverslips were incubated in a moist 
chamber for 2 hours at room temperature. Coverslips were transferred to wells in a 
clean 12-well plate and washed three times with 1X PBS for 5 minutes each time. After 
transferring coverslips back to the parafilm-covered lid, coverslips were incubated with 
100µl of secondary antibody (see Table 2-9) diluted in 1% BSA-PBS and incubated for 1 
hour at room temperature in a moist chamber protected from light. Coverslips were 
washed two times with 1X PBS as before and then incubated for 1 minute with 500µl of 
1X Hoescht solution to stain cell nuclei. After two washes with 1X PBS for 5 minutes each 
to remove excess Hoescht staining, coverslips were mounted onto microscope slides cell 
side down using 5µl of ProLong Gold Anti-Fade Mountant (Invitrogen, #P36930). The 
microscope slides were incubated at room temperature overnight in a dry and dark 




storage or -20oC for long-term storage. Cells were visualised and imaged as Z-stacks 
using a spin disc confocal system (CARV from Digital Imaging Solutions) with an EM-CCD 
camera (Rolera/QI Cam 3500) combined with Image Pro 6.0 software. 
 
2.7 Data Analysis and Statistics 
Microsoft Excel was used to calculate percentage and ratio-fold changes from raw data. 
Statistical analysis of data was carried using GraphPad Prism 7 software. Initially, a 
Shapiro-Wilk normality test was performed to determine whether the data followed a 
normal distribution. Once confirming that the data were parametric, statistical 
significance was tested using either a Student’s t-test or a one-way ANOVA followed by a 
Tukey’s multiple comparison test on GraphPad Prism 7 software, as appropriate. 
GraphPad Prism 7 software was also used for graphical presentation of data, where all 
error bars shown are based on standard error of the mean (SEM). The measurement of 
data variability reported in text with the mean is SEM. N numbers represent 
independent experiments. Independent experiments involving primary neuronal 





Chapter 3 Aß42 AND VPA AFFECT SYNAPSIN I REGULATION 
3.1 INTRODUCTION 
Synaptic dysfunction and loss is considered an early event that correlates strongly with 
cognitive decline in AD (Davies et al., 1987, Terry et al., 1991, DeKosky and Scheff, 1990, 
Scheff et al., 2006, Scheff et al., 2007). Whilst the molecular basis for this is still unclear, 
there is mounting evidence supporting the involvement of soluble Aß oligomers. Indeed, 
accumulation of soluble Aß oligomers has been linked to deficits in cognitive function 
and memory (Tomiyama et al., 2010, Umeda et al., 2014) and this is thought to be partly 
caused by an impairment of synaptic plasticity (reviewed in sections 1.5.4 and 1.5.5). 
Interestingly, there is evidence to suggest that the effects of Aß on synaptic plasticity 
may occur through Aß affecting multiple aspects of SV dynamics at the presynapse in a 
concentration and time dependent manner. It has been demonstrated that low 
concentrations or short exposure of hippocampal neurons to Aß oligomers increase the 
release probability of the RRP at the presynapse and induce LTP (Puzzo et al., 2008, 
Parodi et al., 2010, Russell et al., 2012), whereas high concentrations or longer exposure 
times disrupt endocytosis and SV recycling, reducing the size of the RRP and inhibiting 
LTP (Puzzo et al., 2008, Parodi et al., 2010, Kelly and Ferreira, 2007). Although the 
mechanisms underlying this are still not fully understood, it is increasingly evident that 
this involves interference with the function of proteins that regulate SV dynamics. 
Indeed, studies have shown that Aß oligomers can disrupt the function of proteins that 
modulate priming of SVs for neurotransmitter release and SV endocytosis (Kelly et al., 
2005, Kelly and Ferreira, 2006b, Kelly and Ferreira, 2007, Yang et al., 2015, Russell et al., 
2012). However, considering that there are many proteins that regulate SV dynamics 
(Rizzoli, 2014), it is possible that there are other proteins that may also be affected by 
Aß oligomers either directly, or indirectly through Aß-mediated alterations in calcium 
signalling. Since deregulation of SnpI, a key SV-associated protein, has been linked to AD 
(Parks et al., 1991), the present study explored the hypothesis that Aß42 oligomers 
deregulate SnpI. 
 
SnpI belongs to a family of neuronal phosphoproteins that play an important role in 




SVs under resting conditions and during neuronal activity through transient interactions 
with SVs and cytoskeletal components (Cesca et al., 2010, Fornasiero et al., 2012, 
Baldelli et al., 2007). This function is tightly regulated by activity-dependent cycles of 
phosphorylation and dephosphorylation at multiple residues across the protein, which 
alter the binding affinity of synapsins for SVs, other synaptic proteins and the actin 
cytoskeleton (Cesca et al., 2010, Shupliakov et al., 2011). One such residue is Ser9 (site 
1), which is located within a small lipid binding domain of the N-terminus and is 
conserved amongst all synapsin isoforms (Cesca et al., 2010). Cycles of phosphorylation 
and dephosphorylation at Ser9 of synapsins modulates the proteins phospholipid-
binding activity, enabling the protein to act as a transient linker between SVs and actin, 
clustering them in the reserve pool (Huttner et al., 1983, Hosaka et al., 1999, Benfenati 
et al., 1989). It has been proposed that the activity-dependent phosphorylation of Ser9 
by PKA and CAMKI/IV results in dissociation of SnpI from SVs, enabling them to 
participate in neurotransmitter release (Huttner et al., 1983, Hosaka et al., 1999, 
Fiumara et al., 2004). Conversely, dephosphorylation at Ser9 by PP2A increases the 
affinity of SnpI for SVs, tethering them to the actin cytoskeleton and replenishing the 
reserve pool (Jovanovic et al., 2001, Ceccaldi et al., 1995, Bloom et al., 2003). There is 
evidence to suggest that this function of SnpI may be affected in AD, as an early study 
showed that the levels of SnpI phosphorylated at Ser9 (pSer9-SnpI) were higher in post-
mortem brain tissue from AD patients (Parks et al., 1991). Moreover, previous 
immunocytochemistry experiments in our lab indicated that this may be related to Aß42 
oligomers. In this earlier work, Aß42 oligomers were found to induce an increase in the 
localisation of pSer9-SnpI at synaptic boutons of cultured hippocampal neurons 
recovering from neuronal activity, suggesting that Aß42 oligomers either affect the 
distribution of pSer9-SnpI or the phosphorylation cycle of SnpI at Ser9. Hence whether 
Aß42 oligomers deregulate the phosphorylation or dephosphorylation of SnpI at Ser9 
was explored in the present study by examining the levels of SnpI, pSer9-SnpI and the 
active form of PP2A by western blotting. Here, the data revealed that Aß42 oligomers 
induce sustained phosphorylation of SnpI at Ser9 in neurons recovering from neuronal 





There are few studies that have examined whether currently available drugs can block 
or reverse the effects of Aß42 on SV-associated proteins and SV dynamics. Interestingly 
though, a recent study showed that VPA, a short branch-chained fatty acid, can prevent 
Aß-induced reduction in SV recycling (Williams and Bate, 2016). In addition, this 
compound was previously shown to promote clustering of SnpI in cultured neurons (Hall 
et al., 2002). In view of these reports and the Aß42-mediated deregulation of SnpI 
shown here, VPA was considered a candidate therapeutic drug to attenuate the effect of 
Aß42 on SnpI. Therefore, the work in this this chapter also explored the hypothesis that 
the therapeutic action of VPA in SV recycling could be mediated through protection of 
SnpI regulation. 
 
To investigate the above hypotheses, Aß42 and/or VPA was applied to primary 
hippocampal neurons that that had been cultured for 18-21DIV, because at this time 
point, neurons exhibit established synaptic junctions and increased levels of synaptic 
proteins (Grabrucker et al., 2009, Kim and Lee, 2012, Sapoznik et al., 2006). Since it has 
previously been shown in our lab that intraneuronal accumulation of Aß42 has been 
linked to SV-associated protein disruption (Russell et al., 2012), it was of interest to 
explore whether intraneuronal Aß42 oligomers deregulate SnpI. To do so, neurons were 
exposed to Aβ42 peptides for 30 minutes followed by a 2-hour period in the absence of 
peptide because immunocytochemistry experiments showed that Aß42 can be 
internalised and localised to the presynapse during this time-frame (Russell et al., 2012). 
Moreover, to assess whether Aß42 oligomers affect the activity-dependent 
phosphorylation cycle of SnpI at Ser9, neurons were depolarised with KCl for 5 minutes 
to induce neuronal activity and SnpI phosphorylation, and allowed to recover for 15 
minutes after KCl-induced neuronal activity to allow time for SnpI dephosphorylation at 
Ser9. 
 
The work presented here shows for the first time that Aß42 oligomers affect the 
regulation of SnpI phosphorylation at Ser9, thus indicating a possible mechanism for 
how Aß contributes to defects in SV dynamics and neurotransmitter release. The data 




play a part in its therapeutic role in restoring physiological SV dynamics. Hence, the work 
here provides support for its use in the treatment of AD, in addition to its clinically 





3.2.1 Characterisation of synthetic Aß42 peptide preparations 
Since reconstituted synthetic Aß42 peptides readily aggregate to form oligomers, 
protofibriils and fibrils, it was important to routinely examine the aggregation state of 
the Aß42 peptide mixture for consistency between different preparations. Commercially 
available synthetic Aß42 was reconstituted in DMSO and diluted to working aliquots in 
1X PBS. A sample of stock Aß42 was separated on both native and SDS polyacrylamide 
gels to examine the assembly state of each Aß42 preparation. The native gels were 
stained with GelCode blue stain reagent to reveal protein bands, and protein on SDS gels 
was transferred to nitrocellulose membrane and probed with a monoclonal anti-Aß 
(6E10) antibody that recognises 1-17aa of Aß.  
 
On native gels, a single band with a molecular weight of  2̴0 kDa (Figure 3-1, A) was 
routinely observed indicating that the peptide preparations consist of small pentameric 
oligomers. Hence, the method of Aß42 preparation was efficient for the production of 
low molecular weight oligomeric Aß42, which are believed to be the more toxic 
assembly states of Aß42 to neurons (Ahmed et al., 2010b). These oligomers could be 
broken down into monomers ( ̴4.5 kDa) and dimers/trimers ( ̴13.5 kDa) on an SDS PAGE 
gel (Figure 3-1, B). This indicated that the pentameric oligomers were not SDS-stable and 
that they had not adopted a ß-sheet conformation (Ahmed et al., 2010b), a secondary 
structure that is characteristic of the less toxic, fibrillar form of the peptide (Kirschner et 
al., 1986). Indeed, this is in accordance with work showing that Aß42 does not exhibit a 
ß-sheet structure when dissolved in DMSO (Shen and Murphy, 1995). Considering this 
preparation method consistently produced low molecular weight oligomers, all Aß42 





Figure 3-1 Aß42 preparation contains aggregated assembly states 
 (A) Native gel electrophoresis of increasing concentrations of synthetic Aβ42 reveals a single band at ~20 
kDa, indicating a pentameric assembly state. (B) SDS-PAGE of increasing concentrations of synthetic Aβ42 
shows that the oligomers can be broken down into monomers (4.5 kDa) and trimers (13.5 kDa) in the 






3.2.2 Characterisation of primary hippocampal cultures 
Since primary hippocampal neuronal cultures are typically not uniform and contain a 
combination of GABAergic interneurons and glutamatergic pyramidal neurons, the 
heterogeneity of the cultures were first assessed. Cultures were immunolabelled for  the 
glutamate transporter, vGlut, and the GABA producing enzyme, GAD65, to visualise the 
proportion of glutamatergic and GABAergic synapses respectively (Figure 3-2). 
Immunostaining revealed a stronger and more wide-spread staining for vGlut compared 
to GAD65. This suggests that the neuronal cultures used were enriched in glutamatergic 
synapses. Hence any effects of Aß42 on the cultured hippocampal neurons are likely 
associated with an effect on glutamatergic neurons. 
 
 
Figure 3-2 Primary hippocampal cultures are enriched in glutamatergic synapses. 
Immunolabelling of primary hippocampal neurons for vGlut (A) and GAD65 (B) reveals that the primary 
cultures are enriched in glutamatergic synapses. Scale bar 50 μM. 
 
3.2.3 Aß42 disrupts the phosphorylation cycle of SnpI 
Previous immunocytochemistry experiments in our lab showed that the localisation of 
pSer9-SnpI at synaptic boutons remained elevated in cultured hippocampal neurons 
exposed to Aß42 oligomers and that this effect could be attenuated when neurons were 
treated with VPA after exposure to the peptide. This was hypothesised to be due to 
either an Aß42-induced restriction of pSer9-SnpI dispersal and/or disruption of the 
phosphorylation cycle of SnpI at Ser9. Hence in the present study, western blotting was 
performed to determine whether the phosphorylation cycle of SnpI at Ser9 was affected 




total SnpI and pSer9-SnpI in protein extracts from Aß-treated, VPA-treated and Aß/VPA-
treated synchronised and recovering neurons were compared. First the effect of Aß42 
and VPA on the relative levels of total SnpI was examined by densitometric analysis of 
SnpI and actin protein bands on immunoblots (Figure 3-3, A). The ratio of SnpI to actin 
was calculated for each condition, and then normalised to the SnpI/actin ratio of 
synchronised control neurons (considered as 100%). The relative levels of SnpI for each 
condition are shown in the bar chart in Figure 3-3, B. Statistical analysis  of total SnpI 
levels did not reveal any significant differences between conditions in synchronised 
neurons (Figure 3-3, B; black bars; 147.6%±8.6 VPA 1mM, 124.8%±34.7 VPA 10mM, 
222.2%±33.4 Aß42, 269.9%±70.6 Aß42/VPA 1mM, 166.2%±51.2 Aß42/VPA 10mM; 
p>0.05). or recovering neurons (Figure 3-3, B; grey bars; 87.1%±14.1 VPA 1mM, 
123.9%±35 VPA 10mM, 195.5%±41.7 Aß42, 193.7%±63.1 Aß42/VPA 1mM, 125.2%±27.4 
Aß42/VPA 10mM; p>0.05). Although there was an increase in the levels of SnpI in Aß42- 
and Aß42/VPA- treated neurons, this was not statistically significant because of high 
variation between experiments. Therefore, these data indicate that acute treatment of 





Figure 3-3 SnpI levels are unaffected by acute Aß42 or VPA treatment in rat hippocampal neuronal 
cultures 
(A) Representative western blots showing SnpI and actin protein from synchronised or 15 minute post-
synchronised rat hippocampal neuronal cultures treated with 300nM Aß42 for 30 minutes and/or VPA (1 
or 10mM) for 2 hours after exposure to the peptide. Neurons were synchronised by a 5 minute KCl 
application to induce depolarisation. (B) Bar chart showing the levels of SnpI based on the intensity 
ratios of SnpI to actin. The ratio values were normalized to control as 100% for all conditions. The black 
bars show SnpI levels in synchronised neurons and the white bars show SnpI levels in neurons 15 
minutes after synchronisation. Statistical anlaysis of SnpI levels by a one-way ANOVA followed by a 
Tukey’s multiple comparison test did not reveal any significant differences for SnpI levels between 
conditions (p values >0.05). Data are mean ±SEM; n=4. 
 
The effect of Aß42 and VPA on the relative levels of pSer9-SnpI was next examined by 
densitometric analysis of immunoblots probed for pSer9-SnpI and total SnpI protein 
(Figure 3-4, A). The ratio of pSer9-SnpI to SnpI was calculated for each condition and 




(considered as 100%). The relative levels of pSer9-SnpI for each condition are shown in 
the bar chart in Figure 3-4, B. Statistical analysis of pSer9-SnpI levels did not reveal 
significant differences between conditions from synchronised neurons to control 
synchronised neurons (Figure 3-4, B; black bars; 100.3%±17.5 VPA 1mM, 92.2%±6.7 VPA 
10mM, 88.9%±5.8 Aß42, 101.4%±15.1 Aß42/VPA 1mM, 99.54%±17.1 Aß42/VPA 10mM; 
p>0.05). This suggests that the activity-dependent phosphorylation of SnpI at Ser9 is not 
affected by Aß42, VPA or their combination in neuronal cultures. However, significant 
differences in pSer9-SnpI levels were found in neurons recovering from neuronal activity 
relative to synchronised neurons (Figure 3-4, B; grey bars). The level of pSer9-SnpI was 
significantly reduced in recovering control neurons compared to synchronised control 
neurons (48.7%±6 recovering control neurons, p=0.003), which is consistent with studies 
showing that the Ser9 residue of SnpI is dephosphorylated after neuronal activity 
(Hosaka et al., 1999). Likewise, a significant reduction in the level of pSer9-SnpI was 
observed in recovering VPA-treated neurons when compared to synchronised neurons 
(42.5%±5.7 recovering 1mM VPA-treated neurons and 47.8%±7.2 recovering 10mM 
VPA-treated neurons, p<0.05), suggesting that VPA does not affect the phosphorylation 
cycle of SnpI at Ser9. In contrast, the level of pSer9-SnpI in recovering Aß42-exposed 
neurons was not significantly different to synchronised Aß42-exposed neurons 
(74.1%±2.1 versus 88.9%±5.8, p>0.05). Moreover, recovering Aß42-treated neurons 
showed higher levels of pSer9-SnpI compared to recovering control neurons (74.1%±2.1 
versus 48.7%±6, p=0.015). These data suggest that exposure of neurons to Aß42 either 
prevents dephosphorylation of SnpI at Ser9 or induces sustained phosphorylation of 
SnpI at Ser9 after neuronal activity. Interestingly, a significant reduction in the levels of 
pSer9-SnpI was observed in recovering Aß42/VPA-treated neurons compared to 
recovering Aß42-treated neurons (60.8%±9.2 recovering Aß42/1mM VPA-treated 
neurons, p=0.045 and 40.1%±7.1 recovering Aß42/10mM VPA-treated neurons, 
p=0.005). Moreover, recovering Aß/VPA-treated neurons showed similar pSer9-SnpI 
levels to recovering control neurons (p>0.05). Therefore, these data indicate that VPA 
may attenuate the Aß42-mediated deregulation of SnpI 






Figure 3-4 Aß42 and VPA affect pSer9-SnpI levels in rat hippocampal neuronal cultures 
(A) Representative western blot showing pSer9-SnpI and SnpI protein from synchronised or 15 minute 
post-synchronised (recovering) rat hippocampal neuronal cultures treated with 300nM Aß42 for 30 
minutes and/or VPA (1 or 10mM) for 2 hours after exposure to the peptide. Neurons were 
synchronised by a 5 minute KCl application to induce depolarisation. (B) Bar chart showing the levels of 
pSer9-SnpI based on the intensity ratios of pSer9-SnpI to SnpI. The ratio values were normalized to 
synchronised control neurons as 100% for all conditions. The black bars show pSer9-SnpI levels in 
synchronised neurons and the grey bars show pSer9-SnpI levels in neurons 15 minutes after 
synchronisation (recovering neurons). No significant differences for the levels of pSer9-SnpI were found 
between conditions in synchronised neurons. However, significant differences for pSer9-SnpI levels 
were found in recovering control and Aß42-treated neurons. Significant differences were also observed 
between recovering Aß42-treated neurons, Aß42/1mM VPA-treated neurons and Aß42/10mM VPA-
treated neurons. Data are mean ±SEM, and differences were assessed using one-way ANOVA followed 





3.2.4 Aß42 induces sustained phosphorylation of SnpI at Ser9 
It was hypothesised that the elevated levels of pSer9-SnpI induced by Aß42 in recovering 
neurons could be due to sustained phosphorylation at Ser9 by PKA and/or CAMKI/IV 
(Czernik et al., 1987), or due to reduced dephosphorylation by PP2A (Jovanovic et al., 
2001). The phosphatase function of PP2A is regulated by phosphorylation at Tyrosine 
307, which is located within the conserved C-terminus of the catalytic regulatory subunit. 
Phosphorylation at this site inactivates PP2A, decreasing its phosphatase activity (Chen 
et al., 1992). Hence to investigate whether the elevated levels of pSer9-SnpI in 
recovering neurons exposed to Aß42 were due to reduced dephosphorylation activity, 
the relative levels of pTyr307-PP2A were examined for protein extracts from neurons 
treated as previously described. Western blotting was performed using anti- pTyr307-
PP2A and anti- actin antibodies (Figure 3-5, A) and the relative levels of pTyr307-PP2A 
were calculated by densitometric analysis of pTyr307-PP2A and actin protein bands. The 
ratio of pTyr307-PP2A to actin was calculated for each condition and normalised to the 
pTyr307-PP2A:actin ratio of synchronised control neurons (100%). Statistical analysis 
was performed by a one-way ANOVA followed by a Tukey’s multiple comparison post-
hoc test to examine for significant differences in pTyr307-PP2A between conditions. The 
relative levels of pTyr307-PP2A for each condition are shown in the bar chart in Figure 
3-5, B. No significant differences in the levels of phosphorylated Tyr307-PP2A were 
found in synchronised neurons (Figure 3-5, B; black bars; 136.1%±16.1 VPA 1mM, 
109.8%±6.7 VPA 10mM, 126.5%±22.3 Aß42, 139.5%±27 Aß42/VPA 1mM, 115.3%±15.4 
Aß42/VPA 10mM; p>0.05) or in recovering neurons (Figure 3-5, B; grey bars; 104.3%±7.7 
control, 136.7%±30.8 VPA 1mM, 101.1%±9.6 VPA 10mM, 107.5%±17.5 Aß42, 
128.5%29.2 Aß42/VPA 1mM, 105.7%±15.5 Aß42/VPA 10mM; p>0.05). This result 
suggests that acute exposure of neurons to Aß42 does not alter the catalytic activity of 
PP2A. Therefore, the elevated levels of pSer9-SnpI in Aß42-exposed recovering neurons 
are likely not due to defective dephosphorylation of Ser9 by PP2A, but may instead 





Figure 3-5 Aß42/VPA treatment does not affect the phosphorylation of PP2A at Tyrosine 307 in rat 
hippocampal neuronal cultures 
(A) Representative western blots showing pTyr307-PP2A and actin protein from synchronised or 15 
minute post-synchronised (recovering) rat hippocampal neuronal cultures treated with 300nM Aß42 for 
30 minutes and/or VPA (1 or 10mM) for 2 hours after exposure to the peptide. Neurons were 
synchronised by a 5 minute KCl application to induce depolarisation. (B) Bar chart showing the levels of 
pTyr307-PP2A based on the intensity ratios of pTyr307-PP2A to SnpI, expressed as percentages of 
synchronised control neurons. The black bars show pTyr307-PP2A levels in synchronised neurons and 
the white bars show pTyr307-PP2A levels in neurons 15 minutes after synchronisation. Statistical 
analysis by a one-way ANOVA followed by a Tukey’s multiple comparison test did not reveal any 
significant differences for pTyr307-PP2A levels between conditions in both synchronised and recovering 






The work presented in this chapter was carried out to investigate the molecular basis of 
Aß-mediated SV disruption and the protective effect of VPA on SV dynamics through 
exploring the hypothesis that Aß oligomers deregulate SnpI and that VPA may attenuate 
this effect. The data confirmed that Aß42 does indeed deregulate SnpI and that VPA can 
attenuate this, highlighting a novel molecular mechanism underpinning Aß42-mediated 
disruption and the therapeutic effect of VPA in AD. 
 
3.3.1 Aß42 oligomers deregulate the phosphorylation cycle of SnpI at Ser9 
To investigate the effect of Aß42 oligomers on SnpI regulation, the assembly state of 
synthetic Aß42 used in this work was first characterised to confirm that the preparation 
method used could generate low molecular weight oligomeric Aß42. This was of 
importance since these assemblies of Aß42 are thought to be more toxic compared to 
higher molecular weight aggregates of the peptide (Ahmed et al., 2010a). Moreover, low 
molecular weight oligomers have been shown to disrupt the function of other SV-
associated proteins such as synaptophysin (Russell et al., 2012). Having confirmed this, 
the effect of Aß42 oligomers on the levels of SnpI protein was assessed. The results 
presented here showed that the overall levels of SnpI were unaffected in neurons 
exposed to Aß42 for a short time-period, indicating that Aß42 oligomers do not affect 
the expression or degradation of SnpI under the conditions used here. It is notable 
though that several studies have reported a reduction of synaptic proteins in neurons 
exposed to Aß oligomers, including SnpI (Parodi et al., 2010, Kelly et al., 2005, Ripoli et 
al., 2013). There are several factors that could contribute to this difference, such as the 
length of time neurons are incubated with the peptide and concentration used. Indeed, 
a time- and concentration- dependent effect on the reduction of the levels of synaptic 
proteins by Aß oligomers has been demonstrated (Kelly et al., 2005, Parodi et al., 2010). 
For instance, a significant reduction in SnpI levels was only evident in neuronal cultures 
after a continuous exposure to 500nM oligomeric Aß for 12 hours in the study by Parodi 
and colleagues. Taken together, this finding supports the notion that the reduction of SV 
proteins associated with Aß42 is likely a chronic effect, occurring in the later stages of 




were next examined to determine if Aß42 oligomers affect the regulation of SnpI. 
Neurons that were exposed to Aß42 and recovering from neuronal activity exhibited 
elevated levels of SnpI phosphorylated at Ser9. Consistent with this observation, a later 
independent study also showed that Aß42 increased SnpI phosphorylation at Ser9 in 
primary neuronal cultures, but also in cultured neurons from 5XFAD rodents (Park et al., 
2017). Overall, these data demonstrate that Aß42 oligomers disrupt the physiological 
regulation of SnpI phosphorylation at Ser9.  
 
3.3.2 Aß42 oligomers induce sustained phosphorylation of SnpI at Ser9 
The mechanism underpinning the deregulation of SnpI by Aß42 oligomers was also 
explored in this work. The sustained phosphorylation of SnpI at Ser9 could be due to 
sustained kinase activity by CAMKI/IV and/or PKA, or reduced phosphatase activity by 
PP2A. To determine whether sustained pSer9-SnpI levels was a result of reduced 
phosphatase activity, the activity of PP2A was examined. Since PP2A is inactivated by 
phosphorylation at Tyrosine-307 (Chen et al., 1992), the relative levels of pTyr307-PP2A 
were calculated to provide an indicator of its activity. The results presented here 
showed similar levels of pTyr307-PP2A in all conditions suggesting that the activity of 
PP2A was unaffected by acute exposure of neurons to Aß42. This result indicates that 
the sustained phosphorylation of SnpI in Aß42-exposed neurons is likely due to 
maintained activity-dependent kinase activity. Indeed, this has since been confirmed by 
Park and colleagues who showed that levels of activated CAMKIV (pThr196-CAMKIV) 
were higher in neurons following acute application (2-hours) of Aß42 at a similar 
concentration (200nM) (Park et al., 2017). In addition, inhibition of CAMKK, the kinase 
responsible for increasing CAMKIV activity by phosphorylating CAMKIV at Threonine 196 
(Selbert et al., 1995), reduced the levels of pSer9-SnpI in Aß42-exposed neurons (Park et 
al., 2017). In further support of a relationship between Aß42 and enhanced CAMK 
signalling, AD rodent models such as 3xTG-AD mice have been reported to display high 
levels of pThr196-CAMKIV (Muller et al., 2011). Importantly, initial activation of CAMKIV 
is dependent on intracellular calcium levels and calmodulin, since calcium/calmodulin 
binding is required for exposure and thus phosphorylation of the Thr196 site by CAMKK 




activity is autonomous and persists for a period after the calcium stimulus. In view of 
this and studies showing that Aß42 induces increased calcium influx in primary neurons 
(Parodi et al., 2010, Park et al., 2017), it is feasible that the sustained phosphorylation of 
SnpI at Ser9 is mediated by autonomous CAMKIV activity triggered by Aß42-induced 
calcium influx. It is also tempting to hypothesise that the autonomous CAMKIV activity 
triggered by Aß42 oligomers may lead to prolonged SnpI deregulation, thereby also 
implicating SnpI deregulation in chronic effects of Aß42 too. In summary, these findings 
suggest that Aß42-induced deregulation of SnpI phosphorylation dynamics may be 
consequent to Aß-mediated calcium influx, which in turn promotes CAMK signalling, 
thus altering the regulation of CAMK substrates such as SnpI. Further work could involve 
confirming that the levels of activated CAMKIV are increased under the experimental 
conditions used here.  It would also be of interest to investigate whether the regulation 
of other CAMK substrates at the pre-synapse are affected in further work. 
 
3.3.3 Aß42-mediated deregulation of SnpI may contribute to SV cycle defects 
Aß42-induced deregulation of SnpI is notable since SnpI plays a key role in the 
availability of SVs for neurotransmission and organisation of the SV reserve pool. As 
mentioned previously, these functions are tightly regulated by activity-dependent cycles 
of phosphorylation and dephosphorylation at various residues across the protein. The 
Ser9 residue is responsible for modulating the phospholipid-binding activity that 
facilitates SnpI to act as a transient linker between SVs and actin (Huttner et al., 1983). 
Whilst the activity-dependent phosphorylation of Ser9 has been suggested to promote 
dissociation of SnpI from SVs and subsequently enable SVs to participate in 
neurotransmission, dephosphorylation of Ser9 is thought to promote SnpI-SV 
association, leading to SV re-clustering and replenishment of the reserve pool (Hosaka et 
al., 1999, Fiumara et al., 2004, Ceccaldi et al., 1995, Bloom et al., 2003). On this basis, it 
is possible that sustained phosphorylation of SnpI at Ser9 by Aß42 could result in 
increased availability of SVs for neurotransmitter release. Indeed, this hypothesis is in 
accordance with studies which have shown that acute exposure of neurons Aß 
oligomers promotes neurotransmitter release (Puzzo et al., 2008, Abramov et al., 2009, 




CAMKIV activity could disrupt SnpI-SV association during recovery from neuronal activity, 
which in turn, could impair SV recycling and the maintenance of the reserve pool. Hence 
it is conceivable that Aß42-mediated deregulation of SnpI may contribute to the 
reported deficits in SV recycling, but also the depletion of SV pools observed in primary 
neurons following chronic exposure to Aß oligomers (Kelly and Ferreira, 2007, Parodi et 
al., 2010, Williams and Bate, 2016). Overall, these findings support the notion that the 
deregulation of SnpI by Aß42 oligomers may contribute to both the early and chronic 
deficits in SV dynamics and synaptic transmission triggered by Aß oligomers. Indeed, 
SnpI phosphorylation at Ser9 may initially enhance glutamate release during the early 
stages of synaptic dysfunction, which could promote excitotoxicity. However, the 
possible reduction in SV recycling and clustering of SVs in the reserve pool due to 
sustained phosphorylation of SnpI at Ser9 could gradually lead to depletion of SVs and 
impaired neurotransmission. For further work, the functional effect of sustained 
phosphorylation of SnpI at Ser9 by Aß42 could be investigated by comparing the 
recycling of SVs in Aß42-exposed cultured hippocampal neurons that are WT or 
expressing a Ser9-phospho-deficient mutant of SnpIa. 
 
3.3.4 VPA attenuates the disruptive effect of Aß42 oligomers on SnpI regulation 
Since the data presented here revealed that Aß42 oligomers affect SnpI regulation, it 
was of interest to look for available drugs that could potentially interfere with this effect. 
VPA was selected as a candidate molecule because it has been shown to induce 
clustering of SnpI (Hall et al., 2002), as well as to restore physiological SV recycling that 
was reduced in neurons exposed to Aß42 (Williams and Bate, 2016). Treatment of 
neurons with VPA did not affect the physiological regulation of SnpI protein levels or 
phosphorylation. Remarkably however, the results showed that treatment of Aß42-
exposed neurons with VPA restored physiological pSer9-SnpI levels in a concentration 
dependent manner, suggesting that VPA may act antagonistically of Aß42. Since this 
could occur through reduced kinase or increased phosphatase activity, the levels of 
pTyr307-PP2A were examined for Aß42/VPA-treated neurons. The data showed that 
VPA treatment did not affect the levels of inactivated PP2A. Therefore, it is plausible 




by interfering with the maintained kinase activity of CAMKIV that is triggered by Aß42-
mediated calcium influx (Park et al., 2017). There is very little evidence in the literature 
on whether VPA affects CAMK signalling, and given the data discussed here, it would be 
an interesting avenue to explore in future studies. One possible mechanism underlying 
the protective effect of VPA in SnpI regulation which warrants investigation, is 
downregulation of CAMK signalling and thus decreased SnpI phosphorylation at Ser9, 
through altered phosphoinositide signalling. The basis for this speculation stems from a 
study that showed constitutive CAMKIV hyperphosphorylation was reduced when 
phosphoinositide signalling was attenuated (Muller et al., 2011), and other studies 
which demonstrate VPA can also alter phosphoinositide signalling (Xu et al., 2007b, 
Chang et al., 2012). It is also possible that VPA may interfere with the other kinases 
responsible for phosphorylation Ser9 of SnpI such as PKA. Indeed, VPA has also been 
shown to downregulate PKA activity through inhibiting the accumulation of cAMP 
(Chang et al., 2010), thus highlighting another potential mechanism underpinning the 
antagonistic effect of VPA on Aß-mediated SnpI deregulation. In view of the protective 
effect of VPA on SnpI regulation and SV dynamics (Marsh et al., 2017, Williams and Bate, 
2016), VPA may provide therapeutic benefit in AD, particularly during the early stages of 
Aß-mediated synaptic dysfunction, which is likely when SnpI deregulation is triggered. In 
support of this hypothesis, it was reported that memory deficits observed in transgenic 
AD mouse models were reduced to a greater extent when VPA treatment was used early 
(Qing et al., 2008). 
 
3.3.5 Conclusion 
To conclude, the work in this chapter highlights a novel mechanism for how 
accumulation of intraneuronal Aß42 can contribute to synaptic dysfunction during the 
early stages of AD. The evidence suggests that Aß42 deregulates SnpI phosphorylation 
through altered CAMK signalling, leading to sustained CAMKIV kinase activity. It also 
highlights a novel therapeutic mode of action for VPA in AD, since VPA treatment can 
attenuate the effect of Aß42 on SnpI. From this data, a model can be proposed to 




reported defects in neurotransmission and SV pool organisation and how VPA may 






Figure 3-6 Model illustrating the early effects of Aß42-mediated deregulation of SnpI on SV dynamics 
and the therapeutic effect of VPA 
(A) Physiological SV dynamics involves a balance between SV recycling and neurotransmitter release. 
SVs are released from the reserve pool to participate in neurotransmitter (NT) release following 
neuronal activity via CAMKIV-induced SnpI phosphorylation at Ser9. SVs dock via SNARE complex 
assembly and then fuse with the membrane following calcium influx, releasing NT. SVs are tethered 
back to the reserve pool following endocytosis via PP2A-mediated dephosphorylation of SnpI. (B) Aß 
oligomers disrupt SV recycling and enhance NT release. Aß increases the availability of SVs for NT 
release and reduces the reserve pool due to increased calcium influx and elevated CAMKIV/SnpI 
phosphorylation. The greater number of SVs in the RRP combined with an Aß-mediated increase in 
calcium influx results in aberrant neurotransmitter release. VPA abolishes this effect by attenuating Aß-
induced phosphorylation of SnpI at Ser9, possibly through downregulating CAMK signaling. Image 




Chapter 4 DEVELOPMENT OF APOE LENTIVIRAL VECTORS 
4.1 INTRODUCTION 
Whilst neuronal expression of apoE4 has been considered to be an additional 
contributor to AD pathology (Brecht et al., 2004b, Harris et al., 2004, Buttini et al., 2010), 
the processing and role of neuronally expressed apoE is still not fully understood. Hence 
the work in this thesis aimed to explore this by overexpressing apoE in suitable cell 
models. One such model is primary rat neuronal cultures, a commonly used in vitro 
model for neurodegeneration that has similar physiological properties of neuronal cells 
in vivo such as functional synapses, unlike neuroblastoma cell lines which are tumor-
derived. However, a disadvantage is that primary neuronal cultures can contain non-
neuronal cells such as astrocytes and glia, to varying degrees. Although drugs such as 
cytosine arabinoside (AraC) can be used to inhibit dividing cells, they often affect the 
viability of primary neurons in culture (Dessi et al., 1995). Whilst neuronal cultures can 
be made using either prenatal or early postnatal rodent embryos, prenatal tissue was 
used because there are fewer glial cells at this developmental stage compared to mature 
brain tissue. To further minimise the number of non-neuronal cells in culture, the 
meningens were removed during the isolation of the hippocampus from the brain. 
Specific culturing reagents were also used to promote survival of neuronal cells against 
other cell types. Culturing neurons in serum-free neurobasal media reduces the number 
of non-neuronal cells proliferating, whilst supplementing the media with B27 supports 
neuronal growth (Brewer et al., 1993). Collectively, this creates a more simplistic system 
to study neuronal function with minimal influence from other cell types. 
 
Though primary neurons are an advantageous model system for neurodegeneration, 
they are infamously challenging to transfect (Karra and Dahm, 2010). Lentiviral vectors 
however, are an efficient Human immunodeficiency virus 1 (HIV-1)-based tool that 
enables gene delivery into both dividing and quiescent cells such as postmitotic neurons. 
They can transduce mature postmitotic neurons with high efficiency, yielding high 
expression levels and low toxicity, as reviewed in (Karra and Dahm, 2010). Thus, 
lentiviral vectors enable the expression of desired genes to allow for quantitative and 




and used to express the three major human apoE isoforms in 18-21DIV primary 
hippocampal cultures, as evidenced by the results in this chapter, so that the 
fragmentation and cell biology of neuronally expressed apoE could be investigated in 
later chapters. Recombinant lentiviral vectors expressing apoE were generated using a 
third generation lentiviral system for improved biosafety as the Tat viral gene required 
for viral self-replication is absent in this system (Dull et al., 1998). Additionally, an 
integration-deficient lentiviral vector (IDLV) design was used to reduce the likelihood of 
gene dysregulation due to insertional mutagenesis, thus minimising the risk of virus-
mediated effects on neuronal cell biology. Initially, the cDNA sequences for APOE2, 
APOE3 and APOE4 were subcloned into an IDLV transfer plasmid. The transfer plasmids 
were sequenced and functionality verified by transfection into HEK293T cells followed 
by western blotting for apoE protein. Lentiviral vectors containing the apoE transgene 
under the CMV promoter were then generated by calcium phosphate transfection of the 
transfer, regulatory, packaging and envelope constructs into HEK293T cells. The viral 
vectors were titrated by qPCR because they did not contain a fluorescence reporter 
required for titration by FACs analysis. Having established the number of transducing 
units/ml (TU/ml), the optimal ratio of lentiviral vector TU to number of cells/well that is 
required for efficient transduction (termed as MOI), was determined using GFP lentiviral 
vectors as an indicator. Finally, the functionality of the apoE-expressing vectors was 
confirmed by western blotting for apoE protein using lysate from mature primary 







4.2.1 Verification of plasmid sequences by restriction mapping analysis 
Plasmid sequence maps were not available for the pCMV-apoE2 and pCMV-apoE4 
plasmids, however information sheets for these constructs (provided by Professor 
George Dickson) indicated that the cDNA sequences encoding apoE2 and apoE4 were 
inserted into the pCMV backbone using flanking XbaI linkers and that it contained the 
sequence for the apoE signalling peptide (example plasmid map shown in Figure 4-1, C). 
To confirm that this was the case and to determine if XbaI could be used to liberate the 
apoE cDNA, the pCMV-apoE2 and pCMV-apoE4 plasmids were digested with XbaI 
endonuclease. The result from the digestion showed that using XbaI could liberate a 
product around the expected size for apoE cDNA of approximately 1Kb (Figure 4-1, A 
and B). Two other products of sizes  ̴3.7Kb (expected backbone fragment) and 0.2Kb 
were observed, suggesting that the backbone contained a third XbaI cut site. Both 
pCMV-apoE2 and pCMV-apoE4 were then sequenced, which verified that the plasmids 







Figure 4-1 Restriction mapping analysis of pCMV-ApoE2 and pCMV-ApoE4 to confirm XbaI cut sites and 
plasmid maps 
pCMV-apoE2 (A) and pCMV-apoE4 (B) were digested with XbaI to confirm presence of XbaI linkers flanking 
apoE2- and apoE4- cDNA. (C) A general plasmid map for the apoE-containing plasmids was generated 






The backbone of the IDLV transfer plasmid (pRRL-CMV-Wpre) was examined by 
digestion with the HindIII endonuclease to assess the integrity of the plasmid. This 
endonuclease was selected due to the presence of restriction sites within some of the 
lentiviral elements (e.g. LTRs / Gag) that are crucial for the generation of the lentiviral 
vectors (plasmid map shown in Figure 4-2, A). The HindIII endonuclease was predicted to 
cut at six positions within the plasmid, resulting in the generation of six products listed 
in Figure 4-2 B, which were observed by gel electrophoresis of the digest products 
(Figure 4-2, C). Although the fragments of sizes   ̴584bp and  ̴553bp could not be clearly 
distinguished, they appeared as a thicker band, indicating two similar sized products. 
Next, pRRL-CMV-Wpre was digested with XbaI to confirm the presence of unique XbaI 
cut site located after the CMV promoter (Figure 4-2, A), as this was required for cloning 
of apoE cDNA. Examining the digestion products by gel electrophoresis showed a single 
band at approximately 7Kb (Figure 4-2, D), confirming one cut site for the XbaI 






Figure 4-2 Plasmid map of pRRL-CMV-Wpre and restriction mapping analysis to check plasmid backbone 
Plasmid map for pRRL-CMV-Wpre (A) and predicted fragment sizes for the HindIII-HF and XbaI restriction 
endonucleases (B). pRRL-CMV-Wpre was digested using HindIII-HF (C) to check plasmid backbone, as well 





Since the pCMV6-ApoE3 plasmid (map shown in Figure 4-3, A) was composed of a 
different backbone to pCMV-ApoE2 and pCMV-ApoE4, different combinations of 
restriction endonucleases (listed in Figure 4-3, B) were used for restriction mapping 
analysis, but also to isolate the apoE3 cDNA for cloning (strategy described in 4.2.2.2). 
Digestion with EcorI-HF linearised the plasmid, showing a band of   7̴Kb (Figure 4-3, C). A 
double digest using EcorI-HF and XhoI removed   ̴1.2Kb of sequence containing the 
apoE3 insert, leaving the backbone of   ̴5.8Kb. Digestion using the BlpI and SbfI-HF 
restriction endonucleases removed a fragment of apoE3 cDNA containing the SNPs that 
distinguish each isoform. Due to a second BlpI cut site in the Poly(A) sequence, another 
fragment of  ̴708bp was generated. A triple digest was also carried out using BlpI, SbfI-HF 
and XhoI so that the additional fragment of  ̴708bp could be further digested by XhoI, 
yielding two fragments of  ̴379 and  ̴329bp as observed by gel electrophoresis, and thus 
enabling better separation of the apoE3 cDNA fragment (Figure 4-3, C). Taken together, 







Figure 4-3 Plasmid maps of pCMV6-ApoE3 and restriction mapping analysis to check plasmid 
backbone 
Plasmid map for pCMV6-AC-ApoE3 (A) and predicted fragment sizes following digestion using various 
combinations of restriction endonucleases (B). pCMV6-ApoE3 was digested by using different 
combinations of restriction endonucleases (C) to check plasmid backbone. The digest using BlpI + SbfI + 






4.2.2 Generation of IDLV transfer plasmids containing apoE cDNA 
4.2.2.1 Generation of pRRL-CMV-ApoE2-Wpre and pRRL-CMV-ApoE4-Wpre plasmids 
Following verification of the constructs, the apoE2 and apoE4 inserts were then cloned 
into the lentivirus transfer plasmid, as summarised in Figure 4-4. The cDNAs for apoE2 
and apoE4 cDNA were liberated from pCMV-apoE2 and pCMV-apoE4 respectively, by 
digestion with XbaI. The XbaI endonuclease was also used to linearise the target 
plasmid, pRRL-CMV-Wpre. The digest products were separated by agarose gel 
electrophoresis and then extracted from the gel so that the apoE cDNAs could be ligated 
into the linearised pRRL-CMV-Wpre plasmid using different vector:insert ratios (1:1, 1:3, 
1:5 and 1:10). The ligated products were transformed into Top10 E. Coli cells and 
random colonies were screened for a positive clone that contained the insert in the 
correct orientation. This was achieved by digesting the purified plasmid DNA from 
selected colonies with both Ndel and BlpI since the recognition sites of these 
endonucleases are located within the CMV promoter region and the 5’-end of the apoE 
cDNA respectively. A positive clone containing the apoE insert in the correct orientation 
within the lentivirus plasmid (Figure 4-5, A) would generate a fragment of 637bp after 
digestion. However, a plasmid containing apoE cDNA in the reverse orientation (Figure 
4-5, B) would generate a larger fragment of 1189bp. The cloning of apoE cDNAs into the 
IDLV transfer plasmid was successful, as a band of   ̴637bp was observed for both pRRL-
CMV-ApoE2_Wpre plasmids derived from clone A and clone B (Figure 4-6, B), and for 
pRRL-CMV-ApoE4_Wpre derived from clone B (Figure 4-6, C). An example IDLV transfer 
plasmid containing apoE4 in the reverse orientation was also generated, as indicated by 
the presence of a   ̴1189bp sized band in Figure 4-6 C. The apoE-IDLV transfer plasmid 
backbones were also validated using a variety of restriction endonucleases as listed in 
Figure 4-6 A. The predicted fragmentation patterns shown in Figure 4-6 A were observed 
for both pRRL-CMV-ApoE2-Wpre and pRRL-CMV-ApoE4 (Figure 4-6, B and C), confirming 
the presence and integrity of the lentiviral elements and the size of the plasmid. 
Sequencing both pRRL-CMV-ApoE2-Wpre and pRRL-CMV-ApoE4-Wpre confirmed that 







Figure 4-4 Cloning strategy used to create pRRL-CMV-ApoE2-Wpre and pRRL-CMV-ApoE4-Wpre 
constructs 
The apoE2 or apoE4 insert was isolated and purified from the pCMV-apoE donor plasmid by digestion with 
XbaI since the apoE cDNA was flanked by XbaI recognition sites. The pRRL-CMV-Wpre backbone was 
linearised by digestion with XbaI aswell (recognition site present after the CMV promoter) so that the 
apoE cDNA could be ligated using the XbaI complementary ends. Ligation of the apoE cDNA with the 




















Figure 4-5 Plasmid maps showing the lentiviral transfer plasmid containing either apoE cDNA in the 
correct orientation (A) or apoE cDNA in the reverse orientation (B). 
The purified apoE cDNA could be ligated into the lentiviral transfer plasmid in either direction since 
using XbaI sticky ends did not provide directionality for insertion. The apoE gene is driven by a CMV 
promoter and its expression is enhanced by the presence of a Woodchuck Hepatitis Virus (WHP) 
Posttranscriptional Regulatory Element (WPRE) sequence. A Central Polypurine tract (cPPT) sequence is 






Figure 4-6 Restriction mapping analysis to identify clones containing pRRL-CMV-ApoE2-Wpre and pRRL-
CMV-ApoE4-Wpre with apoE cDNA in the correct orientation. 
(A) Table showing the predicted fragment sizes for the pRRL-CMV-ApoE-Wpre plasmid digested with 
combinations of restriction endonucleases, including a diagnostic co-digest using NdeI with BlpI to identify 
IDLV transfer plasmids containing apoE cDNA in the correct orientation. Representative gel 
electrophoresis images of restriction digests from plasmid DNA purified from E. Coli transformed with 
pRRL-CMV-ApoE2-Wpre (B) and pRRL-CMV-ApoE4-Wpre (C) to validate the plasmid backbone and to 




4.2.2.2 Generation of pRRL-CMV-ApoE3-Wpre 
An alternative strategy, summarised in Figure 4-7, was used to generate a lentivirus 
transfer plasmid containing apoE3 because the pCMV6-ApoE3 plasmid did not contain 
XbaI linkers. To create lentiviral transfer plasmids that contain the same sequence either 
side of the apoE insert, a fragment of the apoE4 cDNA within pRRL-CMV-ApoE4-Wpre 
was replaced with a fragment carrying the apoE3 specific sequences. Two restriction 
sites recognised by BlpI and SbfI flank a region of apoE cDNA containing the two 
polymorphisms that distinguish the apoE isoforms. Thus, the apoE4 fragment was 
removed from pRRL-CMV-ApoE4-Wpre by a double digest with BlpI and SbfI. Due to the 
presence of a second BlpI cut site within the Poly(A) signal of the pCMV6-ApoE3 plasmid, 
a BlpI and SbfI double digest produced two fragments that were similar in size ( ̴604bp 
and  ̴708bp) and thus difficult to separate (Figure 4-3). It was therefore necessary to 
perform a triple digest so that the  ̴708bp fragment could be cleaved into smaller 
products, enabling isolation of the   ̴604bp apoE cDNA fragment. Since a recognition site 
for XhoI was identified in the   ̴708bp fragment, the apoE3 cDNA fragment was instead 
excised following a triple digest with BlpI, SbfI and XhoI. A  6̴04bp fragment containing 
the apoE3 sequence was liberated by BlpI and SbfI digestion and the second fragment ( 
 ̴708bp) was cleaved into two smaller fragments of   ̴329 and  ̴379bp by XhoI digestion, as 
shown in Figure 4-3. Following separation of the digested products by agarose gel 
electrophoresis, the backbone of pRRL-CMV-ApoE4-Wpre and the apoE3 cDNA fragment 
(containing the SNPs) were purified and ligated together. The BlpI and SbfI 
complementary ends enabled directional insertion of apoE3 into the IDLV transfer 
plasmid. The ligation products were then transformed into Top10 E. Coli cells and a 
restriction digest was used to identify clones containing pRRL-CMV-ApoE3-Wpre 
(plasmid map shown in Figure 4-8 A). Plasmids derived from isolated bacterial colonies 
were transformed using different vector:insert ratios. These were then digested with 
NdeI and BlpI, which cut at unique restriction sites within the CMV promoter and apoE 
segment respectively. Successful ligation of apoE3 would result in two digest products 
(7110bp and 637bp), whereas a self-annealed vector would show a single band of 
7143bp due to linearisation by NdeI. All pRRL-CMV-ApoE3-Wpre plasmids were positive 




4-8, C). A double digest with BlpI and AflII was used to check the LTR sequences and size 
of the construct. The expected fragment pattern and sizes as listed in Figure 4-8 B were 
observed (Figure 4-8, C). Sequencing of pRRL-CMV-ApoE3-Wpre confirmed that the 






Figure 4-7 Cloning strategy used to create pRRL-CMV-ApoE3-Wpre  
A fragment of the apoE3 cDNA containing the two SNPs was excised from the pCMV-AC-ApoE3 donor 
plasmid by a double digestion using BlpI with SbfI restriction endonucleases. XhoI was also used in this 
digestion to further cleave a byproduct from the donor plasmid backbone, enabling the isolation of the 
apoE3 cDNA segment. The apoE4 cDNA fragment was removed from pRRL-CMV-ApoE4-Wpre by digestion 
with BlpI and SbfI and the backbone was purified. The pRRL-CMV-ApoE3-Wpre was generated by ligation 
of the apoE3 cDNA fragment into the pRRL-CMV-ApoE-Wpre backbone in the correct orientation, as 
























Figure 4-8 Restriction mapping analysis to identify clones containing pRRL-CMV-ApoE3-Wpre 
(A) Plasmid map showing the IDLV transfer plasmid containing apoE3 cDNA. (B) Table showing the 
predicted fragment sizes resulting from digestion of pRRL-CMV-ApoE3-Wpre plasmid using combinations 
of restriction endonucleases, including the diagnostic co-digest using NdeI with BlpI to distinguish lentiviral 
transfer constructs containing apoE cDNA from re-ligated plasmids. (C) Gel electrophoresis image of 
restriction digests from plasmid DNA purified from E. Coli transformed with pRRL-CMV-ApoE3-Wpre to 






4.2.2.3 ApoE lentiviral transfer plasmids express apoE protein in transfected HEK293T 
cells 
To confirm that the IDLV transfer plasmids containing apoE cDNA were functional, 
western blotting was performed using lysate from HEK293T cells transfected with pRRL-
CMV-ApoE2-Wpre, pRRL-CMV-ApoE3-Wpre and pRRL-CMV-ApoE4-Wpre. 
Immunoblotting with rabbit anti- apoE 16H22L18 detected a band at   ̴34kDa indicating 
that all three constructs expressed full length apoE protein (Figure 4-9). This was not 
observed in the negative control, confirming that apoE was detected due to expression 
from the constructs. This result verified that all three IDLV transfer plasmids were 
indeed functional. Interestingly, less full length apoE4 was detected compared to apoE2 
and apoE3, although equal amounts of protein were loaded for all samples (as shown by 
the actin loading control in Figure 4-9). It is possible that this could be due to enhanced 
degradation of apoE4 in HEK293T cells, poor transfection efficiency of pRRL-CMV-ApoE4-
Wpre, or greater cell death due to apoE4 expression. 
 
 
Figure 4-9 Western blots show that apoE-lentiviral plasmids express apoE protein in HEK293T cells 
Western blots showing detection of full length apoE protein from HEK293T cells transfected with either 
pRRL-CMV-ApoE2-Wpre, pRRL-CMV-ApoE3-Wpre or pRRL-CMV-ApoE4-Wpre for 24 hours, and ß-actin to 









4.2.3 Transduction of primary neurons with GFP lentiviral vectors  
The optimal MOI to use in mature primary neurons was established using lentiviral 
vectors expressing GFP under a CMV promoter (shown in Figure 4-10). Primary neurons 
were transduced at 18DIV using a range of MOIs: 10, 50, 100, 150 and 200 for a 
qualitative comparison of transduction efficiency. The neurons were imaged three days 
post transduction using brightfield microscopy and fluorescence microscopy (using the 
GFP channel and consistent exposure settings) to examine neuronal morphology and to 
detect GFP fluorescence. Figure 4-11 shows images of primary neurons transduced with 
different MOIs taken in the FITC and brightfield channels. GFP expression in neuronal 
cell bodies and neurite projections, as shown in the merged images, was observed to 
increase as MOI increased. At an MOI of 10, approximately less than 50% of neurons 
showed high GFP expression in the cell bodies, whereas at an MOI of 150, a substantial 
number of neurons ( ̴90%) showed high levels of GFP signal in both cell bodies and 
neurite projections. An MOI of 200 however, appeared to be toxic since the GFP 
expression revealed retraction of the neurite projections. Moreover, GFP signal was 
apparent in smaller cell bodies resembling apoptotic cells. Since the fragmentation of 
apoE was to be characterised by western blotting, high expression levels of the 
transgene was desired so that less abundant fragments were likely to be detected. 
Therefore an MOI of 150 was selected for further experiments, since this showed the 






Figure 4-10 Plasmid map of the GFP-lentiviral transfer plasmid 
The GFP gene is driven by a CMV promoter and GFP expression is enhanced by the presence of a 
Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE) sequence. A Central 






Figure 4-11 Comparison of transduction efficiency by GFP-expressing lentiviruses at increasing MOIs 
in primary neurons 
Primary neurons were transduced at 18DIV with GFP-expressing lentiviral vectors at increasing MOIs: 
10, 50, 100, 150 and 200 for a qualitative comparison of transduction efficiency and expression level 







4.2.4 ApoE-lentiviral vectors express apoE protein in transduced rat primary neurons 
Following the generation and titration of apoE-lentiviral vectors, the functionality of the 
vectors was next assessed. To do so, primary hippocampal neurons were initially 
transduced at 18DIV for 72 hours using apoE-expressing lentiviral vectors at an MOI of 
150. Western blotting was used to confirm the expression of apoE protein in transduced 
neurons. Full length apoE protein was detected in protein extracts of neurons 
transduced with lentiviral vectors expressing apoE2, apoE3 and apoE4 as shown in 
Figure 4-12. No apoE expression was detected in control non-transduced neurons, 
confirming that the presence of apoE was due to expression from the lentiviral vectors. 
This result verified that the apoE-lentiviral vectors were successfully produced and 
showed that they could transduce mature neurons with expression levels suitable for 




Figure 4-12 Western blots show apoE-expressing lentiviral vectors express apoE protein in transduced 
primary neurons 
Western blot showing detection of full length apoE protein in protein extracts from 18DIV primary 
neurons transduced with lentiviral vectors expressing either apoE2, apoE3 or apoE4. These vectors were 
generated using the pRRL-CMV-ApoE2-Wpre, pRRL-CMV-ApoE3-Wpre or pRRL-CMV-ApoE4-Wpre 









Here, lentiviral vectors expressing apoE under the CMV promoter were generated so 
that the three major human apoE isoforms could be expressed in mature primary 
hippocampal cultures. This approach was chosen because gene delivery into postmitotic 
neurons by transfection techniques often requires freshly isolated neurons that yield 
low transfection efficiency and show high toxicity (Washbourne and McAllister, 2002, 
Karra and Dahm, 2010). Lentiviral vectors however, can transduce mature primary 
neurons with high transduction efficiency and little toxicity and result in high expression 
levels (Karra and Dahm, 2010, Royo et al., 2008). The data presented in this chapter 
shows that lentiviral transfer plasmids containing cDNA encoding either apoE2, apoE3, 
or apoE4 were successfully generated. Restriction mapping analysis and sequencing 
confirmed that apoE cDNA for all three isoforms was correctly inserted into the lentiviral 
transfer plasmid backbone. Furthermore, western blotting for apoE protein confirmed 
that the apoE constructs were functional. 
 
The apoE lentiviral transfer plasmids were used as part of the third generation lentiviral 
packaging system to produce lentiviral vectors expressing apoE. Before the apoE 
lentiviral vectors could be used to transduce the neuronal cultures, the optimal MOI had 
to be determined. Since the apoE lentiviral vectors do not contain a reporter transgene, 
GFP lentiviral vectors were used for rapid comparison of transduction efficiencies at 
different MOIs in neuronal cultures by fluorescence microscopy. Typical MOIs used in 
several publications range from 1-10 (Ding and Kilpatrick, 2013, Denning et al., 2013). 
This is because these MOIs are based on titres derived by fluoresence microscopy or 
FACS and so are reflective of functional viral vector. Here however, high MOIs (10-200) 
were selected because the vector titres used to calculate the MOI were determined by 
qPCR analysis, which also accounts for incomplete and non-functional vectors. Although 
the GFP lentiviral vectors could have been titrated by flow cytometry analysis, qPCR 
analysis was carried out so that the titres would be comparable to those obtained for 
the apoE lentiviral vectors. Based on GFP fluorescence images in section 4.2.3, the 
optimum MOI for high expression levels in 18 DIV primary neurons was determined to 




observed. This was surprising since transduction efficiencies of this level are usually 
found in neurons transduced on the day of cell plating (0 DIV) or the day after (1 DIV) 
(Dittgen et al., 2004, Ding and Kilpatrick, 2013). Moreover, transduction efficiency has 
been shown to significantly decrease with increasing age of the primary neuronal culture 
(Wanisch et al., 2013). Nonetheless, the results indicated that this MOI was suitable for 
applications such as western blotting analysis, where high expression levels are required 
for sufficient detection of the protein. Indeed, transduction of mature primary neurons 
using apoE-expressing lentiviral vectors at an MOI of 150 resulted in detectable apoE 
expression for all apoE isoforms.  
 
Collectively, this work in this chapter shows that apoE lentiviral vectors were 
successfully produced and that they could be used to express apoE protein at sufficient 
levels in mature primary neurons for western blotting analysis. Therefore, the apoE 
lentiviral vectors can be used to aid the study of apoE fragmentation and cell biology in 





Chapter 5 CHARACTERISATION OF APOE PROCESSING IN CELL MODELS 
5.1 INTRODUCTION 
Increasing evidence suggests that intraneuronal full length apoE and its proteolytic 
fragments may be key players in AD pathology (Huang et al., 2004, Mahley et al., 2006, 
Mahley and Huang, 2012). This has led to the proposal of a model where fragmentation 
of apoE leads to a loss of protective function, but also a toxic gain of function (Rohn, 
2013, Mahley and Huang, 2012). In this model, apoE expression in neurons is triggered 
by factors such as oxidative stress or Aß42-mediated neuronal dysfunction. 
Intraneuronal apoE protein then undergoes isoform-dependent proteolysis 
(apoE4>apoE3>apoE2) due to differential domain interaction, which produces bioactive 
and toxic fragments. It is thought that these fragments escape the secretory pathway, 
enter the cytosol and induce dysfunction in mitochondria and the cytoskeletal network 
(Huang et al., 2004, Mahley and Huang, 2012).  
 
Although there is mounting evidence to support a role for neuron-specific proteolysis of 
apoE4 and AD pathology, there is very little available data to determine whether the 
contrasting, neuroprotective role of apoE2 is due to differential processing when 
expressed in neurons. So far, fragmentation of apoE has primarily been characterised 
using protein extracts from post-mortem brains of control and AD human patients 
(Jones et al., 2011, Elliott et al., 2011, Harris et al., 2003, Tamboli et al., 2014), as well as 
transgenic AD mouse models (Brecht et al., 2004b). Whilst the majority of these studies 
have shown that proteolysis of apoE4 is associated with greater fragmentation load 
when compared to apoE3, there is little conclusive evidence in the literature regarding 
the proteolytic susceptibility of apoE2. To date, only a single study has shown that apoE2 
fragments also exist in human brain, however fragmentation load between isoforms was 
not compared (Conejero-Goldberg et al., 2014). One reason for the lack of studies 
including apoE2 is that the APOE2 allele is rarer than the other two major isoforms, 
restricting the availability of brain tissue from patients with an APOE2 genotype for 
experimentation. In consideration of this limitation, an alternative approach would be to 
use cell models to investigate the impact of apoE isoform on proteolytic susceptibility. 




been thoroughly explored in cell models either, although in vitro models are frequently 
used to investigate the functional roles of apoE. So far, only one in vitro study has 
compared the total level of fragments for all three apoE isoforms when expressed in 
mouse neuroblastoma cells (Wellnitz et al., 2005). In this study, western blotting using a 
C-terminus specific antibody revealed a single   ̴13kDa C-terminal fragment for all three 
apoE isoforms, which was more abundant for apoE4 expressing cells, followed by apoE3 
and apoE2. Whilst this data supports the apoE proteolysis model, it does not provide 
information on the relative abundancy of other fragments. 
 
The identity of apoE fragments also remains elusive. Whilst apoE fragments have been 
examined either by mass spectrometry or using N- and C- terminal specific antibodies 
(Castano et al., 1995, Wisniewski et al., 1995, Rohn et al., 2012, Tamboli et al., 2014, 
Wellnitz et al., 2005), there is still not a consensus regarding their composition. This is 
partly due to the wide variation in the source of apoE fragments, which range from 
spleen tissue through to fragments obtained via cleavage of recombinant apoE using 
thrombin or chymotrypsin (Castano et al., 1995, Wisniewski et al., 1995, Rohn et al., 
2012, Tamboli et al., 2014). Even though conclusive proof of the apoE fragments 
existence and exact sequences is yet to be provided, several studies have used 
truncated versions of either apoE3 or apoE4 in order to understand the functions of 
these proteolytic fragments (Huang et al., 2001, Harris et al., 2003, Chang et al., 2005, 
Nakamura et al., 2009, Bien-Ly et al., 2011, Tanaka et al., 2006). 
 
Here, three cell models were used to characterise fragmentation of apoE2, apoE3 and 
apoE4. These models were: N2a cells (a murine neuroblastoma cell line), SH-SY5Y cells (a 
human neuroblastoma cell line), and primary hippocampal rat neurons. N2a cells are 
from a mouse neuroblastoma and have a mixed neuronal-like and amoeboid 
morphology in the undifferentiated state. It has been reported that apoE-mediated 
toxicity in N2a cells is comparable to that observed in cultured primary neurons from 
NSE-apoE mice (Chen et al., 2011a). Moreover, N2a cells have been extensively used to 
study the effects of apoE and its fragments on mitochondrial and cytoskeletal function 




useful models for investigating the effects of intraneuronal apoE. For these reasons, N2a 
cells were considered as a suitable cell-based model to examine apoE processing. SH-
SY5Y cells are a human-derived neuroblastoma cell line, which show two phenotypes in 
culture: neuronal-like cells and epithelial-like cells (Ross et al., 1983). Characterisation of 
this cell line by enzymatic assays revealed that whilst the neuronal-like cells exhibit 
markers of dopaminergic neurons (e.g. tyrosine hydroxylase positive), the epithelial-like 
cells lack neuronal markers (Ross et al., 1983). Despite the heterogeneity in cellular 
phenotype, there are benefits to using this cell line such as the expression of human 
protein isoforms (Kovalevich and Langford, 2013). SH-SY5Y cells are homozygous for 
APOE3 and are reported to express apoE mRNA (Soulié et al., 1999). It is notable that 
fragmentation of endogenous apoE has also been observed in SH-SY5Y cells, which 
occurred in response to overexpression of wild type APP751 or the C-terminal domain of 
APP (C99) (Saul and Wirths, 2016). However, whether apoE cleavage is isoform-
dependent in this cell line is unknown. It is also important to consider that 
neuroblastoma cells have drawbacks, such as the lack of mature neuronal structures 
that include synapses and axons. Primary neurons however, are one of the closest 
culture-based models to in vivo systems. Hence, comparing the neuroblastoma cell lines 
to primary neurons, enables evaluation of their use to model apoE processing and 
neurobiology of all three full length apoE isoforms. Furthermore, using multiple in vitro 
cell models enables an assessment of the reproducibility of the observations made 
about the effect of apoE isoform on apoE proteolysis in vitro. Expression of apoE in the 
N2a and SH-SY5Y cell lines was achieved by transient transfection with constructs 
expressing apoE2, apoE3 or apoE4 under a CMV promoter for 48 hours. Primary neurons 
however, were transduced using apoE-lentiviral vectors at an MOI of 150 for 72 hours as 
based on the high expression levels of GFP lentiviral vectors at this MOI and time point 
(shown in the previous chapter). Fragmentation of the ‘protective’ apoE2, the ‘neutral’ 
apoE3 and the ‘toxic’ apoE4 was then characterised in the different cell models to 
address: 
1. The fragmentation pattern of each isoform – are there unique fragments that 




2. The susceptibility of each isoform to proteolysis – could the differential risk in AD 
be due to differences in fragment load? 
3. The composition of apoE fragments - could the differential risk in AD be due to 
differences in fragment composition? 
This is of importance because insights into apoE processing for each isoform may 
partially explain the differential effects these variants have in neurons. In addition, 
determining the identity of these fragments in a cellular context is a necessary first step 
to understanding how they may contribute to neuronal dysfunction and AD, or confer 
neuroprotection against AD. 
 
5.2 RESULTS 
5.2.1 Validation of anti- apoE antibody epitope sites in HEK293T cells 
In order to thoroughly characterise apoE processing, the epitopes that the commercially 
available anti-apoE antibodies recognise were first validated by western blotting. Protein 
extracts used were from HEK293T cells transfected with constructs encoding full length 
or truncated versions of apoE3 (kindly gifted by Professor Tadafumi Hashimoto and 
Professor Bradley Hyman) for 24 hours. The truncated apoE constructs expressed either 
apoE3 NT (192-299), apoE3 CT (1-192), apoE3 243-299, apoE3 243-272 or apoE3 
273-299. A schematic illustration for each of these variants is shown in Figure 5-1. The 
truncated variants of apoE facilitated identification of the regions of apoE that these 
antibodies recognise. For example, antibodies against N-terminal apoE should only 
detect N-terminal fragments and vice versa. Additionally, the C-terminal truncations 
include deletions of either the lipid binding domain or the region after, both of which 
are specific epitopes for commercially available antibodies (anti-apoE 3H1 and anti-apoE 
E-8 respectively). Since not all epitopes were disclosed for some of the antibodies, it was 
imperative to determine as accurately as possible, the domains that these antibodies 





Figure 5-1 Schematic of full length apoE and truncated apoE variants 
Illustrations showing the domain structure of full length apoE and the truncated apoE variants. ApoE3 
full length is composed of an N-terminal domain containing 4 -helix structures, followed by a hinge 
region and a C-terminal domain. The polymorphisms that distinguish the three major apoE isoforms are 
located within the N-terminus: at position 112 in Helix 3 and 158 in Helix 4. The LDLR-binding region 
(134-150aa) is within helix 4 of the N-terminus and the lipid-binding region (242-272aa) is within the C-





Figure 5-2 shows western blots of anti- apoE antibodies that are specific for the N-
terminus of apoE protein. Expectedly, rabbit anti- apoE SP+1-32aa (Aviva) detected full 
length apoE3 and truncated apoE3 variants containing the N-terminus (Figure 5-2, A). 
Additionally, this antibody did not detect a band for apoE3 CT (1-192), thus confirming 
its specificity for the N-terminus of apoE. Likewise, only bands for N-terminal-containing 
apoE3 variants were detected by mouse anti- apoE WU E-4 suggesting that the epitope 
for this antibody is also located within the N-terminus of apoE (Figure 5-2, B). 
Surprisingly, rabbit anti- apoE 16H22L18 detected apoE3 NT (192-299), apoE3 243-
299 and apoE3 243-272 (Figure 5-2, C), even though these variants do not contain the 
advertised epitope of this antibody: the lipid-binding region (240-251aa) of apoE. 
Moreover, apoE3 273-299 was detected, whilst apoE CT 1-192 was not. These 
findings indicate that the advertised epitope is incorrect and that antibody recognises a 







































































































































































































Figure 5-3 shows western blots of anti- apoE antibodies that are advertised as specific to 
the C-terminus of the apoE protein. The advertised epitope of mouse anti- apoE 3H1 is 
243-272aa of apoE. Indeed, the antibody was specific to this region as shown by 
detection of a band for apoE3 273-299 but not for apoE3 NT 192-299, apoE3 243-
272 and apoE3 243-299; all variants in which the epitope is deleted (Figure 5-3, A). As 
anticipated, mouse anti- apoE 3H1 also detected full length apoE3 and apoE3 CT 1-192. 
Likewise, western blotting analysis confirmed the advertised epitope of the mouse anti- 
apoE E-8 as 272-299aa of apoE (Figure 5-3, B). This antibody detected full length apoE3 
and the C-terminal variants containing 272-299aa: apoE3 CT 1-192 and apoE3 243-
272. However, no bands were detected when this epitope was not present, such as in 
apoE3 243-299 and apoE3 ∆273-299, confirming the specificity of this antibody for the 
272-299aa of apoE. Additionally, mouse anti- apoE E-8 did not detect apoE NT ∆192-299, 
confirming that it does not recognise any regions of the apoE N-terminus. 
 
 
Figure 5-3 Western blots validate the epitopes of C-terminal anti- apoE antibodies  
The epitopes of C terminal specific anti- apoE antibodies were verified by western blotting using full 
length and truncated apoE3 protein expressed by transient transfection in HEK293T cells. (A) Western 
blot showing immunoreactivity of anti- apoE 3H1 to full length or truncated apoE3 variants containing 
the epitope 243-272aa (apoE3 CT 1-191 and apoE3 273-299 only). (B) Western blot showing 
immunoreactivity of anti- apoE E-8 to full length or truncated apoE3 variants containing epitope 273-




The goat anti- apoE (Calbiochem) antibody raised against the full length apoE protein 
detected full length apoE3 and all truncated apoE3 variants (Figure 5-4). Notably, the 
signal for the  ̴10kDa apoE CT fragment appeared to be lower when using the goat-anti 
apoE (Calbiochem) compared to both mouse anti-apoE 3H1 (Figure 5-3, A) and mouse 
anti- apoE E-8 (Figure 5-3, B) for the same protein extracts, although the same amount 
of protein was loaded. Minor fragments were observed for apoE3 full length, apoE3 
243-272, apoE3 243-299, and apoE3 273-299, suggesting that apoE may be cleaved 
towards the amino-end of the protein in HEK293T cells. This greater range of apoE 
epitopes detected by goat anti-apoE (Calbiochem) antibody highlights its suitability over 
the other antibodies for comparing the proteolytic susceptibility and fragmentation 
profile of all three major isoforms by western blotting.  
 
 
Figure 5-4 Western blot showing immunoreactivity of the polyclonal goat anti- apoE antibody to 
various regions of the N- and C-terminus of apoE 
Goat anti- apoE (Calbiochem) detected full length and truncated apoE3 variants expressed by transient 







Subsequently, the regions recognised by each antibody were identified and summarised 
in a schematic of the apoE protein shown in Figure 5-5. 
 
 
Figure 5-5 Diagram illustrating apoE domain structure and anti- apoE antibody epitopes 
Anti- apoE (Aviva) recognises a region between the signalling peptide and the first 32 amino acids 
within Helix 1 of the N-terminus of apoE. Anti- apoE 16H22L18 and anti- apoE WU E-4 recognise a 
region within the N-terminus of apoE. Anti- apoE 3H1 recognises the lipid binding region (243-272aa) 
within the C-terminus whilst anti- apoE E-8 recognises the remaining residues after the lipid binding 
region (272-299aa). 
 
5.2.2 Optimisation of western blotting for the detection of apoE fragments 
5.2.2.1 Trialling different SDS PAGE systems to resolve apoE fragments  
In order to examine the fragmentation pattern of apoE isoforms, it was first necessary to 
determine the optimal SDS PAGE system for clearly separating the fragments of apoE. To 
do so, hand-cast Tris-glycine gels of different acrylamide percentages and a pre-cast 10% 
Bis-Tris gel were used to separate protein extracts from apoE-transfected and control 
N2a cells. To ensure that the maximum range of apoE fragments were detected, all blots 
were probed with the goat anti- apoE (Calbiochem) antibody. 
 
The blots from hand-cast Tris-glycine gels are shown in Figure 5-6; A-C. Since apoE has 
been shown to generate fragments ranging from 10kDa in size and upwards, a 12% Tris-
glycine gel was first used because this acrylamide percentage is suitable for the 
separation of protein sizes ranging from  ̴10 to 70kDa. Five fragments that were  ̴10 to 
30kDa in size were observed (Figure 5-6, A), and were comparable to those generated 




Wirths, 2016). However, although the   ̴22-30kDa bands were clearly distinguishable, the 
lower molecular weight bands were not sharp, and were partly obscured by the excess 
SDS visible toward the end of the separation gel. Since this would make quantification of 
the relative amounts of each fragment problematic, a 4-20% Tris-glycine gradient gel 
was also trialled (Figure 5-6, B) in an attempt to separate the lower molecular weight 
bands from the SDS front. This gel percentage showed sharper lower molecular weight 
bands (  ̴10 and   ̴14kDa) but poorly separated the higher molecular weight bands ( ̴22-
30kDa). Hence, to increase resolution of the high molecular weight bands too, the 
samples were next resolved on a 10-20% Tris-glycine gradient gel. Whilst this approach 
showed better separation of both the high and low molecular weight fragments, the   ̴10 
and   ̴14kDa bands were still diffuse in comparison to the   2̴2-30kDa bands (Figure 5-6, 
C). In addition, the Tris-glycine gels consistently showed horizontal smearing of the full 
length apoE protein in lanes containing extracts from apoE-transfected N2a cells, but 
also control cells (Figure 5-6, A-C). Because of this, Tris-glycine gels were considered as 
unsuitable for quantification of the relative amount of apoE fragments in extracts from 
overexpression work. 
 
To enhance separation/resolution of the lower molecular weight bands and to see if the 
smear was an artefact of using the Tris-glycine gels, a pre-cast 10% Bis-Tris NuPAGE 
protein gel using MES buffer was also trialled. The Bis-Tris SDS PAGE system was 
selected since the lower operating pH of 7.0, compared with 9.5 in Tris-glycine gels, is 
reported to promote sample integrity and gel stability. Moreover, using MES buffer in 
conjunction with a gel percentage of 10% is advertised as suitable for resolving proteins 
ranging from   ̴2.5-55kDa, which is ideal for resolving apoE fragments that are within this 
range. Surprisingly, immunoblotting for apoE revealed differences in the number of 
distinct fragments observed when using the 10% Bis-Tris gel (Figure 5-6, D) compared to 
the Tris-glycine gels (Figure 5-6, A-C). A total of   ̴6 distinct fragments were detected in 
the blots from using 10% Bis-Tris gels, compared to  ̴5 observed when using Tris-glycine 
gels. Interestingly, although the faint   ̴30kDa fragment was no longer visible, a strong  
 ̴32kDa fragment was detected, suggesting that the full-length band observed in the Tris-




an additional lower molecular weight band at   ̴17kDa was clearly visible, indicating that 
the   ̴14kDa band observed in the Tris-glycine gels likely comprised the    ̴14kDa and   
 ̴17kDa fragments. The horizontal smear observed the Tris-glycine gels was not apparent 
when using the 10% Bis-Tris gel, likely due to improved separation of both full length 
apoE and the   ̴32kDa fragment. Collectively, results from the use of the Bis-Tris gel 
system showed optimal separation of the apoE fragments and enabled quantitation of 




Figure 5-6 Separation of apoE full length protein and fragments using different acrylamide percentages 
and gel systems 
Western blots showing the separation of apoE fragments from 20µg of apoE-transfected and control N2a 
cell extracts by SDS PAGE using different acrylamide percentages and gel systems: (A) 12% acrylamide Tris-
glycine gel, (B) 4-20% acrylamide Tris-glycine gradient gel, (C) 10-20% acrylamide Tris-glycine gradient gel, 






5.2.2.2 Optimisation of the incubation time for primary anti- apoE antibodies in 
western blotting 
Following optimisation of SDS PAGE for resolving the apoE fragments, the optimal 
incubation time for the goat anti- apoE (Calbiochem), rabbit anti- apoE SP+1-32aa (Aviva) 
and mouse anti- apoE E-8 antibodies was next determined. This was carried out because 
the time of primary antibody incubation during western blotting can affect the 
specificity and efficiency of staining. Blots showing protein extracts from control and 
apoE-transfected N2a cells were incubated with the anti- apoE antibodies for either 2 
hours at room temperature (RTP) (Figure 5-7, A) or overnight at 4°C (Figure 5-7, B).  
 
An incubation time of 2 hours at RTP resulted in detection of full length apoE protein 
from apoE-transfected N2a extracts for all antibodies. Both the polyclonal goat anti- 
apoE (Calbiochem) and the mouse anti- apoE E-8 antibody detected the  ̴32kDa fragment, 
indicating that this was generated by a small cleavage at the N-terminus. No other 
fragments were detected by either the anti- N- or C-terminal specific apoE antibodies, 
suggesting that these fragments were deletions at both the N- and C-terminus of apoE. 
Intriguingly though, changing the incubation conditions to overnight at 4°C resulted in 
the detection of additional bands by the mouse anti- apoE E-8 antibody in lanes 
containing apoE-transfected N2a cell extracts. Since no additional bands were observed 
in lanes containing control N2a cell extracts, it is likely that these additional bands are 
apoE fragments generated from proteolysis of overexpressed full length apoE. This 
result suggests that an overnight incubation time at 4°C is necessary for optimal 
performance of the mouse anti- apoE E-8 antibody in detecting apoE and its proteolytic 
fragments. This contrasting data also highlights the importance for this optimisation step 
because the data obtained from a 2-hour incubation time would have otherwise 
incorrectly indicated that these fragments lacked the C-terminal end of the protein. On 
the other hand, no additional bands were detected by either the goat anti- apoE 
(Calbiochem) or rabbit anti- apoE SP+1-32aa (Aviva) antibodies as a result of the 
extended incubation time. Nonetheless, an overnight incubation period at 4°C was 
determined to be optimal for the panel of anti- apoE antibodies and this incubation step 





Figure 5-7 Optimisation of primary antibody incubation time during western blotting for the detection 
of apoE fragments 
Western blots of protein extracts from apoE-overexpressing N2a cells, immunoblotted with anti- apoE 
SP+1-32aa (Aviva), goat anti- apoE (Calbiochem) or anti- apoE E-8 for either 2 hours at RTP (A) or 
overnight at 4°C (B). Increasing the incubation time from 2 hours (A) to overnight (B) for anti- apoE E-8 





5.2.3 Characterisation of apoE proteolysis susceptibility in cell models 
Several lines of evidence have shown that apoE4 undergoes proteolysis more readily 
than apoE3, generating a greater amount of total fragments (Huang et al., 2001, Brecht 
et al., 2004b, Jones et al., 2011). However, the proteolytic susceptibility of the 
‘protective’ apoE2 has not been examined comprehensively in human brains, transgenic 
models such as NSE-apoE mice or cell models. In view of this, N2a cells, SH-SY5Y cells 
and primary neurons were used to examine the fragmentation pattern and the 
proteolytic susceptibility of all apoE isoforms here. Equal amounts of protein from each 
cell model were separated using 10% Bis-Tris gels with MES buffer. Western blotting was 
carried out using a polyclonal goat anti- apoE (Calbiochem) due to its ability to 
consistently detect the largest number of fragments with a high degree of sensitivity in 
extracts from human brain and brain homogenates of transgenic AD models (Huang et 
al., 2001, Harris et al., 2003, Brecht et al., 2004b, Zhou et al., 2006, Jones et al., 2011). 
Also, since the epitope mapping data (shown in Figure 5-4) revealed that the goat anti- 
apoE (Calbiochem) antibody is not specific to either of the apoE termini, it is more likely 
to recognise additional intermediate cleavage products than the other anti- apoE 
antibodies. The signal intensity of full length apoE and apoE fragment bands were 
determined by selecting each band within discrete boxes in the Image Studio software 
4.0 (LI-COR). 
 
The percentage of total apoE fragments was calculated based on the following equation: 
 
% 𝑎𝑝𝑜𝐸 =  
𝑆𝑢𝑚 𝑜𝑓 𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
(𝑆𝑢𝑚 𝑜𝑓 𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 + 𝑓𝑢𝑙𝑙 𝑙𝑒𝑛𝑔𝑡ℎ 𝑏𝑎𝑛𝑑 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦)
 ×  100  
 
The percentage of total apoE fragments for apoE2 and apoE4 was then measured 
against total apoE fragments for apoE3 as 100% to compare proteolysis susceptibility 
between the isoforms. Additionally, the relative size (kDa) of each fragment was 
determined by the Image Studio 4.0 software (LICOR), which based its size estimation 





5.2.3.1 ApoE is cleaved in an isoform-dependent manner 
Figure 5-8 shows a representative western blot of apoE-transfected N2a cell extracts 
probed with goat anti- apoE (Calbiochem). Similar sized bands were detected for all 
isoforms (Figure 5-8, A), indicating that each isoform is processed similarly. Fragments 
observed were major bands of   ̴32 and   ̴26kDa, and minor bands ranging between   ̴10-
22kDa. However, differences in the abundance of total fragments between the isoforms 
was revealed by densitometric analysis (p=0.0011) as displayed in the graph in Figure 5-8 
B.  As expected, apoE4-expressing N2a cells displayed a greater abundance of fragments 
compared to apoE3-expressing N2a cells (117.8%±3.7 apoE4 versus apoE3, p=0.0381). 
Surprisingly though, apoE2-expressing N2a cells accumulated a significantly greater 
amount of apoE fragments when compared to apoE3 as 100% (131.8%±6.8 apoE2 versus 
apoE3, p=0.0008). No statistical difference was observed for the total % of fragments 
between apoE2 and apoE4 (apoE2 versus apoE4, p=0.1073). 
 
 
Figure 5-8 Isoform-specific apoE fragmentation in N2a cells 
(A) Representative western blot of protein extracts from N2a cells transiently transfected with pCMV-
ApoE2, pCMV4-ApoE3 and pCMV-ApoE4 constructs, showing full length apoE for all isoforms and up to 6 
apoE fragments ranging from   ̴32-11kDa. (B) Quantification of blots revealed significant differences in 
total apoE fragment levels for both apoE2 (131.8%±6.8) and apoE4 (117.8%±3.7) compared against 
apoE3 as 100%, indicating cleavage occurs in the order of E2>E4>E3 in N2a cells. Data are mean ±SEM, 
and differences were assessed using one-way ANOVA followed by a Tukey's multiple comparisons test. 
*p<0.05; ***p<0.001; (n=5). 
 
Figure 5-9 shows a representative western blot of apoE-transfected SH-SY5Y cell extracts 




fragments from N2a cells, similar sized bands were detected for all isoforms (Figure 5-9, 
A). Fragments observed were major bands of   ̴32,  ̴26 and   1̴0kDa; and minor bands 
ranging between   ̴13-22kDa. Differences in the percentage of total fragments between 
apoE isoforms were also observed in SH-SY5Y cells (p<0.0001) as shown in the graph in 
Figure 5-9, B. Greater levels of fragments were observed for apoE2, followed by apoE4 
when compared to apoE3 as 100% (157.1%±6.8 apoE2 versus apoE3, p<0.0001; 
136%±7.0 apoE4 versus apoE3, p=0.0012). Surprisingly, a small statistical difference was 
also observed for apoE fragment levels between apoE2 and apoE4, as apoE2 showed a 




Figure 5-9 Isoform-specific apoE fragmentation in SH-SY5Y cells 
(A) Representative western blot of protein extracts from SH-SY5Y cells transiently transfected with pCMV-
ApoE2, pCMV4-ApoE3 and pCMV-ApoE4 constructs, showing apoE fragments ranging from   ̴32-11kDa. (B) 
Quantification of blots revealed significant differences in total apoE fragment levels for both apoE2 
(157.1%±6.8) and apoE4 (136.0%±7.0) compared against apoE3 as 100%, indicating cleavage occurs in the 
order of E2>E4>E3 in SHSY5Y cells. Data are mean ±SEM, and differences were assessed using one-way 
ANOVA followed by a Tukey's multiple comparisons test. *p<0.05; **p<0.01; ****p<0.0001; (n=6). 
 
Figure 5-10 shows a representative western blot of apoE-transduced primary neuron 
extracts probed with goat anti- apoE (Calbiochem). Similar sized bands were also 
observed for all apoE isoforms in this in vitro model (Figure 5-10, A), albeit at noticeably 
differing intensities. Fragments detected were major bands of   ̴26,   ̴22,   ̴15 and   ̴10kDa; 
and minor bands of   ̴32,  ̴20,  ̴18 and   ̴16-20kDa. Interestingly, the 18kDa band was more 




neuroblastoma cell models. Differences in the percentage of total fragments between 
apoE isoforms were revealed by densitometric analysis (p=0.0002) as shown in the 
graph in Figure 5-10 B. In contrast to the cell lines, apoE4 showed the highest level of 
fragments in primary neurons when compared to both apoE3 and apoE2 (145.3%±6.4 
apoE4 versus apoE3, p=0.0009; 145.3%±6.4 apoE4 versus 85.96%±4.2 apoE2, p=0.0002). 
Analysis of fragment levels in apoE2- and apoE3- overexpressing primary neurons 




Figure 5-10 Isoform-specific apoE fragmentation in rat primary neurons 
(A) Western blots of protein extracts from rat primary neurons transduced with apoE-expressing lentiviral 
vectors showed up to   ̴10 apoE fragments ranging from   ̴32-11kDa. (B) Quantification of blots revealed 
significant differences in total apoE fragment levels for apoE4 (145.3%±6.4) compared to apoE3 (100%) 
apoE2 (85.9%±4.2), indicating that cleavage occurs in the order of E4>E3>E2 in rat primary neurons. Data 
are mean ±SEM, and differences were assessed using one-way ANOVA followed by a Tukey's multiple 
comparisons test. ***p<0.001; (n=3). 
 
5.2.4 Screen for N-terminal apoE fragments in cell models 
The western blotting data using the goat anti- apoE (Calbiochem) antibody so far 
showed that similar fragments were generated for all the apoE isoforms in vitro, based 
on the patterning and size (kDa). However, whether they do indeed contain the same 
domains is not known. Here, western blotting using three N-terminal specific anti- apoE 
antibodies was carried out to screen for fragments containing the N-terminal domain in 
protein extracts from N2a cells, SH-SY5Y cells and primary neurons overexpressing the 





5.2.4.1 ApoE fragments comprise N-terminal deletions 
Figure 5-11 shows western blots of N2a extracts probed with N-terminal specific anti- 
apoE antibodies. Unexpectedly, rabbit anti- apoE (Aviva) which is raised against the first 
50aa of the N-terminus (SP+1-32aa) detected only full length apoE (Figure 5-11, A). 
Likewise, rabbit anti- apoE 16H22L18 detected only full length apoE (Figure 5-11, B). 
Mouse anti- apoE WU E-4 however, detected both full length apoE and a   ̴32kDa 
fragment (Figure 5-11, C). Failure to detect the range of apoE fragments (  ̴10-32kDa) 
reported in the literature and detected by goat anti- apoE in section 5.2.3.1 indicates 
that these fragments do not contain an intact N-terminus. 
 
 
Figure 5-11 Fragments in N2a cells are not detected by anti- N-terminal specific apoE antibodies 
Representative western blots of protein extracts from control and apoE-overexpressing N2a cells were 
probed using N-terminal specific anti- apoE antibodies. Anti- apoE SP+1-32aa (Aviva) (A) and anti- apoE 
16H22L18 (B) detect only full length apoE protein, whereas anti- apoE WU E-4 (C) detects both full 
length apoE and a 32kDa fragment. (n=5). 
 
Similarly to N2a cells, western blots of extracts from apoE-transfected SH-SY5Y cells also 
indicated that the fragments are at least partially truncated at the N-terminus, since N-
terminal specific anti- apoE antibodies detected only full length apoE (Figure 5-12 A, B 
and C). Interestingly though, mouse anti- apoE WU E-4 did not detect the   ̴32kDa 
fragment, suggesting that there may be cell-type dependent differences in the cleavage 





Figure 5-12 Fragments in SH-SY5Y cells are not detected by anti- N-terminal specific apoE antibodies 
Representative western blots of protein extracts from SH-SY5Y cells transfected with either apoE2, apoE3 
or apoE4- expressing plasmids were probed with N-terminal specific anti- apoE antibodies. (A) Anti- apoE 
SP+1-32aa (Aviva), (B) anti- apoE 16H22L18 and (C) anti- apoE WU E-4 detected only full length apoE 
protein for all isoforms. (n=6). 
 
Western blots of extracts from apoE-overexpressing primary hippocampal neurons 
probed with N-terminal specific anti- apoE antibodies are shown in Figure 5-13. 
Consistent with western blotting data from the neuroblastoma cell lines, all three 






Figure 5-13 Fragments in primary neurons are not detected by anti- N-terminal specific apoE 
antibodies 
Representative western blots of protein extracts from rat primary neurons transduced with apoE-
expressing lentiviral vectors were probed using N-terminal specific anti- apoE antibodies. (A) Anti- apoE 
SP+1-32aa (Aviva), (B) anti- apoE 16H22L18 and (C) anti- apoE WU E-4 detected only full length apoE 
protein for all isoforms. (n=3). 
 
Collectively, these data suggest that proteolysis of full length apoE involves cleavage 
within the vicinity of the first 32aa of apoE, at least, since this is the epitope for the anti- 
apoE SP+1-32aa (Aviva) antibody. Based on these data, apoE proteolysis in vitro does 
not lead to the generation of fragments with intact N-termini for any of the three major 
apoE isoforms. 
 
5.2.5 Screen for apoE fragments containing either an intact or truncated C-terminus 
in cell models 
Data in section 5.2.4 showed that apoE fragments may be produced through N-terminal 
cleavages, thus giving rise to the possibility that C-terminal fragments of apoE may exist. 
To test this hypothesis, two C-terminal specific antibodies were used. The mouse anti- 
apoE 3H1 antibody which recognises an epitope between 243-272aa (lipid binding 
domain) of apoE was selected since studies have shown that it can detect a wide range 
of fragments ( ̴10-32kDa) in human brain tissue (Cho et al., 2001, Jones et al., 2011). The 
mouse anti- apoE E-8, which recognises an epitope within 272-299aa, was also used to 
enable identification of fragments with an intact C-terminus. Moreover, this antibody 




binding domain: those detected by mouse anti- apoE antibody 3H1 but not mouse anti- 
apoE E-8. This is of interest because exposure of this domain through C-terminal 
truncations is thought to be responsible for mitochondrial localisation and neurotoxicity 
(Mahley and Huang, 2012). For example, overexpression of a 1-272aa fragment of apoE 
has been shown to induce cytoskeletal and mitochondrial dysfunction in in vitro model 
systems, as well as induce neurodegeneration when expressed in transgenic rodent 
models (Huang et al., 2001, Nakamura et al., 2009, Harris et al., 2003). 
 
5.2.5.1 ApoE fragments contain an intact C-terminus  
Figure 5-14 shows western blots of control and apoE-transfected N2a cells probed with 
C-terminal specific anti- apoE antibodies. Mouse anti- apoE antibody 3H1 detected full 
length apoE and three major fragments of   ̴32,  ̴26 and   ̴10kDa (Figure 5-14, A). 
Additionally, a very faint fragment of   ̴20kDa was observed for apoE2, which was barely 
detectable for the other two isoforms. The anti- apoE E-8 antibody however, detected 
the   ̴20kDa fragment for all isoforms and other bands of similar sizes to those observed 
when using the other C-terminal specific antibody (see Figure 5-14, B), but generally 
with a stronger signal intensity. It is notable that the patterning and sizes of the bands 
detected by both C-terminal specific anti- apoE antibodies are similar to those observed 





Figure 5-14 Anti- C-terminal specific apoE antibodies reveal fragments to be N-terminally truncated in 
apoE-overexpressing N2a cells 
Representative western blots of protein extracts from N2a cells transfected with either apoE2-, apoE3- 
or apoE4- expressing plasmids were probed using C-terminal specific anti- apoE antibodies. Both (A) 
anti- apoE 3H1 and (B) anti- apoE E-8 detected full length apoE protein and several apoE fragments. 
(n=5). 
 
Figure 5-15 shows western blots of apoE-overexpressing SH-SY5Y cells probed with the 
C-terminal specific anti- apoE antibodies.  Mouse anti- apoE antibody 3H1 detected full 
length apoE and two fragments of   ̴32 and   ̴10kDa (Figure 5-15, A). Likewise, mouse 
anti- apoE E-8 detected these bands, but also a faint   ̴26kDa band and a nonspecific 





Figure 5-15 Anti- C-terminal specific apoE antibodies reveal fragments to be N-terminally truncated in 
transfected SH-SY5Y cells 
Representative western blots of protein extracts from SH-SY5Y cells transiently transfected with either 
apoE2, apoE3 or apoE4 expressing constructs were probed using C-terminal specific anti- apoE 
antibodies. Both (A) anti- apoE 3H1 and (B) anti- apoE E-8 detected full length apoE protein, the 32kDa 
fragment and the 10kDa fragment. (B) anti- apoE E-8 also faintly detected the 26kDa fragment. (n=6). 
 
Figure 5-16 shows western blots of extracts from apoE-transduced primary neurons 
probed with the C-terminus specific apoE antibodies.  Mouse anti- apoE antibody 3H1 
detected full length apoE and six fragments for apoE4: three major fragments of   ̴26,  
 ̴22 and  ̴10kDa; and three faint fragments of  ̴32,  ̴20 and  ̴15kDa (Figure 5-16, A). 
Likewise, mouse anti- apoE E-8 detected these bands for apoE4. In contrast, both C-
terminal antibodies barely detected the minor bands for apoE2 and apoE3, likely due to 





Figure 5-16 Anti- C-terminal specific apoE antibodies reveal majority of fragments to contain an intact 
C-terminus in transduced primary neurons 
Representative western blots of protein extracts from rat primary neurons transduced with apoE-
expressing lentiviral vectors were probed using C-terminal specific anti- apoE antibodies. Both (A) anti- 
apoE 3H1 and (B) anti- apoE E-8 detected full length apoE protein and a range of major and minor apoE 
fragments. (n=3). 
 
Collectively, these data indicate that many of the apoE fragments detected by the goat 
anti- apoE (Calbiochem) antibody in each cell model are likely generated by sequential 
cleavage within the N-terminus, since they contain the 272-299aa epitope that is 
detected by the anti- apoE E-8 antibody. Furthermore, the western blotting data did not 
reveal the presence of a fragment with an exposed lipid binding domain in any of the 
cell models when overexpressing full length apoE, since the anti- apoE E-8 detected the 
same bands as the anti- apoE 3H1 antibody. Finally, qualitative comparisons of the 
fragments detected by both C-terminus specific antibodies in each cell model show that 
apoE fragmentation likely occurs to a greater extent in primary neurons, followed by 






The work presented in this chapter provides a clearer understanding of apoE proteolysis 
in neurons and the identity of apoE fragments, which is pivotal to discovering how apoE 
fragments may contribute to AD pathology. This work involved: validating the epitopes 
of the commercially available anti- apoE antibodies, optimising conditions for anti- apoE 
antibodies for western blotting and characterisation of intracellular apoE fragmentation. 
To do so, apoE2, apoE3 and apoE4 were expressed in N2a cells, SH-SY5Y cells and 
primary rat neurons since cell models are extensively used to model apoE neurobiology, 
but little is known about the fragmentation profile of apoE in vitro. 
 
5.3.1 Epitope mapping and optimisation of commercial anti- apoE antibodies 
To unambiguously identify apoE fragment composition, the epitopes of the 
commercially available anti- apoE antibodies used throughout this work were first 
validated. Results showed that all antibodies were specific to the regions advertised 
except for the rabbit anti- apoE 16H22L18. Although it is advertised as an antibody that 
binds to the lipid-binding domain (240-251aa) of apoE, it instead recognised a region 
within the N-terminus of apoE. This result was significant since the use of this antibody 
would have produced conflicting data when compared with the mouse anti- apoE 3H1, 
which is indeed specific to 243-272aa of apoE. In addition, the specificity of the mouse 
anti- apoE 3H1 antibody for 243-272aa shown here is in line with an earlier study which 
also demonstrated that this antibody recognises a region within 243-272aa of apoE 
(Weisgraber et al., 1986). Overall, these data highlight the necessity to validate the 
epitopes of antibodies when using them to determine protein fragment composition. 
 
After verifying the specificity for the anti- apoE antibodies, the effect of incubation time 
for a number of anti- apoE antibodies was examined to determine optimal conditions for 
apoE fragment detection. The results showed that incubation time and temperature 
were crucial for accurate observation of apoE fragments, since less abundant fragments 
were only detected by mouse anti-apoE E-8 following an overnight incubation at 4°C. 
Incubation for 2 hours at room temperature revealed only abundant fragments, which 




termini. This result shows the importance of antibody optimisation for examining apoE 
fragmentation. 
 
5.3.2 ApoE proteolysis is isoform- and cell- dependent 
Characterisation of apoE fragmentation using the goat anti- apoE (Calbiochem) antibody 
showed that isoform-specific cleavage of apoE does occur, and that this is cell-
dependent. There was scant evidence to suggest that apoE isoforms are differentially 
cleaved in a manner that produces unique fragments. However, these data showed 
significant differences in proteolytic susceptibility between isoforms. Interestingly, this 
occurred in the order of apoE2>apoE4>apoE3 for the N2a and SH-SY5Y cell lines, and 
apoE4>apoE3>apoE2 in primary neurons. The data from the cell lines was unexpected 
since the apoE proteolysis model proposes that apoE4 should be the most susceptible to 
cleavage followed by apoE3 and apoE2 due to isoform-associated differences in protein 
structure (Huang et al., 2004). The basis for this hypothesis is that the presence of an 
arginine residue at position 112 in apoE4 causes greater N-/C-terminal domain 
interaction due to a salt bridge formation between Arg61 and Glu255. Since apoE2 and 
apoE3 have a cysteine at position 112, the inter-domain interaction is thought to be 
reduced (Dong and Weisgraber, 1996, Hatters et al., 2005). Although the data from the 
primary neurons support this model, the greater abundance of fragments for apoE2 
compared with the other two apoE isoforms in the neuroblastoma cells does not. It is 
notable though, that a greater abundance of apoE2 fragments has been observed in 
human plasma when compared to the other two isoforms (Xu et al., 2015a). In view of 
this and studies which have detected apoE fragments in the culture media of apoE-
overexpressing cells (Wellnitz et al., 2005, Munoz et al., 2018), it is conceivable that the 
differing levels of intraneuronal fragments for each isoform may also involve differences 
in secretion versus retention of fragments. To determine if this is the case, the profile 
and levels of fragments secreted by apoE-overexpressing cells could be assessed by 
western blotting in further work. It is also possible that vulnerability of apoE to 
proteolysis may not be entirely due to the native protein structure, but could involve 
cell-dependent post-translational modifications (PTMs) that affect the structural 




glycosylation of apoE may be able to confer secondary polymorphism to the genetic 
isoforms (Zannis and Breslow, 1981) and protect apoE from proteolysis (Wernette-
Hammond et al., 1989). Intriguingly, multiple glycosylation sites have been identified 
across apoE in subsequent studies (Halim et al., 2013, Nilsson et al., 2009, Lee et al., 
2010), however it is still not fully understood how these modifications affect apoE 
structure and function. It is notable though, that a recent structural study found that 
inter-domain interactions were mediated by residues within the hinge region and the C-
terminus of apoE, both of which contain several sites for glycosylation (Williams et al., 
2015). In addition to the increasing evidence suggesting an effect of glycosylation on 
apoE structure, glycosylation has also been shown to affect its function. Mutation of an 
apoE glycosylation site (Thr194) was observed to impair its binding affinity to Aß42 
(Sugano et al., 2008), likely due to alterations in structure. In addition, a study 
investigating the role of apoE in the Niemann Pick Type C (NPC) cholesterol storage 
disorder observed changes in the glycan profile of apoE prior to the onset of 
neurological abnormalities in an animal model of the disease (Chua et al., 2010), 
indicating that there may be a link between altered apoE glycosylation and CNS 
pathology. However, this study did not examine whether this altered the fragmentation 
profile of apoE. Therefore, even though glycosylation affects the function of apoE, 
whether it also directly alters its proteolytic susceptibility remains an elusive, but 
intriguing possibility. It is also possible that differential glycosylation of the apoE 
isoforms may affect their respective fragmentation profiles on western blots due to 
altering the mass and thus mobility of apoE fragments in SDS-PAGE. Of note, Chua and 
colleagues examined the glycan profile of apoE in total brain homogenate from NPC 
rodent models by performing a lectin-ELISA using a panel of biotinylated lectins (Chua et 
al., 2010), glycoproteins that have distinct sugar-binding specificities. This approach 
could also be used in future work to determine whether the glycan profile of apoE 
differs between isoforms, but also between cell models; providing more insight into the 
basis of the differential proteolytic susceptibility of the apoE isoforms in the three cell 





Detection of fragments using goat anti- apoE (Calbiochem) revealed similarities in the 
fragmentation pattern of apoE between cell models. Importantly, this pattern resembles 
the apoE fragment profile found in murine apoE in APP/PS1K1 mice (Saul and Wirths, 
2016) and in human brains of AD patients (Huang et al., 2001, Zhou et al., 2006, Jones et 
al., 2011). This indicates that the proteolytic processing of the three major apoE 
isoforms in vitro is similar to processing of apoE in vivo and thus supports the use of 
these cell models to investigate apoE proteolytic processing. Having established the 
fragmentation profile of the three major apoE isoforms in N2a cells, SH-SY5Y cells and 
primary neurons, the composition of the apoE fragments was next addressed. 
 
5.3.3 ApoE fragment characterisation reveals fragments are likely to be N-terminally 
truncated 
The work in sections 5.2.4 and 5.2.5 set out to characterise the composition of these 
fragments in vitro. Determining the composition of these fragments is necessary to 
better guide future studies using artificial truncated variants of apoE to either explore 
how apoE fragments contribute to Alzheimer’s disease pathology, or in the case of 
apoE2, to use as possible therapeutic compounds. Initially, a screen using a panel of N-
terminal specific anti- apoE antibodies was used to identify which of the fragments 
detected using the goat anti- apoE (Calbiochem) contained an intact N-terminus (if any). 
Unexpectedly, all of the N-terminal specific antibodies failed to detect fragments from 
any of the apoE isoforms in each model system, with the exception of a   ̴32kDa band 
revealed by mouse anti- apoE WU E-4 in N2a cells. Although the binding specificities of 
these antibodies were mapped to the N-terminus in section 5.2.1, only the exact epitope 
of rabbit anti- apoE (Aviva) was known (SP+32aa). Therefore, this data suggests that the 
fragments observed using the goat anti- apoE (Calbiochem) either do not contain the 
first 32aa or that the antibody epitopes are occluded. For the first scenario, a very small 
portion of apoE containing the first 32aa would need to be initially cleaved and either 
degraded or secreted since smaller fragments (<4kDa) weren’t detected by any of the 
three antibodies. Interestingly, there is evidence from sequencing studies that have 
identified apoE fragments which are truncated at position 32, thus supporting this 
hypothesis (Jahn et al., 2011, Lonn et al., 2018). There is also evidence from a structural 




to adopt a molten globule structure (Morrow et al., 2002), which could affect 
accessibility of antibodies to their respective epitopes. Nonetheless, failure to detect N-
terminal apoE fragments was surprising because such fragments have been detected in 
extracts from human AD brains by antibodies that recognise the amino portion of apoE 
(Cho et al., 2001, Jones et al., 2011). Indeed, the use of two such antibodies (mouse anti- 
apoE 6C5 and mouse anti- apoE 1D7 from Ottawa Heart Institute) revealed high 
molecular weight fragments ranging between   ̴22-32kDa in extracts from human AD 
brain (Cho et al., 2001, Jones et al., 2011). The data from these studies suggest that 
many of the high molecular weight fragments detected (between   ̴22 and 26kDa) 
contained an intact N-terminal since these antibodies are reported to recognise residues 
1-15 and 140-160 respectively (Weisgraber et al., 1986). However, these studies also 
showed that fragments of similar sizes were detected by mouse anti- apoE 3H1 
(recognising the lipid binding domain), thus indicating that these proteolytic products 
must be cleaved after position 272aa. However, cleavage of apoE only after the lipid 
binding domain would generate fragments of   ̴31kDa or more. This suggests that either 
the reported epitope of the anti- apoE 6C5 is incorrect, or that the fragments detected 
by both the anti- apoE 6C5 and anti- apoE 3H1 antibodies are different in composition 
but are of similar size. Nonetheless, there are other studies which lend support to the 
notion that fragments generated in vitro may be N-terminally truncated. For example, 
only full length apoE and a   ̴32kDa fragment were detected by mouse anti- apoE 6C5 in 
apoE4-expressing N2a cells (Huang et al., 2001). Additionally, reduced binding of 
recombinant apoE to mouse anti- apoE 6C5, which was used as an anchor antibody in a 
solid phase apoE sandwich immunometric assay, was proposed to be the result of 
amino-terminal proteolysis (Raffai et al., 1995). 
 
Although the data indicated that apoE is cleaved at the N-terminus, it was still plausible 
that apoE could be truncated at the C-terminus too. Indeed, it has been postulated by 
other researchers that apoE fragments are cleaved after the lipid binding domain within 
the C-terminus (Huang and Mahley, 2014, Mahley and Huang, 2012). The basis for this 
stems from earlier work using human brain samples. Fragments detected by goat anti- 




either human AD brains or mice expressing apoE under an NSE promoter (Huang et al., 
2001, Brecht et al., 2004b). This observation led to a vast number of studies using a 
range of truncated variants of apoE with an exposed lipid binding domain (x-272aa) 
which could induce neuronal dysfunction (Harris et al., 2003, Chang et al., 2005, 
Nakamura et al., 2009, Huang et al., 2001). The most toxic of these was reported to be 
apoE4 1-272aa, and it was suggested that the presence and exposure of the lipid binding 
domain seemed necessary for toxicity (Chang et al., 2005). Moreover, apoE4 variants 
were found to be more toxic than the apoE3 versions, and since these fragments 
contained the SNPs, it provided an explanation for the increased risk for AD associated 
with the APOE4 gene. It is notable though that the identity of a fragment containing an 
exposed lipid binding domain had not yet been conclusively determined, likely due to 
the lack of commercially available antibodies at the time to distinguish between 
fragments with an intact or truncated C-terminus. Additionally, it was not known 
whether apoE2 also generates these fragments, and if so, if they would be 
neuroprotective. Therefore, western blotting using antibodies against the lipid binding 
domain (243-272aa) of apoE and the region after (272-299aa) were used here to confirm 
that these fragments were C-terminally truncated and to identify the generation of a 
fragment containing an exposed lipid binding domain. The range of fragments detected 
by the anti- apoE 3H1 is consistent with that shown in western blots using protein 
extracts from human AD brains (Cho et al., 2001, Jones et al., 2011). Notably, both the 
anti- apoE 3H1 and the anti- apoE E-8 antibodies detected fragments of similar sizes to 
those revealed by the goat anti- apoE (Calbiochem) antibody, suggesting that the 
majority of apoE fragments do contain the last 27aa and are thus generated by 
proteolysis of apoE within the N-terminus. This observation also suggests that the 
absence of fragments detected by the N-terminal specific anti- apoE antibodies (in 
section 5.2.4) was not solely due to cleavage of apoE within 1-32aa of the N-terminus, 
but rather due to progressive N-terminal cleavages. The range of fragments detected by 
the anti- apoE E-8 antibody however, contrasts with western blots from other studies 
that used an in-house made antibody against the same epitope (272-299aa) (Huang et 
al., 2001, Harris et al., 2003, Brecht et al., 2004b), which suggest that apoE fragments 




due to low immunoreactivity or sensitivity of the in-house generated antibody. 
Moreover, it is notable that although the anti- apoE (272-299aa) antibody used by these 
researchers was produced by passing the goat anti- apoE antibody through a column of 
beads bound to apoE3 1-272aa and apoE4 1-272aa, the specificity and reactivity of the 
unbound fraction of antibody for 272-299aa of apoE was not demonstrated. Importantly, 
a fragment containing an exposed lipid binding domain was not observed in any of the 
three cell models, for any apoE isoform, suggesting that human apoE is not cleaved 
within the end of the C-terminus. To validate the finding that apoE fragments contain 
intact C-termini in vitro, apoE fragments in lysates from the apoE-overexpressing cells 
could be isolated by immunoprecipitation and sequenced by mass spectrometry in 
future work. It would also be of interest to confirm that apoE is cleaved at the N-
terminus in the human brain, by western blotting analysis of protein extracts from post-
mortem AD human brains using the panel of commercially available antibodies used in 
this chapter. 
 
In support of the data presented in this chapter, there is also a significant body of 
evidence within the literature to support that apoE fragments contain an intact C-
terminus and are thus N-terminally truncated. For example, Saul and co-workers 
observed a range of C-terminal fragments in AD mouse models by using an anti- apoE 
antibody raised against the C-terminus of murine apoE (Saul and Wirths, 2016), 
supporting the existence of C-terminal fragments in vivo. As for in vitro work, Wellnitz et 
al sequenced a   ̴13kDa fragment derived from apoE-transfected N2a cells and 
determined that it contained residues 182-299 (Wellnitz et al., 2005). Interestingly, 
there is also evidence from much earlier work for the existence of C-terminal apoE 
fragments in human tissue. Microsequencing analysis of fibrillar amyloid A from spleen 
tissue of human patients revealed the presence of a 216-299aa C-terminal apoE 
fragment (Castano et al., 1995). ApoE fragments of similar sequence identity (193-299aa 
and 216-299aa) have also been identified in amyloid fibrils isolated from AD brain tissue 
(Wisniewski et al., 1995), providing further evidence to implicate C-terminal apoE 
fragments in amyloid plaque pathology. Furthermore, Aizawa and colleagues found that 




terminal antibodies that recognise a region within the first 100aa of apoE (Aizawa et al., 
1997). As a result, they proposed that the fragments observed in amyloid plaques were 
truncated within the first 100aa of apoE, a conclusion that also lends support to the data 
presented in this chapter. 
 
5.3.4 A role for differential proteolysis of apoE and N-terminally truncated apoE 
fragments in AD 
Collectively, these data add clear evidence to the theory that apoE fragments are 
generated by cleavage within the N-terminus of apoE and that these fragments may 
contribute to AD pathology. An interesting question arises from this data: how do 
carboxyl-fragments account for isoform-specific toxic effects if the SNPs are in the 
amino-terminal portion of apoE? It is important to consider that many of the larger and 
abundant apoE fragments could still include the SNPs, which are at positions 112 and 
158, and thus form isoform-specific structures that could account for differences in 
toxicity. For instance, cleavage up to 111aa of apoE could generate an SNP-containing 
carboxyl fragment spanning between 112-299aa of approximately 22kDa, as based on 
the average of every amino acid being equal to 0.11kDa. Hence, it is possible that apoE 
fragments of 22kDa and above in size could have different structures. Interestingly, the 
data here demonstrate that N-terminally truncated fragments of such sizes exist in cell 
models and are likely similar to fragments of similar size observed in extracts from CSF 
and human AD brain (Marques et al., 1996). Following this notion, the major   ̴26kDa 
fragment observed in all three model systems using the goat anti- apoE (Calbiochem) 
and C-terminal specific anti- apoE antibodies likely also contains these SNPs. It is 
probable that this fragment is generated by cleavage within the second -helix (42-71aa) 
of apoE which is interesting because it has been reported that deletion of residues 1-71 
increases the structural variance between apoE4 and apoE3 (Chou et al., 2005), 
supporting the possibility of isoform-specific differences between N-terminally 
truncated apoE fragments. Intriguingly, Chou and colleagues also identified that deletion 
of the first two -helices for apoE4 promoted concentration-dependent aggregation of 
apoE4, raising the possibility that apoE4 may also induce toxicity in neurons through 
accumulating as aggregates. In support of this, high and low molecular weight apoE 




brain tissue (Jones et al., 2011). Interestingly, this property could also partially explain 
earlier work by Huang and colleagues which found that N2a cells overexpressing an 81-
272aa fragment of apoE displayed a greater number of tangle-like structures than N2a 
cells overexpressing a 1-272aa apoE fragment (Huang et al., 2001). In consideration of 
these findings, it can be reasonably assumed that cleavage within the N-terminus of 
apoE4 can result in a toxic-gain of function and may contribute to AD pathology. 
 
Although similar fragments are generated for each isoform, the differential proteolytic 
susceptibility of each apoE isoform as based on differing levels of fragments generated, 
could also contribute to the differential effects of each isoform in AD. Indeed, the data 
in this chapter showed that apoE4 undergoes proteolysis more readily in primary 
neurons, indicating that fragments could accumulate at a faster rate which could result 
in increased toxicity. Further to this, the concentration of fragments has been shown to 
affect the propensity of self-assembly in a sedimentation velocity study of apoE isoforms 
(Chou et al., 2005). Therefore, it is possible that a greater load of apoE fragments as 
seen for apoE4 in primary neurons, could be associated with increased amyloidogenic 
potential that may be a factor in its reported toxic-gain of function. It is also important 
to note that increased proteolysis of apoE could lead to a loss of protective function (e.g. 
mediating lipid redistribution during neuronal repair), as has been proposed by Rohn et 
al (Rohn, 2013). 
 
5.3.5 Conclusion 
To conclude, the data presented in this chapter is the first to address the proteolytic 
susceptibility profile and composition of apoE fragments for all three major human apoE 
isoforms in N2a cells, SH-SY5Y cells and primary neurons. The data showed that levels of 
apoE fragments were produced in an isoform and cell-dependent manner, which could 
account for variations in toxic gain or loss of protective function for each isoform in 
these cell models. Of note, apoE processing in primary neurons was more similar to 
published in vivo work and so may be the most suitable in vitro model for apoE 
neurobiology. In addition, the data indicated that apoE2, apoE3 and apoE4 fragments 




sizes of the fragments and using this to estimate the position of cleavage sites, it is 
possible to speculate that the structure of some of these fragments and thus the effects 
on neuronal function may differ for each isoform due to the presence of SNPs. Overall 
this work highlights the necessity for future studies to investigate the structure and 
function of N-terminally truncated apoE fragments. Such studies will help to uncover the 
mechanisms by which C-terminal apoE fragments contribute to AD pathology and may 





Chapter 6 THE ROLE OF INTRANEURONAL APOE 
6.1 INTRODUCTION 
Having confirmed that the three major apoE isoforms undergo isoform-dependent 
proteolysis in the previous chapter, the work presented in this chapter compared the 
impact of the three apoE isoforms on downstream effects associated with expression 
and proteolysis of apoE in neurons (Mahley and Huang, 2012). One key step associated 
with the toxic gain of function for apoE4 in the apoE proteolysis model is the 
translocation of apoE fragments from the secretory pathway to the cytosol of the 
neuron, which is thought to be a prerequisite for cytoskeletal and mitochondrial 
dysfunction and thus toxicity (Chang et al., 2005, Mahley and Huang, 2012). Whilst the 
translocation of apoE4 fragments from the secretory pathway to the cytosol has been 
shown to require the receptor binding region, mitochondrial dysfunction and the 
formation of p-Tau inclusions in vitro has been demonstrated to require exposure of the 
lipid binding region (Chang et al., 2005, Huang et al., 2001). Moreover, it is notable that 
much of the evidence supporting a toxic role for intraneuronal apoE4 stems mostly from 
studies showing that C-terminally truncated variants of this protein (particularly the 1-
272aa fragment) induce neuronal dysfunction and toxicity (Huang et al., 2001, Harris et 
al., 2003, Chang et al., 2005, Nakamura et al., 2009). However, the existence of a 
fragment with an exposed lipid binding region was not supported by the work presented 
in the previous chapter, which instead indicated that fragments of apoE2, apoE3 and 
apoE4 are generated by N-terminal cleavages. In view of this, it was first necessary to 
determine whether the toxic effects associated with apoE4 could be reproduced and 
confirmed as isoform specific in the three neuronal model systems used in the previous 
chapter. In doing so, this work also extended upon previous studies since these did not 
include the apoE2 isoform (Huang et al., 2001, Harris et al., 2003, Chang et al., 2005, 
Nakamura et al., 2009).  
 
One well studied aspect of apoE4-mediated cytoskeletal dysfunction is the deregulation 
and destabilisation of the microtubule network, which is supported by studies showing 
that neuroblastoma cells exposed to or expressing apoE4 exhibit impaired neurite 




Bellosta et al., 1995). Increasing data indicates that apoE4 and its fragments contribute 
to this by disrupting the function of tau, which is partly responsible for the stabilisation 
and polymerisation of microtubules. For instance, studies have shown that neuronal 
expression of full length apoE4 in vivo or the 1-272aa apoE fragment in vitro promote 
tau hyperphosphorylation, and induce and co-localise with p-Tau inclusions (Huang et 
al., 2001, Brecht et al., 2004b, Tesseur et al., 2000b, Tesseur et al., 2000a). In view of 
these findings, the first two aims of this section were to (i) determine whether C-
terminal fragments could be observed in the cytosol for each apoE isoform and (ii) 
determine whether expression and proteolysis of apoE4 affected the organisation and 
regulation of tau as reported in the literature, and to confirm that this was also specific 
to the apoE4 isoform. 
 
The work here next investigated the neuroprotective role of apoE expression in neurons 
by examining the relationship between apoE and vimentin, an intermediate filament (IF) 
protein that has recently been implicated in the neuronal repair response (Levin et al., 
2009). Vimentin is a cytoplasmic protein that is primarily expressed by vascular 
endothelial cells and some glial cells in the mature, healthy brain (Bignami et al., 1982, 
Schnitzer et al., 1981). It is also expressed in developing neurons to initiate and promote 
dendritic branching (Boyne et al., 1996, Levin et al., 2009), but is then replaced by 
neurofilament proteins once neurons become post-mitotic (Cochard and Paulin, 1984). 
Intriguingly, neurons re-express vimentin in AD-relevant brain regions showing 
pathologies such as amyloid plaques and NFTs, as revealed by enhanced staining for 
vimentin in brain tissue from AD donors and AD transgenic mice (Levin et al., 2009). 
Furthermore, it was also shown that traumatic injury to brain tissue of adult mice 
resulted in increased vimentin expression in neurons (Levin et al., 2009). Levin and 
collaborators suggested that this could be a protective response that enables injured 
neurons to delay dendritic and synapse loss, thus implicating vimentin expression as 
part of the very poorly understood repair response mechanism in neurons. Similarly, 
apoE expression in neurons has also been shown to occur in response to neuronal injury 
or stress (Xu et al., 2006b, Boschert et al., 1999), raising the possibility of a connection 




repair. Therefore, the third aim of the work presented in this chapter was to (iii) 
determine whether neuronal apoE expression was associated with vimentin 
upregulation, and to what extent this was an isoform specific effect. 
 
Finally, to investigate whether apoE expression and proteolysis in neurons leads to an 
isoform-dependent toxic or protective gain of function, neuronal viability and survival 
was assessed. Although apoE4 has been associated with a toxic gain of function when 
expressed in neurons, only a single study to date has directly tested whether neuronal 
expression of apoE4 does indeed reduce neuronal viability in vitro (Chang et al., 2005). 
Notably in the study by Chang and collaborators, full length apoE4 expression in 
neuroblastoma cells was found not to be toxic, whereas expression of the 1-272aa 
fragment of apoE4 was. Furthermore, whilst apoE2 is considered neuroprotective due to 
the association of an APOE2 genotype with a decreased risk for AD (Chartier-Hariln et al., 
1994, Corder et al., 1994), it is not known whether expression and proteolysis of apoE2 
in neurons contributes to this neuroprotective effect, or alternatively, also triggers a 
toxic gain of function. Hence the fourth aim of the work presented here was to (iv) 
determine if neuronal viability and survival was affected by neuronal apoE expression in 







6.2.1 Immunocytochemical analysis of apoE distribution in N2a cells 
The data presented in the previous chapter showed that antibodies specific to the N-
terminus of apoE detected only full length apoE protein in western blots, whereas 
antibodies specific to the C-terminus of apoE detected a wide range of fragments. 
Therefore, to determine whether fragments translocate to the cytosol and to provide 
insight for fragment-related functions, immunocytochemistry was used to examine 
whether the fragments containing an intact C-terminus were distributed in subcellular 
compartments where full length was not. This was done by double immunolabelling 
apoE-transfected N2a cells using antibodies specific to the N- and C-terminus of apoE 
followed by imaging with a confocal microscope. Immunolabelling was carried out in 
N2a cells transfected with all three major apoE isoforms to determine if the staining 
distribution differed between isoforms.  
 
There was no clear evidence for differences in the subcellular distribution of either the 
N- or C-terminus of apoE in cells co-stained with anti- apoE 16H22L18 and anti- apoE E-8 
antibodies for all three isoforms of apoE (Figure 6-1). Immunolabelling with both 
antibodies revealed a granular distribution throughout the cell soma and strong 
punctate perinuclear staining for all isoforms of apoE. However, although the 
distribution of full length apoE (staining by the N-terminal specific antibody) was 
observed throughout the cytoplasm, immunoreactivity appeared to be stronger when 
staining with the C-terminal specific antibody. To test whether this was an artefact of 
the N-terminal specific antibody, N2a cells were also labelled using the two other N-
terminus specific antibodies: anti- apoE SP+32aa (Aviva) and anti- apoE WU E-4.  Both 
these antibodies revealed similar cytoplasmic and perinuclear distribution of apoE 
(shown in Figure 6-2) that also appeared to co-localise more than the staining between 
the N- and C-terminal specific antibodies (Figure 6-2 compared to Figure 6-1). This 
suggests that it is possible that there may be increased cytoplasmic labelling for C-
terminal apoE, although this was inconclusive based on the limited resolution of this 
method. Finally, control cells showed negligible staining for all antibodies used here, 





Figure 6-1 Immunofluorescence images showing the distribution of apoE N- and C- terminal specific 
staining in N2a cells 
Representative images of immunolabelling with an N-terminus specific and a C-terminus specific antibody 
of apoE in N2a cells transfected with apoE2, apoE3 and apoE4 for 48 hours and fixed with FA.  Extensive 






Figure 6-2 Immunofluorescence images showing the distribution of apoE N-terminus specific staining in 
N2a cells 
Representative images of immunolabelling with two N-terminus specific antibodies of apoE in N2a cells 
transfected with apoE2, apoE3 and apoE4 for 48 hours and fixed with FA; n=3.  Extensive co-localisation 
was observed. Scale bar = 10µm. 
 
6.2.2 The effect of apoE overexpression on endogenous p-Tau organisation and 
regulation 
6.2.2.1 Validating phosphospecificity of the anti pThr181-Tau antibody 
Since the anti- pThr181-Tau AT270 antibody has been used in studies reporting apoE-
induced tau hyperphosphorylation (Huang et al., 2001, Hoe et al., 2006), this antibody 
was also used in the present study to investigate whether apoE overexpression affects 
the organisation and regulation of p-Tau. However, the phosphospecificity of the anti- 
pThr181-Tau AT270 antibody for the phosphorylated form of tau was first confirmed. 
Usually protein lysate is treated with phosphatases after extraction and then western 
blotting performed, however protease and phosphatase inhibitors were used in the lysis 
buffer to minimise dephosphorylation of Tau due to lysis. Hence to ensure the specificity 
of the anti- pThr181-Tau AT270 antibody for the phosphorylated form of tau, lamba 




transferred onto nitrocellulose blots after SDS PAGE. Lysate used was from control 
mature primary neurons since they endogenously express tau protein. Control primary 
neuron lysate from three independent cultures were loaded in duplicate so that the 
blots could be cut into two after transfer to enable comparison of identical blots that 
were untreated or treated with LPP. Due to limited available protocols for this approach, 
two protocols were trialled. Blots were either treated with LPP before blocking with 5% 
BSA (Figure 6-3, A) or after blocking with 5% BSA (Figure 6-3, B). The blots were then 
immunolabelled using anti- pThr181-Tau AT270, anti- pSer9-SnpI (weakly labels pSer9-
SnpII) as a positive control for antibody phosphospecificity, and anti- actin as a loading 
control. On untreated blots, the anti- pThr181-Tau AT270 antibody detected various 
isoforms of Tau ranging from 52-63kDa (Figure 6-3, A and B, untreated blot). The anti- 
pSer9-SnpI antibody did not detect pSer9-SnpI, likely due to very low basal 
phosphorylation of this protein without induced-neuronal activity, but it did however 
detect low levels of pSer9-SnpII (Figure 6-3, A and B, untreated blot). Treating the blot 
with LPP before blocking resulted in reduced signal for both phospho-antibodies (Figure 
6-3, A), whereas treatment after blocking eliminated the signal (Figure 6-3, B). This data 





Figure 6-3 Western blots of primary neuron lysate showing phospho-specificity of anti- pThr181-Tau 
antibody 
Western blots of primary neuron protein extracts probed with antibodies for tau phosphorylated at 
threonine 181, SynapsinII at Ser9 (positive control) and actin (loading control) before (A) and after (B) 
blocking the blot with 5% BSA. Both untreated blots reveal detection of pThr181-Tau, pSer9-SnpII and 
actin (A and B). Lambda phosphatase (LPP) treatment of duplicate blot before blocking reduces the 
signal for both pThr181-Tau and pSer9-SnpII (A). LPP treatment of duplicate blot after blocking 







6.2.2.2 Comparing the effects of different fixatives on apoE and pThr181-Tau staining 
in N2a cells 
Prior to assessing the effect of apoE isoform on the intracellular organisation of pThr-
181-Tau, the effect of fixative on the staining pattern of apoE and pThr-181-Tau in 
control and apoE3-transfected N2a cells was carried out. Control and apoE3-expressing 
N2a cells were fixed using methanol or FA and then immunolabelled using anti- pThr181 
Tau AT270 and anti- apoE (Calbiochem) to determine the optimal fixation method 
(Figure 6-4). The staining of pThr181-Tau was similar in cells fixed with FA and methanol 
(Figure 6-4 A compared with B), although methanol fixation did appear to enhance its 
cytoplasmic staining. The staining for apoE however, was remarkably altered when N2a 
cells were fixed with methanol. The labelling of apoE appeared more diffused and the 
strong perinuclear staining was no longer distinguishable (Figure 6-4, B compared with 
A). Therefore, FA was used as the fixative for subsequent immunofluorescence 





Figure 6-4 Immunofluorescence images showing apoE and pThr181-Tau staining in N2a cells fixed with 
either formaldehyde or methanol  
Representative immunofluorescence images of formaldehyde- (A) and methanol- (B) fixed control and 
apoE3-expressing N2a cells double immunolabelled for apoE (green) and Tau phosphorylated at Thr181 
(red) using goat anti- apoE (Calbiochem) and mouse anti- pThr181-Tau AT270 antibodies respectively. 





6.2.2.3 ApoE does not co-localise with pThr181-Tau in N2a cells 
it has been demonstrated that GFP-tagged full length apoE4 and C-terminally truncated 
apoE4 (1-272aa) induce and co-localise with p-Tau containing inclusions to a greater 
extent than apoE3 when expressed in N2a cells (Huang et al., 2001). Since the data in 
the previous chapter indicated that C-terminally truncated fragments are not generated, 
and that apoE fragments are instead N-terminally truncated, the present study 
investigated whether the findings reported by Huang and colleagues could be 
reproduced under the same conditions used in the previous chapter. Furthermore, since 
the Huang et al. study did not include apoE2, it was of interest to determine the effect of 
this isoform on the subcellular organisation of pThr181-Tau in N2a cells. To do so, apoE-
transfected N2a cells were immunolabelled using goat anti- apoE (Calbiochem) (Figure 
6-5, green staining) to detect full length apoE and its fragments, and anti- pThr181-Tau 
AT270 (Figure 6-5, red staining)  to detect hyperphosphorylated ‘tangle-like’ inclusions. 
(Huang et al., 2001). 
 
Surprisingly, the immunolabelling revealed intense staining for pThr181-Tau that 
resembled the reported ‘tangle-like’ structures (Huang et al., 2001) in both, control and 
apoE-transfected N2a cells. This suggests that this structure may not be the pathological 
form of tau in N2a cells, or that this staining is not specific to p-Tau. Immunolabelling 
also revealed diffused cytoplasmic staining of pThr181-Tau that was stronger in apoE-
transfected cells compared to control cells, which could suggest increased pThr181-Tau 
levels. This did not appear to be dependent on apoE isoform. Remarkably though, apoE 
staining for all three isoforms did not appear to co-localise with either the cytoplasmic 
or tangle-like staining of pThr181-Tau. Instead, the tangle-like structures of pThr181-Tau 





Figure 6-5 Immunofluorescence images showing the localisation of different human apoE isoforms and 
pThr181-Tau in N2a cells 
Representative immunofluorescence images of N2a cells transfected with either human apoE2, apoE3 or 
apoE4 for 48 hours (n=3), fixed with FA and co-stained for apoE (green) and p-Tau (red) using goat anti- 
apoE (Calbiochem) and mouse anti- pThr181 Tau AT270 antibodies.  No co-localisation was observed 
between apoE and pThr181-Tau in apoE-transfected cells for any isoform. However, pThr181-Tau cage-like 
structures surrounding the perinuclear region of apoE was apparent for all isoforms of apoE, as indicated 





6.2.2.4 ApoE affects tau phosphorylation in an isoform-dependent manner in vitro 
Although full length apoE did not appear to co-localise with pThr181-Tau in N2a cells, 
the diffused cytoplasmic staining for pThr181-Tau seemed to be stronger in apoE-
transfected cells than in control N2a cells. This raised the possibility that apoE 
overexpression may affect the levels of pThr181-Tau. To investigate if this was case, 
western blotting was carried out using anti- pThr181-Tau AT270, anti- Tau-1, anti- Tau D-
8, and anti- actin antibodies for all three cell models overexpressing apoE under the 
same conditions used previously. 
 
Western blots showed very weak detection (near background levels) of tau isoforms 
phosphorylated at Thr181 (Figure 6-6, A;  ̴52-63kDa bands) and Tau-1 (Figure 6-6, B;  ̴52-
63kDa bands) for all conditions in N2a cells, which did not allow for reliable quantitation. 
Immunoblotting using anti- Tau D-8 did not detect any bands (data not shown). These 
findings were surprising considering the intense staining that was observed by 
immunofluorescence in N2a cells labelled with anti- pThr181-Tau AT270. 
Immunoblotting for actin as a loading control revealed strong bands in each lane 
suggesting that the protein quality and amount loaded was adequate for western 
blotting analysis. Despite the weak labelling for p-Tau ( ̴52-63kDa bands), the anti- 
pThr181-Tau AT270 antibody strongly detected high molecular weight bands within 
100kDa-180kDa of size (Figure 6-6, A). These bands were not detected by anti- Tau-1, 
indicating that they may be nonspecific. As a result, whether apoE overexpression 
affected endogenous p-Tau/total tau levels in N2a cells could not be confidently 
determined. 
 
Western blotting analysis of pThr181-Tau and total tau levels in SH-SY5Y cells was also 
not conclusive. Immunoblotting using the anti- pThr181-Tau AT270 antibody revealed 
faint bands for all conditions in SH-SY5Y cells (Figure 6-7, A;   5̴2-58kDa bands). Whilst 
the anti- Tau-1 antibody failed to recognise total tau in this cell line, immunoblotting 
using anti- Tau D-8 (Santa Cruz) showed that there were low levels of total tau for all 
conditions (Figure 6-7, B;   ̴52-58kDa bands). In addition, a strong band of   ̴135kDa was 




Tau D-8 (Figure 6-7, B). This suggests that it is likely a non-specific band, similar to those 
observed in N2a cells. 
 
Finally, these experiments were repeated with extracts from primary neurons. High 
levels of pThr181-Tau and total tau isoforms were detected in these extracts (Figure 6-8, 
A and B respectively;   ̴52-63kDa bands). Notably, high molecular weight bands ( ̴135-
180kDa) were also detected by anti- pThr181-Tau AT270 (Figure 6-8, A; top blot) but not 
by anti- Tau-1 (Santa Cruz). Since the signal for the pThr181-Tau and tau bands were 
strong enough, densitometric analysis was carried out. The levels of pThr181-Tau and 
total tau were determined by normalising the ratios of pThr181-tau/actin and total 
tau/actin to control neurons (Figure 6-9). Densitometric analysis (shown in Figure 6-9, A) 
showed a significant increase in  ̴52kDa pThr181-Tau levels in extracts from primary 
neurons overexpressing apoE3 and apoE4 (134.6%±8.9 apoE3 versus control, p=0.0188; 
145.3%±8.0 apoE4 versus control, p=0.004), whereas extracts from primary neurons 
overexpressing apoE2 showed that similar levels of   ̴52kDa pThr181-Tau to control 
neurons (112.2%±3.5 apoE2 versus control, p>0.05). The levels of pThr181-Tau in 
protein extracts from apoE4-overexpressing neurons were also significantly different to 
those from apoE2-overexpressing neurons (p=0.0237). Collectively this data suggests 
that apoE overexpression induces tau phosphorylation at the Thr181 site of the   ̴52kDa 
tau variant in an isoform dependent manner (E4>E3, whilst apoE2 does not exert an 
effect). This was not the case for   ̴58kDa pThr181-Tau though. The levels of   ̴58kDa 
pThr181-Tau (shown in Figure 6-9, B) in neurons overexpressing the three apoE isoforms 
were similar to control neurons (102.8%±8.1 apoE2, 119%±3.8 apoE3 and 113.8%±2.8 
apoE4; p>0.05). Since the other tau variants were near background levels, the difference 
in the pThr181-Tau levels of these variants between conditions could not be calculated. 
Total tau levels (  ̴52kDa band) in primary neuron lysates were also assessed following 
normalisation against actin (Figure 6-9C). The data revealed no significant in the levels of 
total tau (113.1%±27.4 apoE2, 117.6%±20.1 apoE3 and 130%±18.4 apoE4; p>0.05) 
suggesting that apoE overexpression in neuronal cultures for 3 days does not affect total 
tau levels, and therefore indicates that the increase in pThr181-Tau levels is due to 





Figure 6-6 Western blots of pThr181-Tau and total tau from protein extracts of apoE-transfected N2a 
cells 
N2a cells were transiently transfected with pCMV-ApoE plasmids for 48 hours and protein was 
harvested for western blotting analysis; n=3. (A) Immunoblotting using anti- pThr181-Tau AT270 
revealed faint bands for pThr181-Tau isoforms ranging from 52-63kDa but also intense bands of 
approximately 110kDa and 215kDa. (B) Immunoblotting using anti- Tau-1 detected low levels of 






Figure 6-7 Western blots of pThr181-Tau and total tau from protein extracts of apoE-transfected SH-
SY5Y cells 
SH-SY5Y cells were transiently transfected with pCMV-ApoE constructs for 48 hours and protein was 
harvested for western blotting analysis; n=3. (A) Immunoblotting using anti- pThr181-Tau AT270 
revealed faint bands for pThr181-Tau isoforms ranging from 52-58kDa but also an intense band of 
approximately 150kDa. (B) Immunoblotting using anti- Tau D-8 showed that low levels of endogenous 







Figure 6-8 Western blots of pThr181-Tau and total tau from protein extracts of primary neurons 
transduced with apoE lentiviral vectors 
Primary neurons were transduced using apoE lentiviral vectors at an MOI of 150 for 3 days and protein 
was harvested for western blotting analysis; n=3. (A) Immunoblotting using anti- pThr181-Tau AT270 
revealed pThr181-Tau isoforms ranging from 52-74kDa but also bands of approximately 135kDa and 
215kDa. (B) Immunoblotting using anti- Tau-1 revealed the doublet band of approximately 52-58kDa. 






Figure 6-9 Bar charts showing quantitation of pThr181-Tau (52kDa and 58kDa) and total tau levels in 
lysates of primary neurons transduced with apoE-expressing lentiviral vectors for 3 days 
The intensity of pThr181-Tau, total tau and actin bands were quantified by densitometric analysis and 
the levels of pThr181-Tau and total tau were calculated as a percentage of control levels as 100%. (A) 
Bar chart showing that the levels of   ̴52kDa pThr181-Tau (normalised to actin) significantly increase 
(p<0.05) in apoE3- and apoE4- overexpressing neurons, whereas apoE2-overexpressing neurons display 
similar levels to control neurons. (B) Bar chart showing that levels of   ̴58kDa pThr181-Tau (normalised 
to actin) are similar in apoE2-, apoE3- and apoE4- overexpressing neurons to control neurons. (C) Bar 
chart showing that levels of   ̴52kDa total tau (normalised to actin) are similar in apoE2-, apoE3- and 
apoE4-overexpressing neurons. Data are mean ±SEM, and differences were assessed using one-way 






6.2.2.5 Cell model dependent effects of apoE overexpression on GSK3 kinase 
phosphorylation 
The GSK3 kinase is one of many kinases that modulates tau function through 
phosphorylation events at several sites across the protein, including the Thr181 site 
(Sperber et al., 1995). Since the previous section showed that tau was phosphorylated at 
the Thr181 site to a greater extent in apoE3- and apoE4- overexpressing primary 
neurons, the aim of the work presented in this section was to determine whether apoE 
overexpression alters the levels of inactive GSK3, which could in turn affect the 
phosphate content at Thr181 of tau. Phosphorylation of GSK3ß at Ser9 and GSK3α at 
Ser21 is associated with inhibition of kinase activity, whilst a decrease in the 
phosphorylated form of GSK3 indirectly indicates enhanced kinase activity (Sutherland 
et al., 1993). Here, the levels of phosphorylated GSK3 were quantified from western 
blots of protein extracts from N2a cells, SH-SY5Y cells and primary neurons 
overexpressing apoE isoforms as previously described. Immunoblotting was carried out 
using an antibody that detects GSK3ß phosphorylated at Ser9. 
 
Western blots of N2a cell extracts (Figure 6-10, A) detected pSer9-GSK3ß at   ̴46kDa for 
all conditions, as well as another band at   ̴51kDa that likely represents GSK3α 
phosphorylated at Ser21 due to epitope sequence similarity. Quantification of pSer9-
GSK3ß levels (Figure 6-10, B) revealed a significant reduction in protein extracts from 
apoE3- and apoE4- transfected N2a cells compared to control cells (60.6%±7.6 apoE3, 
p=0.0041 and 59.8%±5.8 apoE4, p=0.0036). The levels of pSer9-GSK3ß in apoE2-
transfected N2a cells were similar to control (100.0%±5.3 apoE2, p>0.05), and so were 
also significantly different to the levels for the other two isoforms (apoE2 versus apoE3, 
p=0.004 and apoE2 versus apoE4, p=0.0035). A reduction in pSer21-GSK3α levels was 
also observed in apoE3- and apoE4- transfected N2a cells compared to control cells 
(66.24%±10.7 apoE3, p=0.0252 and 67.85%±4.6 apoE4, p=0.0322), but not in apoE2-
transfected N2a cells (103.5%±5.6 apoE2, p>0.05). This suggests that in N2a cells, the 






Western blots of SH-SY5Y cell extracts also revealed bands corresponding to pSer9-
GSK3ß and pSer21-GSK3α in all lanes (Figure 6-11, A). However, quantitation did not 
show significantly altered levels of pSer9-GSK3ß (Figure 6-11, B; 87.4%±4.0 apoE2, 
96.3%±6.7 apoE3 and 92.7%±6.5 apoE4; p>0.05) or pSer21-GSK3α (Figure 6-11, C; 
89.6%±5.2 apoE2, 93.1%±5.7 apoE3 and 102.0%±4.8 apoE4; p>0.05) when any of the 
three apoE isoforms were overexpressed. This suggests that apoE expression does not 
affect the kinase activity of either pSer9-GSK3ß and pSer21-GSK3α in SH-SY5Y cells. 
 
pSer9-GSK3ß and pSer21-GSK3α were also detected by western blotting of lysate from 
primary neurons overexpressing the three major apoE isoforms (Figure 6-12, A). 
Quantitation did not reveal any significant differences in the levels of pSer9-GSK3ß 
between apoE-overexpressing neurons and control neurons (Figure 6-12, B; 97.1%±9.6 
apoE2, 90.45%±7.8 apoE3 and 82.1%±8.9 apoE4; p>0.05). Likewise, no significant 
difference was observed in the levels of pSer21-GSK3α (Figure 6-12, B; 108.1%±16.6 
apoE2, 99.8%±14.3 apoE3 and 89.5%±12.9 apoE4; p>0.05). These data indicate that 
neuronal apoE expression does not affect the kinase activity of pSer9-GSK3ß and 
pSer21-GSK3α, which is consistent with that observed in SH-SY5Y cells. Hence the 






Figure 6-10 Western blotting analysis of pSer9-GSK3ß and pSer21-GSK3α levels in lysates of apoE-
transfected N2a cells 
(A) Immunoblotting using anti- pSer9-GSK3ß revealed bands corresponding to pSer9-GSK3ß at   ̴46kDa 
and pSer21-GSK3α at   ̴51kDa in lysates of control N2a cells and N2a cells overexpressing apoE2, apoE3 
and apoE4 for 48 hours. Blots were also labelled for actin as a loading control. Quantitation of pSer9-
GSK3ß levels (B) and pSer21-GSK3α levels (C) showed a significant reduction in apoE3- and apoE4- 
transfected N2a cells, but not in apoE2-transfected N2a cells. Data are mean ±SEM, and differences 
were assessed using one-way ANOVA followed by a Tukey's multiple comparisons test where p<0.05 is 






Figure 6-11 Western blotting analysis of pSer9-GSK3ß and pSer21-GSK3α levels in lysates of apoE-
transfected SH-SY5Y cells 
(A) Immunoblotting using anti- pSer9-GSK3ß (cell signalling) reveals bands corresponding to pSer9-GSK3ß 
at   ̴46kDa and pSer21-GSK3α at   ̴51kDa in lysates of control SH-SY5Y cells and SH-SY5Y cells transfected 
with apoE-expressing plasmids for 48 hours. Blots were also labelled for actin as a loading control. 
Quantitation of pSer9-GSK3ß levels (B) and pSer21-GSK3α levels (C) showed no significant differences 
between control and apoE-expressing SH-SY5Y cells. Data are mean ±SEM, and differences were assessed 






Figure 6-12 Western blotting analysis of pSer9-GSK3ß and pSer21-GSK3α levels in lysates of primary 
neurons transduced with apoE-expressing lentiviral vectors 
(A) Immunoblotting using anti- pSer9-GSK3ß (cell signalling) revealed bands corresponding to pSer9-
GSK3ß at  ̴46kDa and pSer21-GSK3α at  ̴51kDa in lysates of control primary neurons and primary 
neurons transduced with apoE lentiviral vectors (150MOI) for 3 days. Blots were also labelled for actin 
as a loading control. Quantitation of pSer9-GSK3ß levels (B) and pSer21-GSK3α levles (C) revealed that 
there were no significant differences between control and apoE-expressing primary neurons. Data are 
mean ±SEM, and differences were assessed using one-way ANOVA followed by a Tukey's multiple 




6.2.3 ApoE overexpression in neurons enhances vimentin expression in an isoform 
and cell dependent manner 
Although expression of apoE and vimentin in neurons has been proposed to play a role 
in the repair response of stressed or injured neurons, it is not known whether there is a 
relationship between the two. To investigate this, the levels of vimentin were examined 
in neuronal cell models overexpressing either apoE2, apoE3 or apoE4. The levels of 
vimentin were calculated as a percentage of the control (as 100%) from the ratios of 
vimentin/actin band intensity values for each condition. 
 
Unfortunately, western blots of N2a cell extracts using anti- vimentin did not reveal 
bands (not shown), although this was unsurprising since this commercially available 
antibody is reported as unreactive to mouse vimentin.  
 
Western blots of SH-SY5Y cell extracts did however, reveal bands of approximately 
58kDa all conditions (Figure 6-13, A). Quantification of vimentin levels did not reveal any 
statistical differences in SH-SY5Y cells overexpressing apoE2, apoE3, or apoE4 (Figure 
6-13, B; 82.7%±18.4 apoE2, 78.8%±10.8 apoE3 and 117.0%±13.0 apoE4; p>0.05), 
suggesting that total vimentin levels are unaffected by apoE overexpression in SH-SY5Y 
cells under these conditions. 
 
Bands corresponding to vimentin were also detected on western blots of primary 
neuronal extracts, which appeared to increase in intensity for neurons overexpressing 
apoE2 and apoE4 protein, but not apoE3 (Figure 6-14, A). Quantification of vimentin 
levels (Figure 6-14, B) confirmed a significant increase in apoE2- and apoE4-transduced 
primary neurons compared to control cells (239.9%±18.6 apoE2, p=0.0024 and 
208.8%±23.7 apoE4, p=0.0109). Although vimentin levels were marginally increased in 
neurons overexpressing apoE3 compared to control neurons, this was not significant 
(132.9%±19.0 apoE3, p=0.5852). The levels of vimentin in apoE2-overexpressing neurons 
were also found to be significantly greater when compared to apoE3-overexpressing 
neurons (p=0.0120). These results suggest that both apoE2 and apoE4 expression in 






Figure 6-13 Western blotting analysis of vimentin levels in lysates of apoE-transfected SH-SY5Y cells 
(A) Immunoblotting using anti- vimentin revealed bands corresponding to vimentin at   ̴58kDa in lysates 
of control SH-SY5Y cells and SH-SY5Y cells transfected with apoE2, apoE3 and apoE4 constructs for 48 
hours. Blots were also labelled for actin to use as a loading control. (B) Quantitation of vimentin levels 
did not show significant differences between control and apoE-expressing SH-SY5Y cells. Data are mean 
±SEM, and differences were assessed using one-way ANOVA followed by a Tukey's multiple 







Figure 6-14 Western blotting analysis of vimentin levels in lysates of primary neurons transduced 
with apoE-expressing lentiviral vectors 
(A) Immunoblotting using anti- vimentin revealed bands corresponding to vimentin at   ̴58kDa in lysates 
of control primary neurons and primary neurons transduced with apoE2, apoE3 and apoE4 lentiviral 
vectors (150 MOI) for 3 days. Blots were also labelled for actin to use as a loading control. (A) 
Quantitation of vimentin levels revealed significant increases of vimentin protein in apoE2- and apoE4-
overexpressing primary neurons compared to control neurons, whilst this was not the case for apoE3-
overexpressing neurons. The levels of vimentin in neurons overexpressing apoE2 were also significantly 
greater when compared to apoE3-transduced neurons. Data are mean ±SEM, and differences were 
assessed using one-way ANOVA followed by a Tukey's multiple comparisons test where p<0.05 is 






6.2.4 The effect of apoE overexpression on cell viability in vitro 
Whether apoE expression and proteolysis in neuronal cell models leads to an isoform-
dependent toxic or protective gain of function is still not fully established. Therefore, the 
effect of full length apoE overexpression on cell viability of N2a cells, SH-SY5Y cells and 
primary neuronal cultures was explored by using an MTT reduction assay, where a 
reduction in MTT indicates a loss of viable cells. Both N2a and SH-SY5Y cells were 
transfected with plasmids overexpressing apoE2, apoE3 or apoE4 under a CMV 
promoter for 48 hours. MTT reduction values were normalised to control cells 
transfected with an empty plasmid (pCIS backbone) to discount toxicity due to 
transfection reagent and introduction of plasmid DNA into the cell. Primary neurons 
were transduced with apoE-expressing lentiviral vectors for 3 days, at an MOI of 50 to 
reduce the likelihood of toxicity that may accompany high protein expression observed 
when using an MOI of 150. 
 
Bar charts showing the effect of apoE overexpression on the viability of N2a cells, SH-
SY5Y cells and primary neurons are shown in Figure 6-15, where MTT reduction levels 
are normalised to control values where control is 100%. In N2a cells, MTT reduction was 
similar between all conditions (Figure 6-15, A; 93.28%±2.1 apoE2, 98.55%±5.3 apoE3 and 
97.11%±2.6 apoE4; p>0.05). In contrast, significant differences were observed for MTT 
reduction values in SH-SY5Y cells as shown in Figure 6-15, B. Both apoE2- and apoE3-
transfected SH-SY5Y cells displayed significantly greater MTT reduction levels compared 
to control cells (Figure 6-15, B; 125.2%±9.3 apoE2, p=0.0277 and 128.6%±2.9 apoE3, 
p=0.0140), whereas apoE4-transfected cells did not (Figure 6-15, B; 99.8%±1.1 apoE4, 
p>0.05). MTT reduction levels were also significantly greater in SH-SY5Y cells 
overexpressing apoE2 and apoE3 when compared to apoE4 (apoE2 versus apoE4, 
p=0.0268 and apoE3 versus apoE4, p=0.0136). In primary neurons, MTT reduction levels 
were similar between control neurons and neurons overexpressing apoE2, apoE3 and 
apoE4 for 3 days (Figure 6-15, C; 101.7%±1.7 apoE2, 101.2%±3.0 apoE3 and 100.9%±3.9 
apoE4; p>0.05). Collectively apoE overexpression did not appear to be toxic in any of the 
three cell models since no significant decreases in MTT levels were observed. This 




result in toxicity under these conditions. Surprisingly though, apoE2 and apoE3 
expression seemed to enhance cell viability in SH-SY5Y cells, as indicated by the 
significant increases in MTT reduction levels. This result also highlights another cell 
dependent effect of apoE expression since an effect was only observed in the human 






Figure 6-15 Graphs showing the effect of apoE2, apoE3 and apoE4 overexpression on cell viability as 
based on the MTT reduction assay 
(A) Bar chart showing MTT reduction values normalised to control for N2a cells transfected with an empty 
pCIS construct (control) or pCMV-apoE constructs expressing apoE2, apoE3 and apoE4 for 48 hours (n=6). 
Cell viability did not appear to affected by apoE overexpression of any isoform, as indicated by similar MTT 
reduction levels. (B) Bar chart showing MTT reduction values normalised to control for SH-SY5Y cells 
transfected with an empty pCIS construct (control) or pCMV-apoE constructs expressing apoE2, apoE3 and 
apoE4 for 48 hours (n=3). Cell viability was enhanced by overexpression of apoE2 and apoE3, as indicated 
by increased MTT reduction levels. Overexpression of apoE4 however did not affect cell viability. (C) Bar 
chart showing MTT reduction values as a percentage of control for primary neurons transduced with 
apoE2, apoE3 and apoE4 lentiviral vectors at an MOI of 50 for 3 days (n=3). Cell viability appeared similar 
between control neurons and neurons overexpressing all three apoE isoforms affected by apoE 
overexpression of any isoform. Data are mean ±SEM, and differences were assessed using a one-way 
ANOVA followed by a Tukey's multiple comparisons test where p<0.05 is significant. *p<0.05. 
 
6.2.5 The effect of apoE overexpression on apoptosis in vitro 
To further examine and validate whether apoE expression is toxic or neuroprotective to 
neurons, a cell death assay was performed for all three cell models using the Nuclear-ID 
Blue/Red cell viability reagent (Enzo). This assay enables dead cells to be distinguished 




nucleic acid dyes. The blue fluorescent dye is cell-permeable and stains the nucleus, 
whilst the red fluorescent dye is cell-impermeable in healthy cells, but can stain the 
nucleus of dead cells since they have compromised cellular membranes. The ratio of 
live/dead cell populations was determined by FACS analysis for apoE-transfected N2a 
and SH-SY5Y cells (shown in Figure 6-16 and Figure 6-17). This method provides a 
measure of cell populations according to their fluorescence, which in this case, involves 
sorting cells labelled either with both fluorescent dyes compared to cells labelled with 
the blue fluorescent dye alone. Although cells can be fixed for FACS analysis, fixation 
was not used here to ensure that cells were not falsely labelled with the red dye due to 
compromised cellular membrane integrity from the fixation process. Since creating 
single cell suspensions from primary neuronal cultures can be challenging, the number 
of dead primary neurons was assessed by live fluorescence microscopy instead of FACS 
(see Figure 6-18). This approach involved counting the number of dead cells compared 
to the total number of cells using the NUCLEAR-ID cell viability assay and ImageJ. The 
ratio of dead cells for each condition was then calculated by the number of dead cells 
over the total number of cells, and this ratio was then normalised to the ratio of the 
control. Statistical comparisons between control and apoE-expressing cells were made 
by one-way ANOVA followed by a Tukey’s multiple comparison post-hoc test. A students 
t-test was used to statistically compare control and ethanol treated cells. 
 
Representative FACs plots for live/dead cell populations of N2a cells overexpressing 
apoE isoforms or treated with ethanol as a positive control are shown in Figure 6-16, A. 
In these plots, live N2a cells (with blue fluorescence) are shown in Q4 whereas dead cells 
(with blue/red fluorescence) are in Q2. The ratio of dead cells (normalised to the 
control) is depicted in the bar charts in Figure 6-16, B and C. As expected, treatment of 
N2a cells with ethanol resulted in a statistically significant 18.27±1.35 fold increase in 
dead cells compared to control N2a cells (p=0.0002). In contrast, the ratio of dead cells 
was not significantly different in N2a cells overexpressing the three major apoE isoforms 
(1.35±0.15 for apoE2, 1.12±0.11 for apoE3 and 1.00±0.10 for apoE4, p>0.05). These data 




either toxicity or neuroprotection in N2a cells, consistent with observations from the 
MTT assay. 
 
Representative FACs plots for live/dead cell populations of SH-SY5Y cells overexpressing 
apoE isoforms or treated with ethanol as a positive control are shown in Figure 6-17, A. 
Like for N2a cells, live SH-SY5Y cells (with blue fluorescence) are shown in Q4 whereas 
dead cells (with blue/red fluorescence) are in Q2. The ratio of dead cells (normalised to 
the control) is shown in the bar charts in Figure 6-17, B and C. Exposure of SH-SY5Y cells 
to ethanol also resulted in a significant increase of dead cells (17.38±2.30 fold-change, 
p=0.002). A reduction in the ratio of dead cells was observed for SH-SY5Y cells 
overexpressing apoE2 and apoE3, however this was only significant for the apoE2 
isoform (0.62±0.05 apoE2, p=0.0041 and 0.81±0.04, p=0.1420). Moreover, the ratio of 
dead cells was similar between control SH-SY5Y cells and cells overexpressing apoE4 
(1.001±0.08, p>0.05). A significant difference was also observed between apoE2- and 
apoE4- transfected SH-SY5Y cells (p=0.0041). These results are similar to those observed 
for the MTT assay, whereby apoE2 seems to mediate neuroprotection in SH-SY5Y cells. 
Although the neuroprotective effect of apoE3 observed in the MTT assay was not found 
here. Similarly, the apoE4 isoform did not induce toxicity, nor mediate neuroprotection. 
 
Representative fluorescence microscopy images of primary neurons transduced with 
apoE2, apoE3 and apoE4 lentiviral vectors for 3 days are shown in Figure 6-18, A. The 
left panel shows total cells in culture (blue-fluorescence), the middle panel shows dead 
cells (red-fluorescence) and the right panel is a merge of both images. Statistical analysis 
of the ratio of dead primary neurons did not reveal any significant differences between 
conditions (Figure 6-18, B; 1.29±0.14 apoE2, 1.38±0.14 apoE3 and 1.33±0.12 apoE4; 
p>0.05), suggesting that overexpression of full length apoE2, apoE3 and apoE4 for 3 days 





Figure 6-16 FACS analysis of live/dead cell populations of apoE-transfected N2a cells 
(A) Representative FACS plots of live and dead cell populations in apoE-transfected or ethanol treated 
N2a cells, as based on blue fluorescense for live cells (AmCyan-A channel) and red fluorescence for 
dead cells (PerCP-Cy5-5-A channel). (B) Bar chart showing the ratio of dead cells for apoE-
overexpressing N2a cells relative to control cells. The ratio of dead cells for each condition was not 
significantly different from control N2a cells. (C) Bar chart showing a significant increase in the ratio of 
dead N2a cells after ethanol treatment. Data are mean ±SEM, and differences were assessed using a 
one-way ANOVA followed by a Tukey's multiple comparisons test in (B) or a students T-test in (C), 






Figure 6-17 FACS analysis of live/dead cell populations of apoE-transfected SH-SY5Y cells 
A) Representative FACS plots of live and dead cell populations in apoE-transfected or ethanol treated 
SH-SY5Y cells, as based on blue fluorescense for live cells (AmCyan-A channel) and red fluorescence for 
dead cells (PerCP-Cy5-5-A channel). (B) Bar chart showing the ratio of dead cells for apoE-
overexpressing SH-SY5Y cells normalised to control cells. The ratio of dead apoE2-overexpressing SH-
SY5Y cells was significantly lower compared to control SH-SY5Y cells and apoE4-overexpressing SH-SY5Y 
cells. In contrast, overexpression of apoE3 and apoE4 did not affect the ratio of dead SH-SY5Y cells 
compared to control SH-SY5Y cells. (C) Bar chart showing a significant increase in dead SH-SY5Y cells 
after ethanol treatment. Data are mean ±SEM, and differences were assessed using a one-way ANOVA 
followed by a Tukey's multiple comparisons test in (B) or a students T-test in (C), where p<0.05 is 






Figure 6-18 Fluorescence microscopy based quantitation of live/dead cell populations of primary 
neurons transduced with apoE lentiviral vectors for 3 days 
(A) Representative fluorescence microscopy images of control neurons and apoE2-, apoE3- and apoE4-
transduced neurons showing dead cells (red fluorescence) and total cells in culture (blue fluorescence). 
(B) Bar chart shows a small increase in neuronal death when cultures express either of the apoE 
isoforms, although this was not significant. Data are mean ±SEM, and differences were assessed using a 






6.3.1 Subcellular distribution of apoE and insights into apoE function 
The staining distribution of apoE was examined to determine whether N-terminally 
truncated apoE fragments generated in apoE-overexpressing N2a cells localised to the 
cytoplasm without full length apoE, and to see if apoE isoform influenced this. The 
immunolabelling data showed additional cytoplasmic staining for the C-terminal specific 
antibody, suggesting that apoE fragments with an intact C-terminus may indeed 
accumulate in the cytosol. However, these results should be treated with caution 
because this finding could also be a result of a weaker signal from the antibody specific 
to the N-terminus of apoE. Nevertheless, there is evidence in the literature to support 
accumulation of C-terminal apoE fragments in the cytosol. For instance, an electron 
microscopy study that used an antibody specific for lipid binding region within the C-
terminus of apoE (3H1) revealed a cytoplasmic distribution of apoE in human cortical 
neurons from post-mortem AD brain tissue (Han et al., 1994a). Considering that some of 
these fragments may also contain the receptor binding region (135-150aa) that is 
thought to be required for fragment translocation (Chang et al., 2005), it is plausible that 
a portion of N-terminally truncated fragments that retain this region would translocate 
to the cytoplasm. Therefore, under the conditions used here, fragments of apoE appear 
to localise to the cytoplasm as posited in the proteolysis hypothesis, whereby they may 
affect cellular function. Interestingly, the staining of cytoplasmic apoE did not appear 
more pronounced for apoE2- or apoE4- transfected N2a cells despite western blotting 
showing isoform-specific differences in fragment load (apoE2>apoE4>apoE3). This could 
be attributed to the similar abundance of the major    ̴26kDa fragment for all three apoE 
variants, and because the varying load of low molecular weight fragments were less 
abundant. Nonetheless, the majority of C- and N-terminus specific staining appeared co-
localised, suggesting that most of the staining is representative of either full length apoE 
or N-terminally truncated fragments of apoE that are within close proximity to full 
length apoE.  
 
The distribution of intracellular apoE in apoE-transfected N2a cells is similar to 




HepG2 cells and N2a cells (Dekroon and Armati, 2001, Sabaretnam et al., 2009, 
DeMattos et al., 1999). Interestingly, the work here also showed that this pattern was 
similar for all three isoforms of apoE, suggesting that the distribution of neuronally 
expressed apoE and its fragments is not isoform-dependent under basal conditions. The 
immunolabelling for apoE was primarily concentrated in the perinuclear region, but 
diffuse and granular cytoplasmic staining and granular staining in the neurite extensions 
was also observed. It has been suggested that the perinuclear localisation of apoE in N2a 
cells is associated with the Golgi network (Chang et al., 2005). This is likely the case since 
studies have demonstrated co-localisation between perinuclear apoE and markers of the 
Golgi network in Hep2G cells and primary neuronal cultures (Sabaretnam et al., 2009, 
Dekroon and Armati, 2001). This is unsurprising though, since the Golgi apparatus is a 
site of major protein synthesis and modification. It is therefore likely that the intense 
staining within this region could be reflective of high protein overexpression within the 
Golgi network due to the use of a CMV promoter. Indeed, this region of apoE likely 
represents newly synthesised apoE protein since perinuclear staining for apoE was also 
detected by the N-terminus specific antibody that was shown by western blotting in the 
previous chapter to only detect full length apoE. An alternative hypothesis however, is 
that the granular perinuclear staining of apoE could be partially composed of dispersed 
protein aggregates. This hypothesis stems from similarities between the staining pattern 
of apoE to dispersed aggregates of a prion protein called CyPRP that is juxtanuclear in 
N2a cells (Grenier et al., 2006, Beaudoin et al., 2008). Further to this, N-terminal 
deletions of apoE have been shown to enhance the aggregation properties of the 
protein (Chou et al., 2005). Although this region shows co-localisation between the N- 
and C- terminus of apoE, immunofluorescence in conjunction with confocal microscopy 
does not provide sufficient resolution to distinguish between full length apoE and C-
terminal fragments that are in close proximity. Hence, future investigation into whether 
this region of apoE accumulation does indeed contain small aggregates of C-terminal 
fragments is warranted. On the other hand, the punctate staining pattern of apoE in N2a 
cells has also been suggested to be vesicle-bound apoE in the secretory pathway 
(DeMattos et al., 1999), which is also likely here since the apoE secretory signalling 




apoE in neurites of N2a cells was an interesting observation as studies have shown that 
both exogenous application or expression of apoE can affect neurite outgrowth (Nathan 
et al., 1995, Bellosta et al., 1995). Hence, it is conceivable that apoE localised to neurites 
may contribute to this effect. 
 
Notably, other techniques that provide greater resolution could be used in future work 
to acquire more information on the subcellular localisation of full length apoE and 
fragments. For instance, double-label immunoelectron microscopy of apoE-
overexpressing cells could be used. In this technique, antibodies to the N- and C-
terminus of apoE could be detected by secondary antibodies conjugated to colloidal gold 
nanoparticles of different diameter (Hagiwara et al., 2010). Under the scenario where C-
terminal fragments are recognised by smaller sized gold nanoparticles, subcellular 
localisation of the smaller electron-dense spots would reveal more precisely which 
compartments the C-terminal apoE fragments distribute to.  In addition, subcellular 
fractionation of protein lysate from apoE-overexpressing cells and western blotting 
using a panel of terminal specific anti-apoE antibodies could also be used. This approach 
could facilitate identifying the localisation of specific fragments in a range of subcellular 
compartments, such as cytosolic, membrane bound and nuclear compartments 
(Baghirova et al., 2015). Further work using such methodologies to explore which 
intracellular compartments apoE localises to could prove informative in elucidating the 
cellular functions of full length apoE and apoE fragments in neurons. 
 
6.3.2 Does neuronal expression of apoE affect organisation of endogenous p-Tau? 
Whilst the western blotting data in the previous chapter showed that the physiological 
proteolysis of apoE2, apoE3 and apoE4 results in substantial fragment load, the 
immunofluorescence data here indicated that N-terminally truncated fragments of apoE 
may accumulate in the cytosol. Hence, it was plausible that the cytosolic apoE fragments 
may mediate deregulation of tau and promote cytoskeletal dysfunction as suggested in 
the apoE proteolysis model (Mahley and Huang, 2012). However, although it has been 
shown in an earlier study that expression of full length apoE4 and C-terminally apoE4 (1-




the data presented in this chapter did not support a direct association between apoE 
and pThr181-Tau staining in N2a cells. Strong pThr181-Tau staining and tangle-like 
structures were observed in control N2a cells, which was surprising since this suggested 
that the basal levels of pThr181-Tau that are incorporated into perceived NFT like 
structures were high in this cell line. Moreover, staining for apoE and pThr181-Tau did 
not reveal any co-localisation in apoE-transfected N2a cells, irrespective of apoE 
isoform, which initially appeared to conflict with the proposed apoE proteolysis model. 
However, it is notable that in the study by Huang et al., full length apoE4 co-localised 
with tau ‘tangles’ in only a small percentage (  ̴2.7%) of N2a cells, whilst apoE3 did not 
associate with tau at all (Huang et al., 2001). It is also noteworthy that a later 
independent study found that expression of GFP-tagged full length apoE4 (lacking the 
signalling peptide) did not induce intracellular apoE-inclusions in N2a cells at all 
(Ljungberg et al., 2002), which is in accordance with the observations here. Hence there 
is little evidence to support that expression and physiological proteolysis of full length 
apoE in N2a cells leads to apoE/p-Tau inclusion formation. Considering this, the lack of 
association between the three isoforms of apoE and pThr181-Tau observed here is not 
entirely unexpected. Furthermore, it was a C-terminally truncated form of apoE (1-
272aa) that significantly induced and co-localised with p-Tau inclusions in N2a cells 
(Huang et al., 2001). However, in the previous chapter it was revealed that the 
proteolytic fragments of apoE2, apoE3 and apoE4 in all three cell models were N-
terminally truncated fragments with intact C-termini. This confirms that the 1-272aa 
apoE fragment that induces and co-distributes with p-Tau inclusions in the Huang et al. 
study is not produced in the cell models overexpressing apoE here, and is thus one likely 
explanation for the lack of association between apoE and pThr181-Tau staining in the 
apoE-transfected N2a cells. This data also indicates that N-terminally truncated apoE 
fragments do not lead to the formation of apoE-containing tangle-like structures in N2a 
cells. 
 
Intriguingly, pThr181-Tau staining frequently appeared to partially surround the intense 
perinuclear staining of apoE in transfected N2a cells, for all apoE isoforms, indicating a 




the protective response to aggresome formation, this staining pattern is similar to the 
juxtanuclear cage-like staining of cytoskeletal proteins such as vimentin that encase 
aggresomes in cells (Johnston et al., 1998, Beaudoin et al., 2008). This supports the 
intriguing possibility that apoE may exist as small aggregates within this region. This 
hypothesis could be investigated in future work by immunostaining apoE-transfected 
N2a cells with antibodies specific to apoE and aggresome markers such as vimentin and 
γ-tubulin. 
 
6.3.3 Does neuronal expression of apoE affect regulation of endogenous p-Tau? 
To further investigate whether apoE expression in neurons affects the phosphorylation 
of tau as reported in the literature, the levels of pThr181-Tau were examined by western 
blotting analysis. Surprisingly, pThr181-Tau and total tau protein were barely detectable 
in both control and apoE-overexpressing N2a and SH-SY5Y cells, suggesting that these 
cell lines may express very low levels of endogenous tau protein. A search in the 
literature revealed similar reports of very low levels of endogenous tau in both SH-SY5Y 
cells and N2a cells in studies using either immunofluorescence or western blotting 
techniques (Biernat et al., 2002, Bretteville et al., 2012, Khlistunova et al., 2006, 
Ljungberg et al., 2002). This appeared to be the case for a variety of total tau and p-Tau 
specific antibodies including the anti- pThr181-Tau AT270 antibody (Bretteville et al., 
2012), which is consistent with the western blotting data for N2a and SH-SY5Y cells 
presented in this chapter. Furthermore, intense HMW bands were detected by the 
pThr181-Tau antibody in both cell lines, but not by the total tau antibodies used, 
indicating that they are likely nonspecific. This observation raised the possibility that the 
immunofluorescence staining in N2a cells may not be specific to pThr181-Tau. 
Intriguingly, it was reported by Ljungberg and colleagues that the tangle-like structures 
formed by overexpression of apoE4 1-272aa, but also by C-terminally truncated 
fragments of apoE2 and apoE3 in N2a cells, do not contain tau but instead 
neurofilament protein (Ljungberg et al., 2002). In this earlier study, immunolabelling 
using a different antibody specific for tau (DAKO) showed that overexpressed tau does 
not co-localise with apoE-containing tangle-like structures in N2a cells overexpressing 




pThr181-Tau antibody revealed intense staining in control cells, it was considered that 
that the anti- pThr181-Tau antibody may not specific for tau in N2a cells. Nonetheless, 
these data imply that neuroblastoma cells may express low levels of tau or have lower 
basal levels of tau phosphorylated at a variety of sites including the Thr181 site, which 
was probed for here. Because of this, it was not possible to assess the effect of apoE 
overexpression on pThr181-Tau or total tau levels in the WT neuroblastoma cells under 
the conditions used here. Therefore, co-expressing human tau with apoE should be 
considered in future work exploring the effect of apoE expression on tau in the N2a and 
SH-SY5Y cell models. On the other hand, pThr181-Tau and pan tau were detected on 
western blots of primary neuron extracts at levels that were quantifiable. The levels of  
 ̴52kDa pThr181-Tau were significantly increased in an isoform-dependent manner 
(apoE4>apoE3, apoE2 similar to control) in primary neurons. This suggests that neuronal 
expression of apoE4 and apoE3 to a lesser extent, may induce phosphorylation of tau at 
the Thr181 site. This finding is in accordance with in vivo studies that show apoE 
expression is associated with increased levels of p-Tau in an isoform-dependent manner 
(apoE4>apoE3) (Liraz et al., 2013, Brecht et al., 2004b). Overexpression of apoE2 in 
primary neurons however, did not affect pThr181-Tau levels, showing for the first time 
that apoE2 overexpression in neuronal cultures is not associated with increased 
phosphorylation of tau at this site. This finding also further supports the notion that 
apoE2 does not exert a toxic gain of function in neurons. In addition, overexpression of 
the three major apoE isoforms did not significantly increase the levels of total tau, 
confirming that the increases in pThr181-Tau levels in apoE3- and apoE4- overexpressing 
neurons is due to increased phosphate content at Thr181 and not total tau levels. 
Although the evidence here indicates that neuronal expression of apoE may affect the 
regulation of tau phosphorylation at the Thr181Pro motif, the functional implications of 
this are not so clear. This is because regulation of tau function is a complex process that 
involves a vast array of post translational modifications that includes, for example: 
phosphorylation, glycosylation, glycation, oxidation and proteolysis (truncation) 
(Mietelska-Porowska et al., 2014). Nevertheless, phosphorylation of tau at sites shown 
to be affected in AD such as Thr181, are thought to decrease its affinity for microtubules 




1994, Li et al., 2007). Hence increased phosphorylation of tau by apoE expression in 
neurons, which is supported by the data presented here, could contribute to 
microtubule dysfunction as posited in the apoE proteolysis model (Mahley and Huang, 
2012). Indeed, studies have also shown that application and expression of apoE can 
affect microtubule organisation and neurite outgrowth in vitro (Nathan et al., 1995, 
Bellosta et al., 1995). Furthermore, transgenic mice expressing human apoE in neurons 
of the CNS display tau hyperphosphorylation and prominent axonal defects that are 
thought to be associated with cytoskeletal dysfunction (Tesseur et al., 2000a, Tesseur et 
al., 2000b). However, although the Thr181 phospho-epitope is associated with AD, 
increased pThr181-Tau levels do not necessarily indicate that tau is pathological in this 
cell model under the conditions used. Indeed, ablation of phosphorylation sites in a 
drosophila model revealed that there is not a single essential phosphorylation site for 
neurodegeneration, suggesting instead that alterations at multiple sites are required for 
tau pathology (Steinhilb et al., 2007). This highlights the need for further study of how 
other phospho-epitopes of tau are affected in neuronal cell models expressing the three 
major apoE isoforms. Nevertheless, the data here supports a role for apoE in the 
regulation of tau and shows that apoE-transduced primary neurons can be used to 
investigate the relationship between apoE and p-Tau. Therefore, apoE-transduced 
primary neurons appear to be a suitable model to explore which other phospho-
epitopes of tau are affected by apoE expression, the mechanisms underlying apoE-
induced phosphorylation of tau and for investigation into the functional implications 
related to this. 
 
How apoE overexpression affects tau phosphorylation was also addressed in this chapter. 
The phosphorylation status of tau involves a careful balance between kinase and 
phosphatase activity, and either could be affected in apoE3- and apoE4- overexpressing 
primary neurons. Here, the activity state of a candidate tau kinase GSK3 was examined 
because this kinase targets the Thr181 site of tau amongst others, and changes in its 
kinase activity have been strongly implicated in AD pathology (Sperber et al., 1995, 
Hooper et al., 2008). The data revealed similar levels of inactive GSK3 in control primary 




levels is not due to alleviating the inhibition of GSK3 activity. In agreement with this 
finding, an earlier in vivo study similarly showed that inactive GSK3 levels were also 
unaffected by neuronal expression of human apoE in transgenic rodent models (Harris 
et al., 2004). It is notable though that some studies have demonstrated apoE-mediated 
alterations in GSK3 signalling in neuroblastoma cells and primary neuronal cultures 
(Cedazo-Mínguez et al., 2003, Hoe et al., 2006). One possible explanation for these 
differences is that recombinant apoE was exogenously applied to cultured cells in these 
experiments, and so the changes in GSK signalling were likely receptor mediated. This 
contrasts to the approach used in the work here, whereby apoE was overexpressed in 
the three cell models by use of either lentiviral vector transduction or transfection 
techniques. Although secretion of apoE in the cell models is likely, the levels secreted 
into the medium may be insufficient to induce significant alterations in receptor 
mediated signalling that affect GSK3 activity. Indeed, Hoe et al demonstrated that 
inhibition of GSK3 signalling in primary neurons by application of recombinant apoE 
occurred only at concentrations higher than physiological levels (Hoe et al., 2006), 
supporting this notion and the lack of effect on GSK activity status here. Taken together, 
these data suggest that the increased pThr181-Tau levels in primary neurons likely 
occurs through alternative mechanisms that may include increased activity of other 
kinases or reduced phosphatase activity. In fact, there is evidence to suggest that 
recombinant apoE does affect other tau-associated kinases (Hoe et al., 2005, Hoe et al., 
2006), however whether neuronal apoE expression mediates similar effects is currently 
not known and could be explored in further work. Furthermore, a recent study showed a 
reduction in the active form of PP2A, a key tau phosphatase, that was associated with 
apoE expression (apoE4>apoE3) in a glioblastoma cell line (Theendakara et al., 2017). In 
consideration of this, it is possible that the increase in pThr181-Tau levels in apoE3- and 
apoE4- overexpressing neurons could be contributed to by apoE-mediated 
downregulation of PP2A activity, which warrants further investigation. It was also 
considered that the differential effects of apoE isoforms on tau phosphorylation in the 
primary neuronal model may be associated with their affinity for binding to tau. Indeed, 
in vitro experiments have shown that the greater binding between apoE3 and tau is 




proposed to occur due to structural protection from kinase action (Strittmatter et al., 
1994a, Strittmatter et al., 1994b). However, since levels of pThr181-Tau in apoE3 
overexpressing neurons were greater than levels in control neurons, it is unlikely that a 
tau-apoE interaction underlies this increase because on this basis, apoE3 overexpression 
should prevent tau phosphorylation. Although the levels of endogenous tau were barely 
detectable by western blotting in the neuroblastoma cell lines, the levels of inactive 
GSK3 were examined in these cell models. The levels of inactive GSK3 were not 
significantly altered in the SH-SY5Y cell line when either of the apoE isoforms were 
overexpressed, which is consistent with that observed in the primary neurons. However, 
the data unexpectedly revealed a significant reduction in inactive GSK3 levels in apoE3- 
and apoE4- overexpressing N2a cells, which is indicative of an increase in GSK3 activity 
and suggests that apoE-mediated effects on GSK3-related cell signalling may be cell-
dependent. On this basis, one would expect to observe significant increases in the levels 
of tau phosphorylated at epitopes targeted by GSK3 in N2a cells. This could be explored 
in future experiments by co-expressing human apoE and human tau in N2a cells and 
performing western blotting analysis using antibodies specific to tau phospho-epitopes 
targeted by GSK3. As for how these cell-dependent differences arise is uncertain, but 
they could involve differences in the levels of apoE-related receptors at the cell surface 
of N2a cells compared to the other cell models. Furthermore, it is also possible that 
modifications of apoE protein in N2a cells may differ to the other cell models as 
discussed in the previous chapter as a possible reason for cell-dependent variations in 
apoE processing, which could alter the functions of apoE. Because of this, it would also 
be interesting to investigate whether there are cell-specific modifications of apoE in 
future experiments. 
 
6.3.4 A possible relationship between neuronal expression of apoE and vimentin 
Although expression of apoE and vimentin has been observed in neurons that are 
stressed or injured and has been proposed to occur as part of the neuronal repair 
response mechanism (Boschert et al., 1999, Xu et al., 2006b, Xu et al., 2008, Levin et al., 
2009), it was not known whether the expression of these two proteins were linked. The 
data in Figure 6-14 show for the first time that expression of apoE is associated with 




apoE expression may act as a trigger for re-expression of vimentin to contribute to 
neuronal repair. However, the data also showed that the effect of apoE on vimentin 
expression was isoform dependent whereby increased vimentin levels occurred in the 
order of apoE2>apoE4, whilst apoE3 had no effect. This is puzzling when considering 
that apoE2 is thought to confer neuroprotection whilst apoE4 is associated with toxicity. 
One possible explanation for the differential effect on vimentin by apoE stems from 
another aspect of the apoE proteolysis model where apoE4 increases the risk for AD due 
to a loss of protective function compared to the other two variants. On this basis, one 
would expect to see a greater protective response in the order of apoE2>apoE3>apoE4, 
which is partially supported by the data here when considering vimentin expression as 
an indicator of protective response. However, apoE3 did not affect vimentin levels in 
primary neurons, which could suggest that this variant plays a more neutral role. 
Nonetheless, the data here reveal a relationship between apoE and vimentin expression. 
It also suggests a new potential role for apoE in affecting the IF network and modulating 
the neuronal repair response, two hypotheses which warrant further investigation. 
 
The data also showed that the effect of neuronal apoE expression on vimentin levels is 
dependent on the cell model used. Whilst the data showed increased vimentin levels in 
apoE2- and apoE4- overexpressing primary neurons, no differences were observed in 
SH-SY5Y cells. One possible explanation for this is that the regulation of vimentin 
expression between these cell models is likely different since the SH-SY5Y cell line is a 
proliferating neuroblastoma cell, whereas the 18-21DIV primary neuronal model likely 
contains relatively mature post-mitotic neurons (Sapoznik et al., 2006). Evidence for this 
proposal comes from studies which have shown that vimentin is readily expressed in 
neuronal precursors to initiate neuritogenesis (Shea, 1990, Boyne et al., 1996, Levin et 
al., 2009), but is then downregulated when neurons are mature (Cochard and Paulin, 
1984), thus indicating that differentiation status plays a key part in the regulation of 
vimentin expression. Therefore, this data indicates that a mature neuronal model may 
be required to explore the role of apoE on vimentin expression, and possibly other 





6.3.5 Is neuronal expression of apoE neurotoxic or neuroprotective? 
The three major isoforms of apoE have been associated with different effects on 
neuronal viability such that apoE2 is thought to be neuroprotective, apoE3 neutral or a 
little protective and apoE4 neurotoxic. Whilst it has been proposed that neuron-specific 
proteolysis of apoE4 contributes to a toxic gain and loss of protective function, this was 
not reflected in the data from the viability (section 6.2.4) or cell death assay (section 
6.2.5). Overexpression of apoE4 in all three cell models did not significantly reduce cell 
viability or increase the number of apoptotic cells, suggesting that overexpression and 
proteolysis of apoE4 in neurons does not induce toxicity under physiological conditions. 
These data are surprising because apoE4 fragments are thought to promote toxicity, 
partly through cytoskeletal and mitochondrial dysfunction, yet the apoE4 fragments 
generated in vitro here did not appear to induce significant toxicity. An important 
question arises from this data: if fragments are generated in vitro, why was toxicity not 
observed here? It is notable that many of the in vitro studies of apoE-related 
neurotoxicity supporting this working model are based on overexpression of C-
terminally truncated apoE4 (Chang et al., 2005), or application of full length/truncated 
apoE4 in cell cultures (Marques et al., 1996, Tolar et al., 1999, Veinbergs et al., 2002, 
Persson et al., 2017). Hence, these studies do not directly test whether neuronal apoE4 
expression and the physiological generation of apoE4 fragments leads to a toxic gain of 
function. Whilst conclusive evidence for the existence of such fragments remains to be 
seen in the literature, the data from the previous chapter showed that apoE may be N-
terminally cleaved instead. Therefore, the results from the published in vitro studies 
may not be an accurate representation of the role of neuronal apoE4 and fragments in 
vivo. Interestingly, the only study in the literature that tested whether overexpression of 
full length apoE4 affects neuronal viability showed that MTT reduction was not 
significantly affected in N2a cells (Chang et al., 2005), supporting the data presented 
here. In consideration of the hypothesised protective function of apoE expression in 
neurons and that the majority of apoE protein observed by western blotting is full length 
(see previous chapter), it is possible that full length apoE4 may act antagonistically to 
neurotoxic apoE4 fragments (if any). In support of this, application of full length apoE4 




149aa) of apoE4 in embryonic chick sympathetic neurons, in a concentration dependent 
manner. To test this hypothesis, future work could compare the effect of overexpressing 
N-terminally truncated apoE4 fragments with and without full length apoE4 on neuronal 
viability and survival. Another possibility is that the cellular environment may influence 
whether apoE expression is toxic. For instance, pH levels have been shown to affect the 
structure and aggregation properties of apoE (Garai et al., 2011), raising the possibility 
that changes in cellular environment (such as pH levels) could also influence the 
structural and functional properties of intraneuronal apoE. In support of the hypothesis 
that apoE4 has differential effects relating to cellular state, a recent study showed that 
application of apoE4 to N2a-APP cells only promoted apoptosis when N2a-APP cells 
were injured by application of ethanol (Li and Cheng, 2018). Considering that apoE 
expression is reported to occur in neurons following a form of injury such as from 
oxidative stress, this may be a key factor to include in future in vitro studies exploring 
the role of intraneuronal apoE in AD. Nonetheless, there is also in vivo data showing that 
expression of apoE4 in CNS neurons of transgenic mice is associated with enhanced 
neurodegeneration with and without excitotoxic triggers (Buttini et al., 2010, Zhang et 
al., 2012, Raber et al., 1998, Tesseur et al., 2000a). One explanation for why apoE4 has 
this effect in vivo is that these rodents are ageing, and so can accumulate cellular stress 
over time in a manner that could alter the properties of apoE4 as described above. 
Indeed, cognitive deficits and markers of neurodegeneration associated with apoE4 
expression in neurons has been shown to increase with age in NSE-apoE4 mice, but not 
in NSE-apoE3 and wild-type mice (Buttini et al., 1999, Raber et al., 1998). 
Overexpression of full length apoE3 did not affect cell viability or survival in any of the 
three cell models used, which is in accordance with independently published data 
showing that apoE3 overexpression does not affect N2a cell viability (DeMattos et al., 
1999). This result supports the notion that apoE3 expression has a more neutral/ slightly 
protective effect in neurons, although whether this is the case under conditions of 
cellular stress in vitro remains to be confirmed. Overall, the findings discussed here 
highlight that additional work should be carried out to determine whether different 




apoE processing and function in neuronal cell models, and to explore how this affects 
neuronal viability and survival. 
 
Intriguingly, both the MTT and cell death assays revealed an increase in SH-SY5Y cell 
viability and survival when apoE2 was overexpressed, which is the first direct in vitro 
evidence to support the hypothesis that this isoform is neuroprotective. It is notable 
though that apoE2 also displayed the greatest fragmentation load in the SH-SY5Y cell 
line, suggesting that the load of fragments may not necessarily be the major factor for 
apoE-related toxicity. This finding also supports the hypothesis that the fragments 
generated from each isoform may differ structurally and so have different effects, which 
in this case, may confer neuroprotective properties, although this remains to be 
confirmed. As for why a neuroprotective effect was observed only in SH-SY5Y cells could 
be attributed to it being a human neuroblastoma cell line, indicating that it may be 
important for human protein orthologues to be present to study the protective role of 
human apoE2 and to determine interacting partners of this isoform. Furthermore, this 
cell-dependent observation suggests that the neuroprotective effect of apoE2 may go 
beyond its reported role in ameliorating oxidative stress such as through its antioxidant 
activity and ability to bind the toxic lipid peroxidation product, 4-hydroxynonenal (HNE) 
(Miyata and Smith, 1996, Pedersen et al., 2000). In view of this finding, it would be of 
interest to validate the neuroprotective effect of apoE2 in another cell model such as 
iPSC-derived neurons. Further work could also involve investigating the molecular 
mechanisms underpinning the neuroprotective properties of apoE2. 
 
6.3.6 Conclusion 
Although there was no conclusive evidence to support that apoE induces the formation 
of tangle-like structures containing apoE and p-Tau, the data showed that apoE 
expression and proteolysis in primary neurons was associated with increased tau 
phosphorylation at Thr181 in an isoform-dependent manner (apoE4>apoE3), which is 
consistent with published studies. The work here is also the first to show that 
overexpression of apoE2 in primary neuronal cultures does not promote tau 
phosphorylation at Thr181, supporting the hypothesis that apoE2 does not deregulate 




expression (apoE2>apoE4, no effect for apoE3) on the upregulation of vimentin was also 
observed in primary neurons, indicating that neuronal apoE expression may affect the IF 
network and modulate the repair response of injured or stressed neurons. Surprisingly, 
none of the isoforms were found to be toxic to neurons despite evidence supporting the 
cytosolic localisation of N-terminally truncated fragments and increased levels of 
pThr181-Tau. Therefore, these findings indicate that the cytosolic localisation of 
fragments and the increased phosphorylation at the Thr181 site of tau does not 
necessarily confer toxicity. Moreover, these data suggest that conditions of cellular 
stress may be required to model the toxic gain of function associated with apoE4 
expression and proteolysis, since the physiological generation of fragments was not 
sufficient to induce toxicity. Remarkably though, the data presented here show for the 
first time that expression of apoE2 is neuroprotective in human neuroblastoma cells. 
Whilst the protective mechanisms are unknown, this result reveals that a human 
neuronal model, such as SH-SY5Y cells, may be more suitable for elucidating the 
protective functions of neuronally expressed apoE2 in AD. This data also indicates that 
the trigger of apoE2 expression after injury or stress in human neurons may contribute 
to decreased risk for AD. Collectively, the data demonstrate that the effects of apoE on 
neuronal function and viability are isoform-dependent, and support the hypothesis that 






Chapter 7 FINAL DISCUSSION 
7.1 Project 1: Role of Aß42 and VPA in SnpI regulation 
Extensive research has revealed that Aß42 oligomers contribute to synaptic dysfunction 
during the early stages of AD, partly through deregulating SV dynamics and thus 
neurotransmitter release (Kelly and Ferreira, 2007, Parodi et al., 2010, Russell et al., 
2012, Park et al., 2013, Park et al., 2017, Park and Chang, 2018). Therefore, the work 
presented in chapter 3 was carried out to investigate the molecular basis of Aß42-
mediated disruption to SV dynamics and synaptic function by determining whether Aß42 
oligomers deregulate SnpI, a key SV-associated protein. The data confirmed that Aß42 
does indeed deregulate SnpI by promoting sustained phosphorylation of SnpI at Ser9, an 
effect which has since been replicated in recent studies (Park et al., 2017, Park and 
Chang, 2018). Because the data also suggested that the phosphatase activity of PP2A 
was unaffected by Aß42 oligomers, the deregulation of SnpI was hypothesised to occur 
through maintained CAMKIV kinase activity instead. This hypothesis has been confirmed 
in later independent studies demonstrating that Aß42 oligomers induce autonomous 
CAMKIV activity (Park et al., 2017, Park and Chang, 2018). In addition, Park and co-
workers showed that the autonomous CAMKIV activity was due to Aß42 oligomers 
triggering an increase in cytosolic calcium through extracellular calcium influx and 
calcium release from mitochondria. Interestingly, it was also shown that Aß42-mediated 
calcium release from mitochondria alone was sufficient to induce sustained 
phosphorylation of SnpI at Ser9 (Park and Chang, 2018). Importantly, this finding 
highlights a molecular mechanism that may partly underlie the deleterious effects of 
intraneuronal Aß42 oligomers on SV-associated proteins that are regulated by calcium-
signalling like SnpI, and thus SV dynamics and synaptic function. 
 
Since phosphorylation of SnpI at Ser9 has been suggested to modulate the availability of 
SVs to participate in neurotransmitter release via reversible tethering and clustering of 
SVs from the recycling pool to the reserve pool (Hosaka et al., 1999, Fiumara et al., 2004, 
Ceccaldi et al., 1995, Bloom et al., 2003), it was hypothesised that the maintained 
phosphorylation of SnpI induced by Aß42 oligomers could contribute to the deregulation 




could increase the availability of SVs for neurotransmitter release during the early stages 
of Aß42-mediated synaptic dysfunction and thus contribute to the reported increased 
release probability of SVs and aberrant neurotransmitter release triggered by Aß 
oligomers in vitro (Parodi et al., 2010, Puzzo et al., 2008, Russell et al., 2012). On the 
other hand, prolonged phosphorylation of SnpI at Ser9 by autonomous CAMKIV activity 
could contribute to defective SV recycling and lead to SV pool depletion as reported in 
the literature (Williams and Bate, 2016, Kelly and Ferreira, 2007, Parodi et al., 2010). 
However, these hypotheses remain to be confirmed. Nevertheless, two recent studies 
have demonstrated by using a quantum dot-based single-SV tracking assay and 
fluorescence recovery after photobleaching (FRAP) experiments, that the maintained 
phosphorylation of SnpI at Ser9 by CAMKIV autonomous kinase activity inhibits 
intersynaptic vesicle trafficking in Aß42-exposed cultured rat hippocampal neurons (Park 
et al., 2017, Park and Chang, 2018). In these studies, overexpression of a phospho-
deficient mutant of SnpI or using an inhibitor of CAMKK, blocked the inhibition of 
intersynaptic vesicle trafficking, confirming that phosphorylation of SnpI at Ser9 has a 
direct effect on the lateral sharing of SVs between neighbouring synapses. Interestingly, 
inhibition of CAMKK signalling was also shown to block the inhibitory effect of Aß42 
oligomers on chemically induced LTP in rat hippocampal cultures (Park et al., 2017). In 
view of these findings, Park and co-workers proposed that phosphorylation of Snp at 
Ser9 and subsequently inhibition of intersynaptic vesicle trafficking mediated by Aß42 
oligomers may partly contribute to the Aß42-induced defects in synaptic plasticity (Park 
et al., 2017). Taken together, these studies support the hypothesis that the deregulation 
of SnpI phosphorylation at Ser9 could have a substantial impact on SV dynamics and as a 
result, may contribute to synaptic dysfunction in AD. It is therefore reasonable to 
suggest that SnpI may be a suitable candidate target for therapeutic intervention in AD. 
However, it is notable that Aß42 oligomers have also been reported to directly interact 
with proteins involved in SV docking and fusion and therefore neurotransmitter release, 
such as synaptophysin (Russell et al., 2012) and syntaxin Ia (Yang et al., 2015). In 
addition, Aß42 oligomers have been shown to indirectly affect proteins involved in 
endocytosis, such as dynamin I, through interfering with signalling mechanisms (Kelly et 




the mechanisms underpinning the effect of Aß42 oligomers on synaptic function involve 
an additive disruption to multiple aspects of SV dynamics through affecting several key 
SV-associated proteins that regulate this process. Hence future studies are needed to 
improve our understanding of the temporal effects of Aß42 oligomers on SV dynamics 
and presynaptic function so that an effective therapeutic treatment can be found for the 
early stages of AD. One such therapeutic treatment could involve the use of VPA, a 
compound that has been shown to have therapeutic benefit in transgenic AD mouse 
models (Qing et al., 2008, Hu et al., 2011b, Noh and Seo, 2014) and to prevent Aß42-
induced reduction in SV recycling (Williams and Bate, 2016). Although the molecular 
basis of the protective effect of VPA on SV recycling is still not fully understood, the work 
presented in chapter 3 showed for the first time that VPA could abolish the sustained 
phosphorylation of SnpI at Ser9 in Aß42-exposed cultured hippocampal neurons. This 
prompted the hypothesis that the molecular mechanisms underpinning the protective 
role of VPA may involve attenuating the disruptive effect of Aß42 oligomers on SnpI 
regulation and subsequently SV dynamics. It is also possible that VPA may disrupt other 
SV-associated proteins, although this remains to be tested. Interestingly, VPA has been 
reported to suppress Aß-induced elevations of intracellular calcium in cultured rat 
hippocampal neurons (Mark et al., 1995). Hence it is possible that this compound could 
attenuate the disruptive effect of Aß oligomers on SV-associated proteins by blocking Aß 
oligomers from altering calcium signalling. VPA has also been shown to inhibit cyclin-
dependent kinase 5 (Cdk5) (Hu et al., 2011a), an important kinase that has numerous 
presynaptic substrates, including SnpI (Matsubara et al., 1996) and dynamin I (Tan et al., 
2003), and has been shown to regulate SV endocytosis (Tan et al., 2003, Tomizawa et al., 
2003, Nguyen and Bibb, 2003) and the release of SVs from the resting pool to participate 
in neurotransmitter release (Kim and Ryan, 2010, Verstegen et al., 2014). It is therefore 
likely that VPA affects multiple aspects of SV dynamics, raising the need to further 
explore the effect of VPA on SV-associated proteins and the SV life cycle to evaluate its 





7.2 Project 2: Role of apoE isoform on apoE processing and function in 
neurons 
In this thesis, the role of apoE expression and proteolysis on neuronal function and 
viability was assessed for the three major isoforms of apoE (apoE2, apoE3 and apoE4) in 
an effort to understand their differential effects on the risk for AD. Although the 
expression and proteolysis of apoE4 in neurons has been proposed to result in a toxic 
gain of function and thus increase the risk for AD (Huang et al., 2004, Mahley et al., 
2006, Mahley and Huang, 2012), the impact of proteolysis on the role of the ‘protective’ 
apoE2 isoform in neurons has been largely understudied. To address this, the three 
major apoE isoforms were expressed in neuronal cell models so that the fragmentation 
(profile, load and composition of fragments) of each isoform could be characterised and 
their effect on cytoskeletal-associated proteins and neuronal viability could be assessed. 
Together, these data also enabled an assessment of the relationship between the 
fragmentation of each isoform and their effects on neurons, as discussed here.  
 
Importantly, the data in this thesis show for the first time, a comprehensive analysis of 
the fragmentation of apoE2 when expressed in neuronal cell models. Examination of the 
fragmentation profile for each apoE isoform in vitro did not reveal any unique apoE 
fragments. This indicates that the differential effects that these isoforms have on 
neuronal function may instead be due to differences in the levels of fragments 
generated, and/or the structure of fragments (containing SNPs) and the full length 
protein. Indeed, the proteolytic susceptibility of apoE was shown to be isoform-
dependent, but surprisingly, also cell-dependent. The proteolytic susceptibility of each 
isoform in primary neurons followed the order of apoE4>apoE3>apoE2, consistent with 
the proposed proteolysis model that posits that apoE4 is more susceptible to proteolytic 
cleavage due to a stronger domain interaction that is induced by the presence of 
Arg112. It is notable that this work provides the first direct evidence that the apoE2 
isoform is the least susceptible to cleavage in primary neurons, a hypothesis which has 
previously only been inferred in the literature on the basis of structural studies of 
domain interaction (Mahley and Huang, 2012, Dong et al., 1994, Xu et al., 2004). 




with that found in APOE-genotyped human AD brains and NSE-apoE mice brain extracts 
(apoE4>apoE3) (Harris et al., 2003, Jones et al., 2011, Tamboli et al., 2014, Brecht et al., 
2004b), indicating that apoE processing in this in vitro model is comparable to 
processing of apoE in vivo. In contrast, the apoE fragmentation load for each apoE 
isoform in the neuroblastoma cells followed the order of apoE2>apoE4>apoE3, raising 
the prospect that the proteolytic susceptibility of apoE may involve other factors such as 
PTMs (Zannis and Breslow, 1981, Wernette-Hammond et al., 1989). Although, it should 
not be discounted that isoform-specific variation in the secretion of apoE fragments may 
underlie the differences in the levels of intracellular fragments, as studies have reported 
the presence of apoE fragments in extracellular fractions (Wellnitz et al., 2005, Munoz et 
al., 2018). Examination of fragment composition using a panel of commercially available 
antibodies to specific regions of apoE also provided evidence to support the hypothesis 
that fragments of apoE containing the SNPs may be generated. Thus, fragment load and 
fragment structure may play a role in the differential effects that these isoforms have on 
neuronal function. In addition, this work revealed that apoE fragments contain an intact 
C-terminus and are thus generated by sequential cleavage within the N-terminal 
domain. This finding is of importance because numerous studies have used C-terminally 
truncated apoE4 fragments or N-terminal apoE4 fragments to investigate the role of 
apoE4 proteolysis in neuronal dysfunction and thus AD (Huang et al., 2001, Harris et al., 
2003, Chang et al., 2005, Nakamura et al., 2009, Bien-Ly et al., 2011, Tanaka et al., 
2006). As such, the data presented here suggests that these fragments may not exist in 
vivo and that the findings from these studies may not be an entirely accurate 
representation of the function of apoE fragments in the human brain. The data also 
highlight that work exploring the role of apoE fragments truncated at the N-terminus 
may provide a more accurate insight into the function of these fragments. However, it 
would be better to approach this line of investigation following the identification of the 
amino acid sequence of such fragments. 
 
Investigating the effect of apoE isoform on the levels and regulation of cytoskeletal-
associated proteins as an indicator of a toxic or protective gain of function revealed 




apoE2) and vimentin expression (apoE2>apoE4, no effect for apoE3) in primary neurons. 
The isoform-dependent effect on tau phosphorylation is consistent with that observed 
in the literature (Tesseur et al., 2000b, Brecht et al., 2004b, Lin et al., 2018, Wang et al., 
2018) and suggests that apoE4 may contribute to AD pathology through the 
deregulation of tau and thus microtubule network disruption. Interestingly, the data also 
showed a relationship between vimentin expression, which has been proposed to be 
involved in the neuronal repair response (Levin et al., 2009), and apoE expression in an 
isoform-dependent manner. This supports the hypothesis that expression of apoE in 
neurons may be triggered as part of the neuronal repair response in stressed or injured 
neurons, although it is unclear why no effect was observed for apoE3. This result also 
indicates that apoE expression in neurons may affect the IF network in addition to the 
microtubule network and may modulate the repair response in injured or stressed 
neurons, although this remains to be verified. Surprisingly, none of the isoforms were 
found to be toxic despite substantial fragment load observed for all the isoforms, 
cytosolic localisation of fragments and apoE4- / apoE3- mediated increases in the levels 
of tau phosphorylated at Thr181 that mirrored the level of fragments generated. These 
findings suggest that full length apoE and its fragments are not inherently toxic in vitro 
and that phosphorylation of tau at Thr181 is not necessarily representative of toxic tau. 
However, one important aspect to consider about the work here, is that modelling 
apoE4-mediated toxicity in culture is a more simplistic approach than expressing apoE4 
in vivo, which incorporates longer expression times and age-dependent alterations at 
the cellular and molecular level. Hence it is possible that prolonged expression of apoE 
and/or additional factors such as cellular stress may be required to initiate the reported 
gain of toxic function for apoE4 in vitro, and possibly, to observe subsequent tau-
mediated toxicity (if it all). Indeed, although neuronal apoE4 expression in vivo has been 
demonstrated to induce neurodegeneration (Tesseur et al., 2000a, Tesseur et al., 2000b, 
Brecht et al., 2004a), it is important to note that these effects were age-dependent, 
presenting in aged transgenic mice and worsening over time. Of note, the work in this 
thesis is also the first to demonstrate that apoE2 expression and proteolysis promotes 
cell viability and survival of SH-SY5Y cells, thus supporting the hypothesis that this 




remain to be determined, it is unlikely that this effect involves vimentin expression 
because vimentin levels were unchanged by apoE2 expression in SH-SY5Y cells. Since 
this neuroprotective effect was restricted to SH-SY5Y cells, it is possible that human-
derived neuronal cell models may be required to investigate protective role of apoE2 in 
vitro. In addition, since SH-SY5Y cells expressing apoE2 showed the greatest abundance 
of fragments compared to the other two isoforms, proteolysis of apoE may not 
necessarily result in a loss of protective function. In fact, it is conceivable that apoE2 
fragments may confer neuroprotection, an intriguing possibility that remains to be 
confirmed. Taken together, it is plausible that expression and proteolysis of apoE2 in 
human neurons following stress or injury may partially underlie the decreased risk for 
AD associated with the APOE2 genotype. In conclusion, these findings support the 
hypothesis that the differential effects of each apoE isoform on neuronal function and 
the risk for AD are likely linked to structural differences in the full-length protein and/or 
fragments. Additionally, these findings highlight that research into the role of apoE2 
expression and proteolysis in neurons may be a promising avenue for identifying new 
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